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Chapter	1:	Resumé		
1.1:	English	resumé	Parkinson’s	disease	(PD)	is	the	second	most	common	neurodegenerative	disorder	next	to	Alzheimer’s	disease.	It	is	characterized	by	a	gradual	onset	of	motor	symptoms	such	as	slowness	of	movement,	resting	tremor,	rigidity	and	postural	instability,	related	to	the	degeneration	of	dopaminergic	neurons	in	substantia	nigra,	pars	compacta	(SNpc).	Apart	from	this,	patients	also	suffer	from	increasing	autonomous	dysfunction,	e.g.	drooling,	urinary	incontinence,	constipation,	and	ortostatic	hypotension.	The	risk	of	PD	increases	significantly	with	age,	with	approximately	1%	of	the	population	over	60	years	suffering	from	PD.	The	disease	process	leading	to	PD	may	have	been	taking	place	for	more	than	10	year	prior	to	the	motor	symptom	debut,	since	motor	symptoms	only	occur	after	more	than	30%	of	the	dopaminergic	neurons	in	SNpc	have	deteriorated.	The	current	treatment	options	do	not	include	disease-modifying	drugs,	but	only	symptomatic	treatment.	The	most	effective	symptomatic	treatment	for	PD	is	the	drug	L-DOPA,	which	substitutes	the	loss	of	dopamine	in	the	striatum.	During	the	first	years	of	treatment,	this	drug	can	have	a	marked	effect	on	the	patient’s	motor	symptoms,	but	gradually	the	drug	loses	its	effect.	Apart	from	daily	potentially	severe	fluctuations	in	treatment	effect,	patients	begin	developing	side	effects,	such	as	potentially	debilitating	involuntary	movements	called	L-DOPA	induced	dyskinesia	(LID).	In	total	there	is	a	need	for	earlier	diagnosis	of	PD,	a	better	understanding	of	the	LID	pathogenesis	and	identifying	patients	at	risk	of	developing	LID				The	aims	of	this	thesis	are:	1)	To	identify	diagnostic	biomarker	candidates	for	PD	in	the	cerebrospinal	fluid	(CSF)	and	blood	plasma.	2)	To	identify	biomarker	candidates	for	LID	in	CSF	and	blood	plasma.					In	this	study	we	included	26	patients	with	PD	and	16	controls.	Apart	from	CSF	and	blood	sampling,	PD	patients	were	clinically	rated	using	rating	scales	assessing	the	severity	of	PD	(MDS-UPDRS	part	III),	the	severity	of	LID	(UDysRS	objective	score),	as	well	as	a	cognitive	rating	(MOCA,	MMSE).	8	patients	were	not	treated	with	L-DOPA,	18	patient	were	L-DOPA	treated	and	10	of	them	were	dyskinetic.	Samples	were	analysed	using	high	performance	liquid	chromatography	(HPLC),	liquid	chromatography	mass	spectrometry	(LC-MS),	western	blotting,	enzyme	linked	immune-assays	(ELISA),	Multiplex,	and	fluorescence	assays.		Several	potential	diagnostic	biomarker	candidates	were	identified:	PD	patients	had	a	significantly	decreased	concentration	of	the	protein	α-synuclein	(α-syn)	in	CSF	as	well	as	an	increased	tetramer/monomer	α-syn	ratio.	They	had	significantly	decreased	activity	of	the	enzyme	glucocerebrosidase	in	CSF.	Using	a	potential	prefibrillary	amyloid	marker,	L-Tryptophanol	(Trol),	PD	patients	had	significantly	decreased	Trol	scores	in	CSF	and	significantly	increased	Trol	scores	in	plasma.	The	CSF/plasma	Trol	ratio	and	the	CSF	Trol/CSF	total	protein-ratio	increased	differentiation	between	PD	and	controls.	Several	catecholamines	were	also	decreased	in	L-DOPA-untreated	PD	patients.	In	dyskinetic	patients	significant	changes	in	tryptophan	and	catecholamine	metabolic	pathways	were	identified	as	well	as	an	increased	phosphorylation	of	the	enzyme	extracellular	signal-regulated	kinase	(ERK	1/2).	The	findings	of	this	study	may	further	our	understanding	of	the	underlying	pathogenic	pathways	leading	to	PD	and	LID.	Future	longitudinal	studies	are	needed	to	corroborate	the	usefulness	of	these	biomarker	candidates,	including	age	matched	healthy	controls,	more	patients	as	well	as	patients	with	more	severe	LID.				
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	1.2:	Dansk	resumé:	Parkinson’s	 sygdom	 (PS)	 er	 den	 næsthyppigste	 neurodegenerative	 lidelse	 efter	 Alzheimer’s	 sygdom.	Sygdommen	er	karakteriseret	ved	en	gradvis	udvikling	af	bevægeforstyrrelser	i	form	af	langsomme	bevægelser,	hvilerysten,	 rigiditet	 og	 postural	 instabilitet.	 Dette	 er	 relateret	 til	 en	 degeneration	 af	 dopaminerge	 neuroner	 i	substantia	nigra,	pars	compacta	(SNpc).	Udover	dette	lider	patienterne	også	af	tiltagende	autonome	symptomer	som	f.eks.	savlen,	urininkontinens,	forstoppelse	og	ortostatisk	hypotension.	Risikoen	for	PS	stiger	markant	med	alderen,	 og	 ca.1%	af	befolkningen	over	60	 år	har	PS.	Udviklingen	af	 sygdommen	kan	potentielt	 være	begyndt	mere	end	10	år	før	udviklingen	af	bevægeforstyrrelser,	da	mere	end	30%	af	de	dopaminerge	neuroner	i	SNpc	er	skadet	før	man	udvikler	bevægeforstyrrelser.	Der	findes	ingen	behandling,	som	kan	bremse	sygdommen,	og	den	bedste	symptomatiske	behandling	med	stoffet	L-DOPA,	som	erstatter	den	manglende	dopamin	i	striatum,	mister	gradvist	 sin	 effekt	 efter	 flere	 års	 behandling.	 Udover	 at	 patienterne	 begynder	 at	 opleve	 daglige	 markante	svingninger	 i	effekten	af	L-DOPA,	vil	de	også	udvikle	 flere	bivirkninger	 til	behandlingen.	Dette	er	blandt	andet	potentielt	invaliderende	ufrivillige	bevægelser,	kaldet	L-DOPA-inducerede	dyskinesier	(LID).	Samlet	set	er	der	et	behov	 for	 tidligere	 diagnosticering	 af	 PS,	 en	 bedre	 forståelse	 af	 patogenesen	 bag	 LID	 samt	 at	 identificere	patienter	med	risiko	for	at	udvikle	LID.				Målene	med	denne	afhandling	er:	1)	At	identificere	diagnostiske	biomarkør-kandidater	i	cerebrospinalvæsken	(CSV)	og	blodplasma		fra	patienter	med	PS.	2)	At	identificere	LID	biomarkør-kandidater		i	CSF	og	blodplasma	fra	patienter	med	PS.				I	dette	projekt	inkluderede	vi	26	patienter	med	PS	og	16	kontroller.	Udover	udtagning	af	CSV	og	blodprøvetagning	blev	PS-patienterne	også	klinisk	vurderet.	Dette	blev	gjort	vha.	en	vurderingsskala	for	sværhedsgraden	af	bevægeforstyrrelse	(MDS-UPDRS	part	III)	samt	sværhedsgraden	af	dyskinesi	(UDysRS	ojektiv	score).	Vurderingsskaler	for	kognitiv	formåen	blev	også	brugt	til	PS-patienterne	(MOCA,	MMSE).	8	PS-patienter	modtog	ikke	behandling	med	L-DOPA,	18	patienter		blev	behandlet	med	L-DOPA,	hvoraf	10	havde	LID.	Prøverne	blev	analyseret	ved	brug	af	high-performance	liquid	chromatography	(HPLC),	liquid	chromatography	mass	spectrometry	(LC-MS),	western	blotting,	enzyme	linked	immune-assays	(ELISA),	Multiplex	og	fluorescence-assays.		Flere	mulige	diagnostiske	biomarkør-kandidater	blev	identificeret:	Koncentrationen	af	proteinet	α-synuclein	(α-syn)	var	nedsat	i	CSV,	og	der	var	en	øget	α-syn	tetramer/monomer-ratio.	Aktiviteten	i	CSV	af	enzymet	glucocerebrosidase	var	markant	nedsat	hos	PS-patienter.	Ved	hjælp	af	den	muligt	præfibrillære	amyloide	markør,	L-Tryptophanol	(Trol),	fandt	vi	en	signifikant	nedsat	Trol-score	i	CSV	og	øget	Trol-score	i	plasma	hos	PS-patienter.		Både	CSV	Trol/plasma-Trol-ratio	og	CSV	Trol/CSV	total	protein-ratio	medførte	en	bedre	skelnen	mellem	PS	og	kontroller.	Koncentrationen	af	flere	katekolaminer	var	også	signifikant	nedsat	hos	PS-patienter,	som	ikke	fik	L-DOPA.	Patienter	med	LID	havde	signifikante	forandringer	i	tryptofan-	og	katekolamin-metabolismen	og	en	øget	fosforylering	af	enzymet	extracellular	signal-regulated	kinase	(ERK	1/2).		Disse	fund	kan	bidrage	til	en	bedre	forståelse	af	de	sygdomsmekanismer,	som	giver	PS	og	LID.	For	at	bekræfte	brugbarheden	af	disse	mulige	biomarkører	er	der	brug	for	longitudinelle	studier	inklusive	alders-matchede	raske	kontroller,	flere	PS-patienter	og	PS-patienter	med	mere	alvorlig	LID.	
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Chapter	2:	Introduction	
	
2.1	A	brief	historical	perspective:	
	200	 years	 ago,	 in	 1817,	 James	 Parkinson	wrote	 ”An	 essay	 on	 the	 shaking	 palsy”(Parkinson	2002).	He	discovered	a	pattern	of	symptoms	that	he	believed	encompassed	a	specific	disease	entity,	 the	 shaking	palsy,	which	 later	 came	 to	bear	his	name.	 In	 the	 essay	he	described	 the	insidious	onset	of	this	new	disease;	the	unilateral	mild	weakness	of	an	extremity	and	a	mild	resting	tremor.	And	during	progression,	he	noticed	a	bilateral	spread	of	symptoms,	a	marked	scarcity	of	movements,	small	handwriting	and	a	more	continuous	and	severe	resting	tremor	(”agitation	of	the	limbs”).	Patients	developed	a	gradually	more	pronounced	stooped	posture,	shuffling	 gait,	 tendency	 of	 falling,	 inability	 to	 stop	movements,	 drooling,	 sleep	 disturbance,	constipation,	 incontinence,	 dysarthria,	 and	 dysphagia	 rendering	 the	 patient	 completely	helpless	 in	 the	 latest	 stages	 of	 the	 disease.	 The	 inevitable	 fate	 of	 the	 patient	 is	 dismally	described:			“The	urin	and	faeces	are	passed	involuntarily;	and	at	the	last,	constant	sleepiness,	with	slight	delirium,	and	other	marks	of	extreme	exhaustion,	announce	the	wished-for	release.”		James	Parkinson	believed	 the	disease	 to	be	 inflammatory	of	origin,	potentially	beginning	 in	the	 superior	 part	 of	medulla	 spinalis,	 slowly	 progressing	 to	 involve	 the	medulla	 oblongata.	Contrary	to	future	findings,	he	did	not	believe	the	disease	to	involve	cortical	regions	and	did	not	 identify	 the	 cognitive	 deficiency	 that	 affects	 these	 patients.	 Maybe	 the	 severe	 motor	symptoms	of	the	untreated	patient	precluded	any	evaluation	of	cognitive	function.				
	
2.2	About	Parkinson’s	disease:	
	
2.2.1	Cardinal	symptoms	
	Whereas	 Parkinson	 saw	 resting	 tremor	 as	 one	 of	 the	main	 clinical	 features	 of	 Parkinson’s	disease	 (PD),	 the	 current	diagnostic	 criteria	 for	PD	allow	 for	 a	more	heterogeneous	 clinical	
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picture.	 In	 our	 systematic	 review	 of	 cerebrospinal	 fluid	 biomarkers(Andersen	 et	 al.	2016)(Appendix	 I),	 diagnostic	 criteria	 from	 several	 different	 authors	 have	 been	 used	 to	correctly	identify	PD	patients.	Often	cited,	and	also	used	in	this	project,	is	the	United	Kingdom	Brain	Bank	criteria	(UKBBC)	to	which	several	papers	are	cited(Gibb	&	Lees	1988,	Hughes	et	
al.	 1992,	 Daniel	 &	 Lees	 1993),	 albeit	 it	 seems	 Gibb	 et	 al	 were	 the	 first	 to	 produce	 the	criteria(Gibb	&	Lees	1988).	 In	the	UKBBC,	bradykinesia	 is	 the	main	cardinal	symptom	of	 the	disease	and	either	one	of	muscular	rigidity,	a	4-6	Hz	resting	tremor	or	postural	instability	is	required	 as	 a	 supplementing	 symptom.	 Exclusion	 criteria	 includes	 repeated	 stroke	 and	subsequent	 stepwise	 PD	 symptoms,	 repeated	 head	 injury,	 definite	 encephalitis,	 oculogyric	crisis,	 neuroleptic	 treatment	 at	 onset,	 >1	 affected	 relative,	 sustained	 remission,	 unilateral	symptoms	 after	 3	 years,	 supranuclear	 gaze	 palsy,	 cerebellar	 signs,	 early	 severe	 autonomic	signs,	 early	 severe	 dementia,	 Babinski’s	 sign,	 cerebral	 tumour	 or	 communicating	hydrocephalus,	 no	 L-DOPA-response,	 and	 neurotoxin	 exposure	 such	 as	 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	(MPTP).	For	a	definite	diagnosis	three	supportive	criteria	have	to	be	 fulfilled:	 Unilateral	 onset,	 resting	 tremor,	 progressive	 disease,	 persistent	 asymmetry,	excellent	response	(70-100%)	to	L-DOPA,	severe	L-DOPA-induced	chorea,	L-DOPA	response	>5	years,	or	a	clinical	course	>10	years.	One	of	the	main	differences	between	the	UKBBC	and	other	diagnostic	criteria	set	forth	(Koller	1992,	Calne	et	al.	1992,	Gelb	et	al.	1999),	 is	that	 in	the	latter	three	bradykinesia	is	not	viewed	upon	as	the	main	cardinal	feature	in	the	clinically	probable	 PD	 diagnosis.	 Calne	 et	 al(Calne	 et	 al.	 1992)	 even	 allows	 for	 a	 clinically	 definite	diagnosis	of	PD	without	the	occurrence	of	bradykinesia,	if	either	resting	tremor	or	rigidity	is	asymmetrical.	 After	 commencing	 this	 PhD	 project,	 the	 Movement	 Disorder	 Society	 has	produced	 a	 new	 set	 of	 more	 elaborate	 criteria	 for	 PD	 (Postuma	 et	 al.	 2015).	 Again,	bradykinesia	 (combined	 with	 either	 resting	 tremor	 or	 rigidity)	 is	 defined	 as	 the	 cardinal	symptom	 of	 PD,	 combining	 slowness	 of	 movement	 (bradykinesia)	 and	 gradually	 declining	amplitude	 during	 repetitive	 movements	 (hypokinesia/akinesia).	 New	 supportive	 criteria	include	clinically	established	olfactory	deficiency	or	 loss	of	 cardiac	 sympathetic	 innervation	indicated	by	the	use	of	iodine-123-meta-iodobenzylguanidine	(MIBG)	scintigraphy.	It	is	to	be	noted	that	abnormal	functional	neuroimaging	(such	as	the	much	used	dopamine	transporter	–	single	 photon	 emission	 computer	 tomography	 (DAT-SPECT))	 is	 not	 viewed	 upon	 as	 a	supportive	 criterion	 for	 PD,	 whereas	 a	 normal	 functional	 neuroimaging	 excludes	 the	 PD	diagnoses.	Also	red	flag	criteria	are	included	that	do	not	exclude	a	probable	PD	diagnosis	but	
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has	 to	 be	 counterbalanced	 by	 supportive	 criteria.	 An	 important	 red	 flag	 is	 the	 absence	 of	common	premotor	symptoms	after	5	years	of	disease	duration.	
	
2.2.2.	Demographics	
	A	systematic	review	of	incidence	studies(Twelves	et	al.	2003)	found	that	the	methods	used	in	the	studies	for	identifying	PD	patients	were	heterogeneous	and	oftentimes	insufficient.	Thus,	varying	 inclusion	 and	 exclusion	 criteria	 or	 unspecified	 criteria	 were	 used	 to	 diagnose	 PD	patients	in	the	base	populations;	sources	of	information	also	varied,	and	in	some	studies	none	of	the	patients	had	been	examined	as	part	of	the	study.	Incidence	definitions	also	varied.	Some	studies	used	time	of	diagnosis	and	others	used	time	of	symptom	onset.	Since	there	might	be	a	certain	delay	between	onset	of	symptoms	and	the	 first	contact	 to	a	health	care	professional	this	might	skew	the	incidence	figures.	The	methodologically	most	similar	studies(Granieri	et	
al.	 1991,	 Marttila	 &	 Rinne	 1976,	 Kuopio	 et	 al.	 1999,	 Mayeux	 et	 al.	 1995,	 MacDonald	 et	 al.	2000)	 in	 the	 systematic	 review(Twelves	 et	 al.	 2003)	 show	 a	 marked	 increase	 of	 yearly	incidence	in	the	+60	population,	with	the	highest	incidence	often	in	the	age	between	70	and	79	years,	and	an	average	yearly	incidence	varying	from	8-18/100.000/year.	According	to	the	Danish	 Movement	 Disorder	 Society	 (DANMODIS)(DANMODIS	 2017),	 there	 are	 5000-6000	patients	with	PD	in	Denmark.	It	has	been	suggested	that	men	are	more	prone	to	develop	PD	than	 women(Kessler	 1972).	 A	 large	 study	 including	 17,205	 elderly	 subjects	 from	 several	European	populations(de	Rijk	et	al.	1997)	did	not	find	a	marked	gender	difference,	apart	from	more	men	being	more	affected	after	the	age	of	80	years.	 It	has	to	be	noted,	though,	that	the	diagnostic	 criteria	 used	 in	 that	 study	 were	 not	 as	 rigid,	 with	 the	 possibility	 of	 identifying	subjects	as	having	PD	without	showing	bradykinesia.	In	the	study	the	overall	prevalence	for	elderly	between	65-69	years	was	0.9/100,	increasing	to	3.5/100	in	the	ages	85-89	years.	
	
	
	
	
2.2.3	Medical	treatment	of	Parkinson’s	disease	
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Figure	1:	A	depiction	of	the	metabolic	pathways	for	L-DOPA.		L-DOPA:	L-DOPA	is	the	precursor	to	the	neurotransmitter	dopamine	(DA).	Unlike	DA,	L-DOPA	has	the	ability	 to	 cross	 the	 blood	 brain	 barrier	 (BBB),	 being	 converted	 into	 DA	 in	 especially	dopaminergic	 neurons	 by	 decarboxylation	 (although	 other	 cell	 types	 also	 take	 up	 L-DOPA)(see	 figure	1).	Almost	50	years	after	 the	 initial	 study	using	L-DOPA	 treatment	on	PD	patients(Cotzias	1968),	it		continues	to	be	the	most	efficient	symptomatic	treatment	available	for	PD.	One	year	after	their	initial	discovery,	the	same	author	published	results	from	treating	PD	 patients	 with	 gradually	 increasing	 L-DOPA	 doses(Cotzias	 et	 al.	 1969).	 This	 provided	 a	sustained	response	in	PD	patients	in	terms	of	decreased	akinesia,	rigidity	and	tremor	as	well	as	 attenuation	 of	 autonomic	 dysfunction.	 In	 several	 cases	 patients	 even	 returned	 to	 work.	They	also	showed	psychological	improvements	in	terms	of	“amelioration	of	outlook,	interest	and	 behavior”,	 but	 in	 some	 cases	 also	 a	 marked	 mental	 improvement	 described	 as	 an	“awakening”(Cotzias	 et	 al.	 1969).	 The	 treatment	 responses	were	 not	 homogenous	 and	 side	effects	 occurred	 at	 a	 high	 rate.	 Many	 patients	 suffered	 from	 nausea,	 and	 it	 was	 quickly	hypothesized	that	a	stimulation	of	area	postrema,	which	is	not	protected	by	the	BBB,	was	due	to	 the	 peripheral	 L-DOPA-decarboxylation	 (approximately	 50-80%	 intestinal	decarboxylation)(Marsden	&	Donaldson	2012).	In	the	seventies	L-DOPA	drugs	combined	with	decarboxylase	inhibitors	benserazide	(Madopar®)	and	carbidopa	(Sinemet®,	which	literally	
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is	 latin	 for	 “without	 vomiting”)	 were	 introduced	 to	 avoid	 this	 issue(Marsden	 &	 Donaldson	2012).	The	decarboxylase	inhibitors	were	used	due	to	their	inability	to	cross	the	BBB,	and	this	combination	dramatically	increased	the	amount	of	L-DOPA	available	in	the	CNS.		
Figure	2:	The	three	graphs	show	the	changes	 in	L-DOPA	response	with	 increasing	disease	duration	as	well	as	 the	
advent	of	complications	due	to	L-DOPA	treatment	(Schapira	et	al.	2009).		
	
Motor	 complications	 were	 also	 noted	 in	 the	 early	 days	 of	 L-DOPA	 treatment(Cotzias	 et	 al.	1969),	 and	 affect	 the	 majority	 on	 chronic	 L-DOPA	 treatment(Ahlskog	 &	 Muenter	 2001).	Among	these	were	fluctuations	in	diurnal	response	to	L-DOPA.	Some	patients	in	Cotzias	study	suffered	from	the	abrupt	loss	of	treatment	effect,	leaving	them	hypo-	or	akinetic	for	minutes	to	hours	albeit	continuing	the	same	treatment	regimen.	These	“ON/OFF”-fluctuations	seemed	to	be	related	to	disease	duration	more	than	disease	severity.	As	can	be	seen	in	figure	2,	this	is	a	well	recognized	issue	related	to	L-DOPA	treatment	in	advanced	PD.	Initially	the	fluctuations	are	often	seen	as	a	“wearing	off”-effect	or	“end	of	dose”-deterioration,	but	in	more	advanced	stages	 fluctuations	 become	 more	 severe	 with	 abrupt	 development	 of	 akinesia	 in	 an	increasingly	 random	 pattern.	 Fluctuations	 might	 occur	 when	 insufficient	 dopaminergic	neurons	 remain	 to	 create	 a	 stable	 tonic	 DA	 stimulation.	 As	 discussed	 in	 (Andersen	 et	 al.	2017)(Appendix	 II)	 L-DOPA	 metabolism	 in	 other	 non-dopaminergic	 neurons	 might	 also	contribute	to	these	fluctuations,	as	well	as	post-synaptic	dopamine-receptor	changes.		
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L-DOPA-induced	 dyskinesia	 (LID)	 was	 also	 quickly	 noticed	 in	 the	 early	 days	 of	 L-DOPA	treatment,	initially	described	as	myclonic,	hemiballistic	and	choreic	movements(Cotzias	et	al.	1969).	Roughly	40%	of	patients	will	develop	some	degree	of	dyskinesia	after	4-6	years	of	L-DOPA-treatment,	 increasing	to	around	90%	after	even	longer	treatment	duration(Ahlskog	&	Muenter	2001).	When	LID	develops,	also	called	priming,	it	is	irreversible.	Risk	factor	for	LID	development	 include	 younger	 age	 at	 onset,	 larger	 L-DOPA-doses,	 female	 gender	 and	 lower	body	 weight;	 the	 last	 two	 pointing	 to	 an	 effect	 of	 L-DOPA	 dose	 per	 weight	 (Olanow	 et	 al.	2013).	 In	 general,	 dyskinesia	 is	 divided	 into	 three	main	 categories	 (Marsden	 &	 Donaldson	2012)(see	fig.	3):			
	
Figure	3:	Shows	the	different	types	of	dyskinesia.	The	y-axis	is	the	CNS	concentration	of	L-DOPA,	the	x-axis	is	time,	
and	the	dotted	line	indicates	effect	threshold.	The	asterisk	indicates	the	onset	of	dyskinesia/dystonia.		
	
Peak-dose	dyskinesia:	Choreic,	ballistic	or	stereotype	movements	occurring	when	the	L-DOPA	treatment	is	working	most	efficiently.	
Diphasic	dyskinesia:	 The	 same	movement	 pattern	 as	 peak-dose	 dyskinesia,	 but	 occurring	 at	the	beginning	and	ending	of	the	L-DOPA	effect	threshold.	
Off-dystonia:	 Often	 seen	 in	 the	morning,	when	 L-DOPA-plasma	 levels	 are	 low	 or	 zero,	with	painful	dystonia	in	the	feet.	Dystonia	might	also	be	seen	in	diphasic	dyskinesia.	Peak-dose	dyskinesia	is	not	as	disabling	as	diphasic	 dyskinesia,	 and	 patients	might	 not	 even	 be	 aware	 of	 their	 existence.	 On	 the	 other	hand	dyskinesia	can	be	so	severe	that	it	affects	or	prevents	performing	many	daily	activities.	As	noted,	ON/OFF-fluctuations	are	 frequent	 in	L-DOPA	treated	PD	patients,	and	dyskinesias	will	 successively	 increase	 in	 frequency.	Thus,	 the	primary	 treatment	 strategy	when	LID	has	occured	 involves	 adjusting	 L-DOPA	 treatment	 to	minimize	 fluctuations.	 Stabilizing	 L-DOPA	
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plasma	 levels	 might	 be	 done	 using	 the	 COMT-inhibitor	 entacapone	 (Nutt	 et	 al.	 1994)	(combined	with	L-DOPA	and	benserazid	 in	 the	drug	Stalevo®),	decreasing	 the	pulsatile	DA	distribution	pattern	due	to	an	increased	half	life	of	L-DOPA.	This	was	thought	to	attenuate	LID	(Marin	 et	 al.	 2006),	 but	 in	 the	 study	 STalevo	 Reduction	 In	 Dyskinesia	 Evaluation	 in	Parkinson’s	 Disease	 (STRIDE-PD)(Stocchi	 et	 al.	 2010)	 conversely	 patients	 treated	 this	 way	actually	had	an	increased	risk	of	LID.	The	 most	 frequently	 used	 drug	 against	 LID	 is	 the	 non-selective	 N-methyl-D-aspartate	(NMDA)-antagonist	 amantadine,	 which	 has	 been	 shown	 to	 significantly	 decrease	 the	subjective	experience	of	LID	(da	Silva-Junior	et	al.	2005)	as	well	as	attenuating	intravenous	L-DOPA	 induced	 peak-dose	 dyskinesia(Metman	 et	 al.	 1998).	 A	 study	 showed	 a	 sustained	response	at	1-year	follow	up(Metman	et	al.	1999),	in	contrast	to	a	maximal	8	month	effect	of	amantadine	on	LID	due	to	oral	L-DOPA(Thomas	et	al.	2004).		The	 continuous	 intestinal	 administration	 of	 L-DOPA	 (e.g.	 Duodopa®)	 leads	 to	more	 stable	plasma	 L-DOPA	 levels(Nyholm	 et	 al.	 2013).	 It	 not	 only	 seems	 to	 decrease	 OFF-time	 as	compared	to	immediate	release	L-DOPA,	but	also	increases	patient	reported	ON-time	without	troublesome	dyskinesia(Olanow	et	al.	2014,	Antonini	et	al.	2016).	This	indicates	that	pulsatile	L-DOPA	stimulation	contributes	to	LID,	which	will	be	discussed	later.	Alternatively,	 surgical	 intervention	 is	 also	 possible	 with	 a	 relatively	 low	 complication	rate(Chen	 et	al.	 2016).	 Apart	 from	 providing	 a	 significant	 increase	 in	motor	 function,	 deep	brain	stimulation	(DBS)	of	the	subthalamic	nucleus	(STN)	or	the	internal	globus	pallidus	(GPi)	also	 significantly	 decreases	 dyskinesia	 in	 advanced	 PD(Esselink	 et	al.	 2004,	 Anderson	 et	al.	2005,	Williams	 et	al.	 2010).	 The	 proposed,	 and	 quite	 complex,	 pathophysiology	 behind	 LID	will	be	discussed	in	the	section	“L-DOPA-induced	dyskinesia”.					Dopamine-agonists:	Drugs	such	as	pramipexole	and	ropinirole	work	directly	on	dopamine	receptors	and	do	not	require	 conversion	 to	 a	 functional	 substance.	 Although	 significantly	 less	 effective	 than	 L-DOPA,	 they	are	often	used	 in	 the	earlier	stages	of	 the	disease.	Due	 to	a	 longer	half-life	 they	deliver	a	more	sustained	therapeutic	response.	Using	DA-agonists	before	L-DOPA	delays	the	development	of	dyskinesia.	Side	effects	include	nausea,	orthostatic	hypotension,	various	types	of	mental	disturbances	as	well	as	the	risk	of	impulse	control	disorders.	Monoamine	oxidase-B-inhibitors:	
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The	 drugs	 selegiline	 and	 rasagiline	 provide	 irreversible	 MAO-B-selective	 inhibition,	 thus	decreasing	the	MAO-B-associated	metabolism	of	DA.	Pre-synaptic	DA	autoreceptors	are	also	blocked,	resulting	in	decreased	reuptake	of	DA.	Together,	this	increases	the	availability	of	DA.	The	drugs	can	be	used	in	early	disease	stages,	slowing	disease	progression	and	delaying	the	time	at	which	L-DOPA	treatment	is	necessary.			The	 fact	 that	 these	 drugs,	 used	 for	 more	 than	 40	 years,	 are	 still	 the	 most	 efficient	 drugs	available	 is	 quite	 remarkable,	 and	 there	 is	 a	 continuous	need	 for	 the	 development	 of	more	efficient	 treatment	 options.	 Essentially	 the	 development	 of	 disease	 modifying	 drugs	 that	might	slow	down	the	incessant	neurodegeneration	in	PD	is	much	needed.	
	
2.2.4	Parkinson’s	disease	and	neuropathology	
	Almost	a	hundred	years	after	 James	Parkinson’s	descriptions	of	 the	shaking	palsy,	Friedrich	Lewy	 in	1912	 identified	 cellular	 inclusions	 in	 the	neurons	of	patients	with	PD.	 Seven	years	later,	Konstantin	Tretiakoff,	who	coined	the	term	Lewy	body	(LB),	noticed	the	specific	damage	to	the	substantia	nigra	pars	compacta	(SNpc)	in	PD	(Holdorff	2002).	These	cellular	inclusion	became	one	of	the	neuropathological	hallmarks	of	PD(Dickson	et	al.	2009).	In	1997	Spillantini	et	 al(Spillantini	 et	 al.	 1997)	 identified	 the	 protein	 alpha-synuclein	 (α-syn)	 as	 the	 main	constituent	of	LB.	The	same	year	Polymeropoulos	et	al(Polymeropoulos	et	al.	1997)	identified	a	point	mutation	in	the	α-syn	gene	in	a	family	with	hereditary	PD,	underlining	the	importance	of	α-syn	in	the	PD	pathophysiology.	α-syn	will	be	described	in	detail	later	in	the	thesis.	The	progressive	character	of	the	disease	seems	also	to	be	reflected	in	the	neuropathological	findings.	 In	 a	much	 cited	 article	 from	2003,	Heiko	Braak	 and	 colleagues(Braak	et	al.	 2003),	using	 α-syn	 immunohistochemistry,	 investigated	 the	 brains	 of	 patients	 with	 incidental	 LB	disease.	 They	 identified	 a	 stereotypical	 pattern	 with	 which	 α-syn	 pathology	 spreads,	 and	proposed	6	stages	of	LB	pathology	related	to	the	progression	of	PD	(see	fig.4):			
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Fig.	4:	Progressive	Lewy	Body	(LB)	aggregation	as	proposed	by	Heiko	Braak.	Notice	the	initial	involvement	of	lower	
brain	stem	structures	and	the	olfactory	bulb,	only	in	later	stages	involving	the	substantia	nigra	pars	compacta.	LB	
pathology	in	cortical	regions	entails	the	onset	of	cognitive	impairment	(Olanow	et	al.	2009).	
	
Stages	1	and	2	are	thought	to	be	the	preclinical	stages	of	neurodegeneration:	Initially	LB	and	Lewy	neurites	(LN)	are	found	in	the	dorsal	glossopharyngeal	and	vagal	motor	nucleus	(DMV),	progressing	 in	 stage	 2	 to	 involve	 pontine	 structures	 such	 as	 the	 raphe	 nuclei,	 the	 reticular	substance	and	the	coeruleus-subcoeruleus	complex.				
Stages	3	and	4	mark	the	beginning	of	the	clinical	stage	of	the	disease.	The	occurrence	of	LB	in	melanin-laden	 cells	 progresses,	 and	 mesencephalic	 affection	 is	 now	 evident	 in	 the	 SNpc.	Differing	stages	3	and	4	is	the	initial	involvement	of	mesocortical	areas,	the	macroscopically	recognizable	 depigmentation	 in	 the	 SNpc,	 and	 involvement	 of	 magnocellular	 nuclei	 just	ventral	of	the	basal	ganglia.	
Stages	5	and	6	 are	 characterised	 by	 the	 involvement	 of	 neocortical	 regions.	 From	 a	 severe	affection	 of	 the	 olfactory	 area	 in	 stage	 5,	 stage	 6	 shows	 affection	 of	 almost	 the	 entire	neocortex.		The	 proposed	 staging	 has	 been	 validated	 in	 more	 recent	 studies(Dickson	 et	 al.	 2010,	Kingsbury	 et	 al.	 2010,	 Parkkinen	 et	 al.	 2008).	 Conversely	 one	 study	 criticized	 the	 use	 of	asymptomatic	subjects	with	LB	pathology,	since	it	could	be	questioned	whether	these	subjects	would	 develop	 symptoms	 or	 PD	 at	 all(Kalaitzakis	 et	 al.	 2008).	 In	 that	 study,	 47%	 of	 the	included	PD	patients	did	not	fit	the	rostro-caudal	progression	model,	24%	showed	no	marked	DMV	 affection	 despite	 severe	 SNpc	 affection,	 and	 7%	 did	 not	 show	 affection	 of	 the	 DMV	despite	α-syn	aggregation	in	SNpc(Kalaitzakis	et	al.	2008).	Also,	60%	of	patients	without	DMV	involvement	 had	 α-syn	 lesions	 in	 the	 spinal	 chord	 (SC).	 This	 clearly	 contests	 the	 idea	 of	 a	consistent	medullary	origin	of	α-syn	pathology	in	the	PD	CNS.		
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Interestingly,	 progressive	 α-syn	 pathology	 regardless	 of	 clinical	 appearance	 does	 not	necessarily	correlate	with	extrapyramidal	symptoms	(as	expected	when	SNpc	is	affected)	or	cognitive	decline	(as	expected	when	cortical	α-syn	pathology	is	widespread)(Parkkinen	et	al.	2008).	 It	might	be	 that	 LB	 in	 itself	 does	not	 correlate	well	with	 cell	 damage.	Affirming	 this	notion,	 a	 study(Kalia	 et	 al.	 2015)	 reviewing	 several	 neuropathological	 studies(Ross	 et	 al.	2006,	 Gomez	 &	 Ferrer	 2010,	 Gaig	 et	 al.	 2008,	 Giasson	 et	 al.	 2006,	 Vitte	 et	 al.	 2010,	Poulopoulos	et	al.	2012,	Hasegawa	et	al.	2009,	Ujiie	et	al.	2012,	Wszolek	et	al.	1997,	Khan	et	al.	2005,	Puschmann	et	al.	2012,	Giordana	et	al.	2007,	Rajput	et	al.	2006,	Goldwurm	et	al.	2006,	Ruffmann	et	al.	 2012,	Gaig	et	al.	 2007,	Ling	et	al.	 2013,	Marti-Masso	et	al.	 2009)	of	patients	with	the	hereditary	PARK8	mutation	of	the	leucine-rich	repeat	kinase	2	(LRRK2)	gene	found	that	 several	patients	did	not	have	marked	LB	pathology	despite	having	motor	symptoms.	 It	seems,	though,	that	non-motor	features	such	as	cognitive	impairment,	anxiety	and	orthostatic	hypotension	were	more	prevalent	 in	patients	with	relevant	LB	pathology(Kalia	et	al.	2015).		In	parkin	gene	(PARK2)	related	hereditary	PD,	neuropathological	examinations	do	not	show	LB	accumulation	despite	nigral	degeneration	(Doherty	et	al.	2013);	these	patients	suffer	from	an	earlier	onset	of	PD.	Maybe	LB	generation	could	actually	be	a	resort	for	removing	otherwise	damaging	proteins	when	other	degradation	pathways	are	insufficient,	and	maybe	the	creation	of	LB	is	ubiquitine	dependent?			
A	peripheral	or	central	trigger?	
	Several	 studies	 have	 also	 focused	 on	 peripheral	 α-syn	 aggregation	 in	 PD,	 identifying	phosphorylated	 α-syn	 in	 submandibular	 glands(Beach	 et	 al.	 2013),	 α-syn	 in	 salivary	glands(Cersosimo	et	al.	2011),	intraneuronal	phosphorylated	α-syn	in	skin	biopsies	(Donadio	
et	al.	2016),	α-syn	and	LB	in	the	olfactory	bulb(Daniel	&	Hawkes	1992,	Beach	et	al.	2009),	and	intraneuronal	α-syn	aggregation	 in	 the	enteric	nervous	 system	 (ENS)	of	 the	gastric	mucosa	(Sanchez-Ferro	et	al.	 2015,	Braak	et	al.	 2006).	REM-sleep	behaviour	disorder	 (RSBD)	 in	 the	setting	 of	 a	 degenerative	 dementia	 or	 Parkinsonism	 disorder	 is	 highly	 indicative	 of	 a	synucleinopathy	 (Boeve	 et	 al.	 2001),	 and	 RSBD	 itself	 poses	 a	 10	 year	 risk	 of	 75%	 for	developing	a	neurodegenerative	disorder(Iranzo	et	al.	2014).	A	study	found	phosphorylated	α-syn	 (p-α-syn)	 skin	 deposits	 (especially	 in	 autonomic	 fibres)	 in	 PD	 patients	 (sensitivity	80%),	in	RSBD	patients	(sensitivity	55.6%),	and	in	no	controls	(specificity	100%)	(Doppler	et	
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al.	 2017).	 In	 RSBD	 p-α-syn-deposits	 even	 correlated	 with	 olfactory	 deficiency	 and	 the	probability	 of	 prodromal	 PD	 (Doppler	 et	 al.	 2017).	 α-syn	 can	 spread	 from	 neuron	 to	neuron(Danzer	et	al.	2012,	Masuda-Suzukake	et	al.	2014),	and	it	has	been	hypothesized	that	synucleinopathies	 (such	 as	 PD,	 Lewy	 Body	 Dementia	 (DLB)	 and	 multiple	 system	 atrophy	(MSA))	 are	 to	 a	 certain	 extent	prion	 like	disorders(George	et	al.	 2013,	Dunning	et	al.	 2013,	Ugalde	et	al.	2016).	But	it	does	not	tell	us	where	protein	aggregation	occurs	initially.	Does	the	detrimental	process	begin	in	the	PNS,	just	to	propagate	to	the	CNS?	Some	evidence	points	to	a	peripheral	trigger:	Hyposmia(Ross	et	al.	2008)	as	well	as	constipation(Schrag	et	al.	2015)	are	well-known	 premotor	 symptoms	 of	 PD,	 pointing	 to	 a	 potential	 olfactorial	 or	 ENS	 affection	prior	to	damage	of	the	SNpc.	Exposure	to	environmental	toxins	such	as	pesticides	significantly	increases	the	risk	of	developing	PD(Gorell	et	al.	1998).	Water	consumption	from	private	wells	also	correlates	with	PD	development.	These	wells	are	shallower	and	therefore	more	likely	to	be	exposed	to	ground	toxins.	A	well-known	PD	animal	model	(Pan-Montojo	et	al.	2012)	was	made	 by	 oral	 administration	 of	 rotenone.	 This	 environmental	 toxin	 promoted	 α-syn	aggregation	 in	 the	 ENS,	 with	 progressing	 α-syn	 pathology	 to	 the	 DMV,	 and	 vagotomy	decreased	 the	 severity	 of	 α-syn	 aggregation.	 In	 the	 same	 paper	 they	 found	 a	 retrograde	transport	of	α-syn	in	sympathetic	neurons	connected	to	rotenone	treated	ENS	cells,	all	in	all	indicating	a	potential	spread	of	α-syn	through	sympathetic	and	parasympathetic	fibres	due	to	rotenone	exposure	(Pan-Montojo	et	al.	2012).	Findings	from	a	Danish	register	study	also	seem	to	 corroborate	 the	 notion,	 showing	 a	 decreased	 incidence	 of	 PD	 in	 truncally	 vagotomised	patients	compared	to	age	matched	controls	(Svensson	et	al.	2015).		However,	an	animal	study	has	 shown	 that	 after	 viral	 vector	 mediated	 over-expression	 of	 human	 α-syn	 in	 the	mesencephalon,	α-syn	proteins	spread	to	cholinergic	fibres	in	the	DMV	to	preganglionic	vagal	projections	 of	 the	 myenteric	 plexus(Ulusoy	 et	 al.	 2016).	 This	 could	 warrant	 a	 disease	mechanism	with	central	onset,	spreading	to	the	PNS	through	the	vagal	nerve.		Several	disease	mechanisms	are	involved	in	the	onset	of	PD	(as	will	be	described	later),	which	could	explain	the	 differences	 found	 in	 neuropathological	 studies.	 It	 might	 be	 prudent	 to	 view	 PD	 as	 a	symptomatic	 diagnosis	 with	 several	 neuropathological	 pathways,	 whose	 only	 common	denominator	so	far	seems	to	be	the	marked	degeneration	of	SNpc.	
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2.3	Biomarkers:	
	Since	 this	 thesis	 specifically	deals	with	 the	use	of	biomarkers,	 I	will	 try	 to	describe	what	 is	actually	 meant	 by	 that	 term.	 The	 National	 Institutes	 of	 Health	 Director’s	 Initiative	 on	Biomarkers	and	Surrogate	Endpoints	chose	to	define	a	biomarker	as	“a	characteristic	that	is	objectively	 measured	 and	 evaluated	 as	 an	 indicator	 of	 normal	 biological	 processes,	pathogenic	processes,	or	pharmacologic	responses	to	a	therapeutic	intervention”(Biomarkers	Definitions	 Working	 2001).	 	 Thus,	 biomarkers	 can	 be	 used	 for	 diagnosis,	 disease	 staging,	disease	 prognosis	 indication	 and	 monitoring	 of	 clinical	 response	 (Biomarkers	 Definitions	Working	2001).	The	degeneration	of	SNpc	is	pivotal	for	PD,	and	biomarkers	that	in	some	way	reflect	the	degeneration	of	SNpc	may	be	the	most	optimal	diagnostic	biomarker,	but	since	the	disease	process	are	initiated	way	earlier,	it	might	be	seen	as	a	quite	late	diagnostic	biomarker.	On	 the	 other	 hand,	 the	 further	 away	 focus	 is	 moved	 from	 this	 main	 feature	 of	 SNpc-degeneration,	the	less	certain	we	are	that	a	biomarker	is	a	common	feature	for	all	PD	patients	or	even	PD	as	a	disease	entity	(see	fig.8).		
	
	
	
Figure	 8:	 A	 schematic	
depiction	 of	 the	 challenges	 in	
biomarker	 research.	 Early	
biomarker	 candidates	 for	 PD	
may	 be	 affected	 in	 other	
neurodegenerative	 diseases	
(overlap	 coloured	 green),	 and	
there	 may	 be	 many	 potential	
disease	 triggers.	 Focusing	 on	
early	 biomarker	 candidates	
may	 require	 a	 broader	 focus,	
such	 as	 metabolomics.	 The	
heterogeneous	 disease	
processes	 probably	 converge	
to	 	 the	 endpoint.	 PD;	
Parkinson’s	disease.		
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Also	relevant	for	this	study	is	the	use	of	surrogate	endpoints,	described	as	“A	biomarker	that	is	 intended	to	substitute	 for	a	clinical	endpoint.	A	surrogate	endpoint	 is	expected	to	predict	clinical	 benefit	 (or	 harm	 or	 lack	 of	 benefit	 or	 harm)	 based	 on	 epidemiologic,	 therapeutic,	pathophysiologic,	 or	 other	 scientific	 evidence”(Biomarkers	Definitions	Working	 2001).	 This	thesis	 focuses	 on	 the	 effect	 of	 L-DOPA	 on	 the	 development	 of	 L-DOPA-induced	 dyskinesia	(LID),	 identifying	potential	 surrogate	 endpoints	 for	LID.	The	use	of	 the	 term	 “validation”	 in	that	 context	 is	 being	 questioned(Biomarkers	 Definitions	 Working	 2001,	 Strimbu	 &	 Tavel	2010).	The	most	uncompromising	 interpretation	of	 the	 term	validation	would	 imply,	 e.g.	 in	regards	to	LID,	that	LID	surrogate	biomarkers	identified	represent	all	known	mechanisms	by	which	L-DOPA	is	able	to	induce	LID.	It	is	well	known,	and	will	be	discussed	later	in	this	thesis,	that	 LID	 is	 a	multifactorial	 complex	 side	 effect(Jenner	 2008,	Huot	 et	al.	 2013,	 Bastide	 et	al.	2015);	as	such	the	term	validation,	if	used	e.g.	in	regards	to	stating	that	studies	are	needed	to	validate	our	findings,	should	be	interpreted	as	an	evaluation	rather	than	validation.	Probably	applicable	for	both	PD	diagnostic	biomarkers	and	LID	surrogate	endpoints	is	the	notion	that	“the	 use	 of	 multiple	 biomarkers	 that	 represent	 various	 components	 of	 complex	 disease	pathways”(Biomarkers	Definitions	Working	2001)	will	generate	a	more	complete	estimate.		
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Chapter	4:	Aims	of	the	study	and	hypothesis	
	
4.1	Aims:	In	this	project	there	were	two	major	aims.		1. To	evaluate	biomarker	candidates	for	diagnosing	Parkinson’s	disease.	2. To	evaluate	biomarker	candidates	representing	LID.	Included	in	these	aims	is	also	the	idea	of	further	elucidating	the	complex	underlying	processes	involved	in	both	the	disease	itself	but	also	LID.			
4.2.	Hypothesis:	By	 analysing	 certain	 proteins,	metabolites	 and	 enzyme	 activities	 in	 CSF	 and	 blood	 samples	from	PD	patients,	including	patients	suffering	from	LID,	it	is	possible	to	not	only	differentiate	patients	 from	controls,	but	also	to	 identify	dyskinetic	PD	patients	due	to	specific	changes	 in	certain	metabolic	pathways.		The	 distinct	 biomarker	 studies	 in	 this	 thesis	 are	 involved	 in	 both	 of	 these	 aims.	 Instead	 of	individually	 describing	 the	 studies,	 this	 thesis	 subdivides	 the	 biomarker	 results	 and	biomarker	discussion	section	 into	 the	 two	major	 issues:	Diagnosing	PD	and	 identifying	LID.	Thus,	the	methods	section	will	be	a	walkthrough	of	all	methods	used	during	the	project.	In	the	results	and	discussion	section	I	have	summarized	the	most	important	findings	from	our	articles	 and	manuscript	 (see	 appendix	 I-IV).	 Some	 results	will	 be	 discussed	 in	more	 detail,	since	they	are	not	included	in	the	manuscripts	(GCase,	VEGF,	α-syn).		To	 understand	 the	 rationale	 behind	 the	 choice	 of	 biomarker	 candidates	 in	 the	 thesis,	 it	 is	important	 to	understand	 the	proposed	underlying	pathophysiological	 pathways	 involved	 in	PD	 and	 LID.	 Although,	 from	 a	 pragmatic	 viewpoint,	 any	 biomarker	 that	 specifically	 and	sensitively	 separates	 PD	 from	 controls	 or	 identifies	 LID	 would	 be	 useful,	 even	 if	 the	underlying	 mechanisms	 were	 not	 fully	 understood.	 In	 the	 following	 chapter,	 I	 will	 briefly	discuss	 the	pathophysiological	 pathways	proposed	 in	PD	 and	 in	 the	development	 of	 LID	 as	
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well	as	the	biomarker	studies	focusing	on	these	pathways,	identified	in	our	systematic	review	(Andersen	et	al.	2016)(Appendix	I)	
Chapter	5:	Pathophysiology	and	current	knowledge	in	biomarker	
research	
	
5.1	Biomarkers	for	diagnosing	Parkinson’s	disease:	
	
5.1.1	Preface	
	
“In	most	cases,	especially	in	those	in	which	the	disease	has	been	allowed	to	exist	long	unopposed,	
it	 may	 be	 found	 that	 all	 that	 art	 is	 capable	 of	 accomplishing,	 is	 that	 of	 checking	 its	 further	
progress”	–	James	Parkinson	(1817)	
	Two	important	aspects	with	regards	to	diagnosing	PD	have	to	be	pointed	out:	
Firstly,	 motor	 symptoms	 of	 PD	 occur	 late	 in	 the	 disease	 process.	 One	 study	 found	 a	 31%	degeneration	 of	 dopaminergic	 neurons	 in	 the	 SNpc	 prior	 to	 the	 development	 of	 motor	symptoms,	 and	 following	 the	 advent	 of	 motor	 symptoms	 an	 exponential	 cell	 loss	 not	accounted	for	by	age	(Fearnley	&	Lees	1991).	Interestingly	it	is	noted	that	80%	of	DA	in	the	striatum	 is	 lost	 before	 the	patient	develops	motor	 symptoms(Marsden	1990),	 pointing	 to	 a	dysfunction	 of	 the	 remaining	 dopaminergic	 neurons.	 As	 mentioned	 before	 it	 has	 become	evident	that	pre-motor	features	such	as	olfactory	deficiency,	constipation,	and	RSBD	are	quite	prevalent,	 pointing	 to	 a	 pre-substantia	 nigra	 disease	 activity	 of	 the	 nervous	 system	 in	 the	olfactory	 bulb,	 the	 ENS	 or	 the	 brain	 stem	 respectively.	 Even	 regional	 pain	 symptoms	 can	precede	 the	motor	 symptoms.	 Taken	 together,	 this	means	 that	 it	 is	 potentially	 possible	 to	diagnose	patients	prior	 to	 the	development	of	motor	symptoms	and	 thus	prior	 to	 the	more	pronounced	degeneration	of	dopaminergic	neurons.	
Secondly,	misdiagnosis	in	a	clinical	setting	is	common.	A	metaanalysis	found	a	79.6%	accuracy	of	 expert	 clinical	 diagnosis,	 rising	 to	 83.9%	 at	 follow	 up,	 with	 non-experts	 performing	poorer(Rizzo	et	al.	2016).	In	the	same	review	atypical	Parkinsonian	syndromes	(APD),	such	as	the	 synucleinopathies	 (diseases	 proposed	 to	 be	 caused	 by	 α-syn	 aggregation)	 Lewy	 Body	
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dementia	 (DLB)	 and	 multiple	 system	 atrophy	 (MSA)	 as	 well	 as	 the	 tauopathy	 (diseases	proposed	to	be	caused	by	tau	accumulation)	progressive	supranuclear	palsy	(PSP)	were	often	alternative	diagnoses(Rizzo	et	al.	2016).	MSA	(Ahmed	et	al.	2012)	and	PSP(Steele	et	al.	2014)	have	 several	 symptoms	 that	 distinguish	 them	 from	 PD	 especially	 in	 later	 stages	 such	 as	 a	more	rapid	development	and	 little	 to	no	effect	of	L-DOPA	treatment.	DLB	patients	can	have	Parkinsonian	 motor	 symptoms	 but	 DLB	 is	 characterized	 by	 early	 and	 rapidly	 evolving	dementia	 due	 to	 cortical	 affection	 (Mueller	 et	 al.	 2017).	 Quite	 arbitrarily	 the	 distinction	between	DLB	and	Parkinson’s	disease	dementia	(PDD)	has	been	made	according	to	the	timing	of	dementia.	If	patients	develop	dementia	prior	to	or	within	a	year	of	developing	Parkinsonian	motor	 symptoms,	 they	 are	 diagnosed	 as	 having	 DLB	 (McKeith	 2006).	 The	 new	 diagnostic	criteria	 from	 the	 Movement	 Disorder	 Society	 refute	 this	 distinction(Postuma	 et	 al.	 2015),	advocating	for	labelling	patients	as	“PD	(dementia	with	Lewy	bodies	subtype)”.	These	 two	 points	 are	 important	 because:	 If	 a	 sufficiently	 sensitive	 and	 specific	 diagnostic	biomarker	 for	 PD	 could	 be	 developed,	 investigating	 these	 biomarkers	 on	 people	 with	suspected	 PD	 premotor	 symptoms	 would	 allow	 for	 an	 early	 diagnosis	 and	 intervention,	 if	disease	 modifying	 drugs	 are	 developed.	 This	 would	 be	 essential	 for	 the	 development	 of	disease	 modifying	 treatments.	 And	 if	 the	 biomarker	 candidates	 even	 showed	 specificity	towards	 PD	 compared	 to	 APD,	 misdiagnosis	 could	 be	 limited.	 In	 this	 thesis	 we	 have	 not	included	any	patients	with	APD,	except	 from	one	patient	 suffering	 from	DLB.	Therefore	 the	issue	of	misdiagnosis	will	not	be	further	elucidated	in	this	thesis,	but	discussed	in	the	closing	remarks.		In	our	systematic	review(Andersen	et	al.	2016)	we	found	that	CSF	biomarker	studies	focused	on	the	main	aspects	neurotransmitters,	oxidative	stress	markers,	inflammatory	markers	and	proteins	involved	in	PD	pathology.	The	diversity	of	biomarker	candidates	clearly	reflects	that	PD	is	a	multifactorial	complex	disorder	with	many	potential	pathogenic	pathways.	Initially,	I	will	provide	a	brief	overview	of	known	pathological	pathways.	Pathways	related	to	biomarker	candidates	 involved	 in	 this	 thesis	will	be	described	 in	more	detail.;	either	 in	 this	section	or	in	appendix	I-IV.		
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5.1.2	α-synuclein:	
	
	
Figure	 5:	 A	 schematic	 representation	 of	 the	 alpha-synuclein	 protein.	 The	N-terminal	 is	marked	 in	 blue,	 the	 non-
Amyloid	 β-component	 (NAC)	 colored	 orange	 and	 the	 C-terminal	 colored	 red.	 Alpha-synuclein	 proteins	
phosphorylated	at	the	serine	129	residue	make	up	a	large	part	of	Lewy	Bodies,	and	the	phosphorylation	takes	place	
in	the	C-terminal.	From	(Gallegos	et	al.	2015).	
	This	140	aminoacid	protein	seems	to	link	together	several	putative	PD	disease	pathways	such	as	mitochondrial	dysfunction,	 lysosomal	 and	proteasomal	dysfunction,	 oxidative	 stress,	 and	dopamine	toxicity,	as	discussed	in	reviews	(Moore	et	al.	2005,	Dev	et	al.	2003).	The	protein	is	present	 in	 presynaptic	 terminals.	 Its	 functions	 are	 related	 to	 synaptic	 plasticity	 as	 well	regulating	 vesicular	 trafficking(Outeiro	 &	 Lindquist	 2003),	 and	 it	 seems	 to	 regulate	presynaptic	DA	release(Larsen	et	al.	2006).	Mutations	in	the	α-syn	gene	are	related	to	familial	PD	(PARK1	&	PARK	4)(Polymeropoulos	et	al.	1997,	Singleton	et	al.	2003).	Overexpression	of	α-syn	 and	 the	 subsequent	 conformational	 changes	 such	 as	 oligomerization	 of	 α-syn	 are	related	to	the	PD	pathogenesis.	It	is	shown	to	inhibit	macroautophagy	(Winslow	et	al.	2010),	induce	 lipid	and	ubiquitin	accumulation,	 and	decrease	cell	 growth	and	proteasomal	activity	(Outeiro	&	Lindquist	2003,	Snyder	et	al.	2003).	It	also	induces	oxidative	stress	and	decreases	mitochondrial	 activity	 (Hsu	 et	al.	 2000).	 Subspecies	 of	 oligomeric	 α-syn	 also	 increase	 Ca2+-influx	 potentially	 inducing	 inositol	 3-phosphate	 (IP3)	 related	 apoptosis(Danzer	 et	 al.	 2007,	Angelova	et	al.	2016).		Posttranslational	modifications	of	α-syn	might	play	a	 role	 in	 the	pathogenesis:	Lewy	bodies	consist	 greatly	 of	 phosphorylated	 α-syn	 (e.g.	 phosphorylated	 serine	 129)(Fujiwara	 et	 al.	
Cerebrospinal	fluid	biomarkers	for	Parkinson’s	disease	and	L-DOPA-induced	dyskinesia	
	 28	
2002)	as	well	as	nitrated	α-syn(Giasson	et	al.	2000),	and	nitrosative	stress	has	been	shown	to	induce	aggregation	of	nitrated	α-syn(Paxinou	et	al.	2001).		Results	of	α-syn	biomarker	studies	are	discussed	in	detail	in	both	our	review(Andersen	et	al.	2016)(Appendix	I)	and	the	L-Tryptophanol	(Trol)	manuscript	(Appendix	IV).		
5.1.3	The	complex	interplay	between	oxidative	stress,	mitochondrial	dysfunction	and	
proteasomal	dysfunction:	
	CNS	neurons	have	a	very	high	metabolic	rate,	and	therefore	also	a	high	production	of	reactive	oxygen	species	(ROS)	due	to	the	synaptic	connectivity	and	recovery	from	glutamate	induced	action	 potentials	 as	 well	 as	 mitochondrial	 activity	 (Attwell	 &	 Laughlin	 2001).	 Especially	dopaminergic	neurons	are	intrinsically	exposed	to	higher	levels	of	ROS	due	to	DA	metabolism	(discussed	 in	detail	 in	appendix	 II	 (Andersen	et	al.	2017)).	Neurons	are	provided	with	high	amounts	of	glutathione	(GSH)	precursors	by	astrocytes(Dringen	et	al.	2000),	that	also	contain	high	levels	of	vitamin	E	(Makar	et	al.	1994)	with	the	ability	to	prevent	ROS	from	ravaging	the	cell	through	lipid	peroxidation,	DNA	damage	etc.	Our	review	(Appendix	I,	(Andersen	et	al.	2016))	found	that	CSF	biomarker	studies	focusing	on	oxidative	stress	revealed	differences	in	PD	CSF	compared	to	controls.	This	includes	increased	lipid	 peroxidation,	 increased	 concentrations	 of	 nitrates,	 and	 decreased	 coeruloplasmin	ferroxidase	 and	 Cu/Zn-superoxide	 dismutase	 activity(Boll	 et	 al.	 2008).	 Also	 a	 more	 rapid	production	 of	 advanced	 oxidized	 protein	 products	 (Garcia-Moreno	 et	 al.	 2013),	 decreased	glutathione	 S-transferase	 Pi	 activity(Maarouf	 et	 al.	 2012),	 increased	 levels	 of	 nitrotyrosine	products(Fernandez	 et	 al.	 2013),	 and	 8-hydroxyguanosine(Abe	 et	 al.	 2003,	 Kikuchi	 et	 al.	2002)	has	been	found	in	PD	CSF.	DJ-1	functions	as	a	“sensor	of	oxidative	stress”,	protects	the	cell	 from	 oxidative	 stress	 by	 acting	 as	 a	 ROS	 scavenger	 (Xu	 &	 Moller	 2010),	 protects	mitochondria	 from	 oxidative	 stress	 (Hao	 et	 al.	 2010),	 and	 in	 its	 slightly	 oxidized	 state	prevents	α-syn	fibrillation	by	working	as	a	redox-responsive	molecular	chaperone	(Zhou	et	al.	2006).	Mutations	in	the	DJ-1	gene	are	related	to	autosomal	recessively	inherited	early	onset	PD	 (PARK7)(Bonifati	et	al.	 2003).	A	decrease	 in	DJ-1	would	mitigate	oxidative	 stress,	 and	a	decrease	 of	 DJ-1	 has	 been	 found	 in	 PD	 CSF(Hong	 et	 al.	 2010).	 Interestingly	 it	 seems	 that	oxidative	stress	may	be	more	pronounced	in	early	PD,	as	discussed	in	our	review.	Maybe	the	initially	well	 functioning	cellular	machinery	 (and	 thus	a	high	production	of	ROS),	 combined	
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with	the	PD	trigger	mechanism	(such	as	oligomeric	α-syn)	results	in	higher	levels	of	oxidative	stress	in	early	PD.							Parkin	 is	a	ubiquitin	 ligase	 involved	 in	ubiquitin-dependent	proteasomal	activity.	Mutations	on	 the	 Parkin	 gene	 (PARK2)	 is	 related	 to	 autosomal	 recessively	 inherited	 early	 onset	 PD	(Kitada	et	al.	1998).	Oxidative	stress	causes	Parkin	misfolding	(Winklhofer	et	al.	2003)	which	affects	normal	proteasomal	functioning.			To	 link	 oxidative	 stress	 and	 mitochondrial	 function,	 I	 will	 initially	 mention	 the	 interplay	between	Parkin	and	the	phosphatase	and	tensin	homolog-induced	putative	kinase-1	(PINK1).	PINK1-mutations	 are	 related	 to	 autosomal	 recessively	 inherited	 PD	 (PARK6)(Valente	 et	 al.	2004).	PINK1	is	a	mitochondrial	kinase	that	recruits	Parkin,	marking	damaged	mitochondria	for	destruction	(mitophagy)(Narendra	et	al.	2010),	thereby	maintaining	a	high	mitochondrial	quality	(Pickrell	&	Youle	2015).	Decreased	mitophagy	would	decrease	mitochondrial	function,	which	can	lead	oxidative	stress,	decreased	proteasomal	function	and	α-syn	aggregation	(Ryan	
et	al.	2015).	Decreased	mitochondrial	functioning	due	to	complex-I	inhibition	of	the	electron	transfer	chain	is	a	well	known	effect	of	toxins	such	as	paraquat,	MPTP	and	rotenone,	that	are	all	related	to	the	development	of	PD,	selectively	damaging	dopaminergic	neurons(Bove	et	al.	2005).		
	
5.1.4	Lysosomal	dysfunction:	
	In	 the	most	 common	 autosomal	 recessively	 inherited	 lysosomal	 storage	 disease,	 Gaucher’s	disease	(GD),	a	mutation	occurs	in	the	glucocerebrosidase	gene	(GBA1)	coding	for	the	enzyme	glucocerebrosidase(Hruska	 et	 al.	 2008).	 Symptoms	 generally	 include	 hepatosplenomegaly,	thrombocytopenia,	 bone	 disease	 and	 tendency	 of	 bleeding(Thomas	 et	 al.	 2014),	 but	 the	clinical	 presentation	 is	 very	 heterogeneous	 in	 terms	 of	 symptoms	 and	 age	 at	 disease	 onset	with	 over	 200	 known	 existing	mutations	 in	 the	 GBA1	 gene(Hruska	 et	 al.	 2008).	 A	 general	distinction	can	be	made	between	three	types	of	GD:		
Type	 I	 (non-neuropathic)	generally	 involves	 the	aforementioned	organ	and	bone	affections	(Thomas	 et	 al.	 2014),	whereas	 type	 II	 (acute	 neuropathic)	manifests	 in	 early	 infancy	with	many	symptoms	like	type	I	but	also	involving	aggressive	neurodegeneration	(bulbar	affection,	opisthotonus,	seizures)	with	lethal	outcome	within	the	first	years	of	life.	Type	III	(neuropatic)	does	 cause	 in	 neurological	 symptoms,	 such	 as	 slowing	 of	 horizontal	 eye	 movements,	
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myoclonic	 epilepsy	 and	 sometimes	 cognitive	 impairment,	 but	 neurodegeneration	 is	 less	aggressive	 compared	 to	 type	 II	 with	 patients	 surviving	 into	 their	 third	 or	 fourth	decade(Erikson	et	al.	1997).		For	more	than	a	decade(Aflaki	et	al.	2017),	a	correlation	between	GD	and	PD	has	been	noted,	and	 it	has	been	established	 that	GBA1	mutations	 (especially	 a	missense	mutation	 replacing	leucine	in	residue	483	with	proline	(L444P)	and	a	missense	mutation	replacing	asparagine	in	residue	 409	with	 serine	 (N370S)(Ortiz-Cabrera	 et	al.	 2016))	 represent	 the	most	 significant	genetic	risk	factor	for	the	development	of	PD	(odds	ratio	>5	compared	to	controls)(Sidransky	
et	al.	2009).	Increased	risk	of	PD	in	healthy	relatives	to	GD	patients	exists,	also	pointing	to	a	risk	of	PD	development	in	carriers	of	GBA1	mutations(Goker-Alpan	et	al.	2004).	Parkinsonian	manifestations	due	 to	GBA	mutations	are	associated	with	a	more	 rapid	disease	progression	and	 dementia	 development(Winder-Rhodes	 et	 al.	 2013).	 In	 regards	 to	 the	 earlier	development	of	dementia,	 it	has	been	 shown	 that	DLB	 is	 even	more	 significantly	 related	 to	GBA1	mutations,	and	that	DLB	patients	with	GBA1	mutations	also	suffer	from	an	earlier	onset	of	cognitive	dysfunction(Nalls	et	al.	2013).	One	 of	 the	 substrates	 for	 the	 glucocerebrosidase	 enzyme	 (GCase)	 is	 α-syn,	 and	 it	 has	 been	proposed	 that	 the	risk	of	developing	PD	 is	 linked	 to	 the	dysfunctional	clearance	of	α-syn.	 It	has	been	shown	 in	vivo	 in	mice	that	 inhibiting	glucocerebrosidase	activity	with	conduritol	B	epoxide	 increases	 the	 α-syn	 immunoreactivity	 in	 SNpc	 compared	 to	 untreated	controls(Manning-Bog	et	al.	2009).	 In	an	elaborate	study	(Mazzulli	et	al.	2011)	the	potential	link	 between	 GCase	 and	 α-syn	 was	 elucidated.	 In	 the	 lysosome,	 GCase	 cleaves	 the	glycosphingolipid	 glucocerebroside(Brady	 et	 al.	 1965).	 It	 was	 found	 that	 decreased	 GCase	activity	 in	neurons	both	 increases	 the	amount	of	α-syn	and	glucocerebroside(Mazzulli	et	al.	2011).	Subsequently	glucocerebrosides	aggregate	into	tubules	that	provided	a	scaffold	for	the	formation	and	stabilization	of	oligomeric	α-syn	species.	Furthermore	oligomeric	α-syn	species	effectively	decreased	the	amount	of	GCase	released	from	the	endoplasmatic	reticulum	to	the	lysosomes,	negatively	affecting	the	function	of	GCase,	and	creating	a	potentially	vicious	circle.	In	human	neuroblastoma	cell	lines	(SH-SY5Y)	mutations	in	PINK1	(PARK6)	or	overexpression	of	α-syn	also	leads	to	decreased	GCase	activity(Gegg	et	al.	2012).	A	study	using	induced	pluripotent	stem	cells	(iPSC)	from	patients	with	GBA1	mutations	and	GD	 patients	 compared	 to	 control	 cells	 showed	 an	 increase	 in	 α-syn	 content,	 a	 decreased	autophagosome-lysosomal	fusion	as	well	as	a	disrupted	calcium	homeostasis(Schondorf	et	al.	
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2014);	the	latter	hypothetically	linked	to	the	effect	of	increased	levels	of	o-α-syn(Danzer	et	al.	2007).			
5.1.5	Growth	factors:	
	Several	 growth	 factor	 hormones	 might	 play	 a	 role	 in	 PD.	 An	 increase	 of	 brain	 derived	neurotrophic	 factor	 (BDNF)	 levels	 was	 found	 in	 PD	 CSF(Zhang	 et	 al.	 2008),	 maybe	 as	 a	reaction	to	the	decrease	of	striatal	DA,	since	BNDF	upregulates	D1	receptor	production	(Do	et	
al.	 2007).	 Vascular	 endothelial	 growth	 factor	 (VEGF)	 is	 a	 hormone	 regulating	angiogenesis(Leung	et	al.	1989)	by	 increasing	endothelial	proliferation(Pedram	et	al.	1998),	migration(Barleon	et	al.	1996),	and	survival(Gerber	et	al.	1998),	playing	a	critical	role	during	embryonic	development(Miquerol	et	al.	2000).	VEGF	and	other	markers	of	angiogenesis	have	been	found	to	be	upregulated	in	PD	CSF(Janelidze	et	al.	2015),	and	VEGF	has	been	shown	to	protect	against	dopaminergic	neuron	damage,	possibly	due	to	 its	effect	on	angiogenesis	and	glial	activation	(Yasuhara	et	al.	2005).	 It	could	be	speculated	that	a	combined	stimulation	of	angiogenesis	and	neurogenesis	through	VEGF-	and	BDNF-receptors	is	an	adaptive	response	to	neuronal	damage	in	the	substantia	nigra.	
	
4.1.6	Monoamines:	
	Due	to	 the	marked	damage	 to	dopaminergic	neurons,	many	researchers,	 focusing	especially	on	changes	 in	DA	and	DA	metabolites,	have	performed	CSF	monoamine	analyses.	A	detailed	walkthrough	of	 these	 findings	was	done	 in	our	 catecholamine	article(Andersen	et	 al.	 2017)	(Appendix	II).	
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5.2	Biomarkers	for	L-DOPA	induced	dyskinesia:		
5.2.1	Preface	
	As	 for	diagnostic	biomarkers,	we	need	an	understanding	of	 the	pathways	 leading	 to	LID,	 in	order	to	develop	viable	biomarker	candidates	for	LID.		Few	CSF	biomarker	studies	have	been	made,	actively	distinguishing	dyskinetic	from	non-dyskinetic	PD;	and	it	does	pose	a	challenge:	The	 development	 of	 LID	 is	 highly	 complex,	 involving	 changes	 in	 several	 neurotransmitter	pathways	 (Huot	 et	 al.	 2013,	 Bastide	 et	 al.	 2015),	 but	 LID	 is	 a	 dynamic	 process	 potentially	requiring	 CSF	 studies	 to	 be	 performed	 at	 a	 moment	 where	 dyskinesia	 is	 ongoing.	 Some	important	pathways	related	to	the	project	are	briefly	discussed	below:			
5.2.2	The	dopaminergic	system:	
	The	simplest	model	of	dyskinesia	involves	the	D1	DA	receptor	(see	fig.6).	It	was	proposed	that	direct	pathway	 stimulation	 through	D1	 receptors	 in	 the	 striatum	would	 inhibit	 the	 internal	globus	 pallidus	 (GPi),	 thereby	 increasing	 thalamic	 activity	 in	 the	 ventrolateral	 and	centromedian	 nucleus,	 resulting	 in	 activity	 of	 the	 supplementary	 motor	 cortex	 and	 LID	(DeLong	1990).	D1	activity	has	been	shown	to	relate	to	dyskinesia	in	an	animal	study	(Aubert	
et	al.	2005),	but	the	priming	event	might	be	dependent	on	both	D1-	and	D2-receptors	(Huot	et	al.	 2013),	 the	 two	 most	 frequent	 DA	 receptors	 in	 the	 striatum.	 It	 seems	 that	 a	 decreased	internalisation	 of	 D1-receptors	 due	 to	 decreased	 striatal	 proteasomal	 activity	 (20s	proteasome)	caused	by	L-DOPA	stimulation	of	D1-receptors	in	a	dopamine-depleted	striatum	is	 correlated	 to	 development	 of	 LID(Berthet	 et	 al.	 2012).	 This	 creates	 an	 interesting	 link	between	 α-syn	 aggregation,	 oxidative	 stress	 and	 LID,	 since	 both	 affect	 the	 proteasomal	system.	 Thus,	 increasing	 doses	 of	 α-syn	 in	 its	 monomeric	 state	 inhibits	 20s	 proteasomal	activity(Snyder	 et	 al.	 2003).	 Interestingly,	 patients	 with	 Parkin	 mutations,	 affecting	proteasomal	functioning,	are	more	prone	to	LID	development(Kitada	et	al.	1998).	
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.	 			
Figure	6:	Adapted	from	Bastide	et	al,	2015.	This	is	a	schematic	presentation	of	the	simplest	dyskinesia	model.	Blue	
colors	 indicate	 inhibitory	 effects,	 dark	 blue	 indicates	 higher	 activity,	 lighter	 blue	 lower	 activity.	 Red	 indicates	
excitatory	effects,	dark	red	indicates	higher	activity,	pink	lower	activity.	It	is	thought	that	exogenous	L-DOPA	affects	
parts	of	 striatum	differently.	The	medium	spiny	neurons	 (MSN)	of	 the	 indirect	pathway	(striatum-globus	pallidus	
externus	(GPe)	-	globus	pallidus	internus	(GPi)	–	thalamus	-	cortex)	are	thought	to	be	inhibited	by	the	activation	of	
D2-receptors,	 whereas	 MSN	 of	 the	 direct	 pathway	 (striatum-globus	 pallidus	 internus-thalamus-cortex)	 are	
activated	by	D1-receptor	stimulation.	Increased	GPe	activity	also	inhibites	the	subthalamic	nucleus	(STN)	otherwise	
stimulating	 both	 GPe	 and	 GPi.	 The	 effects	 being	 a	marked	 decrease	 in	 GPi	 activity	 due	 to	 direct	 inhibition	 from	
striatum	 as	well	 as	 inhibition	 from	GPe	 and	 decreased	 stimulation	 from	 STN.	 Decreased	 GPi	 activity	 dis-inhibits	
activity	in	the	thalamic	nuclei	(VL:	ventral	lateral	thalamus,	CM:	Centromedian	nucleus,	PF:	Parafascicular	nucleus)	
increasing	neuroexcitation	in	the	supplementary	motor	cortex.	
		
5.2.3	The	glutamatergic	system:	
	Glutamate	receptors	are	highly	involved	in	synaptic	plasticity	and	memory	function	(Debanne	
et	al.	2003),		potentially	involving	these	receptors	in	LID	development,	since	LID	is	due	to	a	plastic	change	in	neuronal	communication.	A	dopamine	modulated	increased	resting	state	connectivity	between	the	putamen	and	the	primary	sensory-motor	cortex	and	supplementary	
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motor	area	is	highly	predictive	of	LID	development	and	severity	respectively	(Herz	et	al.	2015,	Herz	et	al.	2016).		Previously	mentioned,	the	NMDA-receptor	antagonist	Amantadine	alleviates	LID,	clearly	linking	LID	and	the	glutamatergic	system.	It	has	been	argued	that	a	pulsatile	DA	release	combined	with	glutamatergic	stimulation	might	induce	long	term	potentiation	(LTP),	explaining	these	DA	modulated	plastic	changes(Bastide	et	al.	2015),	and	using	the	radioligand	11C-raclopride	it	has	been	shown	that	acute	DA	release	after	L-DOPA	intake	is	more	pulsatile	in	dyskinetic	patients	(de	la	Fuente-Fernandez	et	al.	2004).		Linking	the	metabolism	of	the	essential	amino	acid	tryptophane	to	glutamatergic	function	and	LID,	the	tryptophane	metabolite	kynurenic	acid	(KYNA)	has	an	inhibitory	effect	on	the	glutamate	N-methyl-D-aspartate	(NMDA)	receptor(Lanthorn	et	al.	1984).	Increasing	KYNA	production	significantly	decreases	LID	in	non-human	primates	(Gregoire	et	al.	2008).	Further	details	on	KYNA	and	the	involvement	of	the	tryptophane	metabolites	3-hydroxykynurenine	(3-HK)	and	quinolinic	acid	(QUIN)	are	discussed	in	our	article	(Havelund	et	al.	2017)	(Appendix	III).	
	
5.2.4	The	serotonergic	system:	
	Serotonergic	neurons	are	important	regulators	of	both	dopamine	(Olijslagers	et	al.	2006)	and	glutamate	signalling	(Lesch	&	Waider	2012).	Due	to	aromatic	L-amino-acid	decarboxylase	activity	in	serotonergic	raphestriatal	neurons(Arai	et	al.	1996),	they	are	able	to	produce	dopamine	from	L-DOPA.	Raphestriatal	serotonergic	neurons	increase	L-DOPA-turnover	due	to	nigrostriatal	degeneration,	potentially	being	a	compensatory	mechanism	to	ensure	sufficient	DA	in	the	striatum	(Carta	et	al.	2007).	DA	production	in	serotonergic	neurons	plays	a	significant	part	in	LID,	and	it	has	been	argued	that	a	lack	of	autoregulatory	feedback	in	serotonergic	neurons	may	cause	an	excessive	DA	release	(Carta	et	al.	2007).	An	increased	CSF	homovanilic	acid	(HVA)/DA	ratio	found	in	dyskinetic	PD	patients	may	support	that	notion(Lunardi	et	al.	2009),	since	dopaminergic	neurons	cannot	produce	HVA.	This	differs	from	our	own	results,	which	will	be	discussed	later.	Serotonergic	neurons	may	also	be	involved	in	the	LID	priming.	Stimulation	of	the	inhibitory	5-hydroxytryptamine	receptor	5-HT1	decreases	serotonergic	DA	release	(Eskow	et	al.	2009),	and	5-HT1A/B	receptor	stimulation	prevents	priming	(Munoz	et	al.	2008).			
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5.2.5	Cyclic	adenosine	monophosphate	activity:	
	Linking	dopamine	and	glutamate	receptor	in	terms	of	LID	development	is	cyclic	adenosine	monophosphate	(cAMP).	A	lack	of	D1	receptor	internalization	or	increased	D1	mRNA	production	due	to	previously	mentioned	reasons,	could	increase	DA	mediated	D1	receptor	activity,	e.g.	both	in	the	striatum	but	also	in	cortical	regions.	The	effect	would	be	a	downstream	production	of	cAMP,	activating	the	dopamine	and	cAMP-regulated	phosphoprotein	of	32	kDA	(DARPP-32),	which	has	been	shown	to	be	involved	in	LID(Aubert	et	al.	2005).	This	in	turn	leads	to	phosphorylation	of	the	glutamatergic	receptor	GluR1	and	phosphorylation	of	the	extracellular	signal-regulated	protein	kinase	1	and	2	(ERK1/2).	Phosphorylated	ERK	(p-ERK1/2)	activates	the	mammalian	target	of	rapamycin	(mTORC1),	which	plays	a	role	in	regulating	protein	synthesis	and	synaptic	plasticity	(Costa-Mattioli	et	al.	2009).		The	net	result	could	be	a	decreased	ability	for	long	term	depression	and	depotentiation	leading	to	LID.	The	key	role	of	mTORC1	is	underlined	by	the	fact	that	a	rapamycin	ester	(an	mTORC1	inhibitor)	significantly	decreased	LID	and	prevented	priming	(Decressac	&	Bjorklund	2013).		
5.2.6	Growth	factors	and	plasticity:	
	VEGF	is	also	of	interest	with	regards	to	LID.	In	one	elaborate	study	(Ohlin	et	al.	2011)	it	was	argued	that	L-DOPA-induced	changes	in	plasticity	not	only	affect	neurons	but	also	the	microvasculature.	They	found	neuropathological	evidence	of	increased	endothelial	proliferation	in	the	putamen	of	dyskinetic	PD	patients,	correlating	with	VEGF	expression.	An	animal	study	in	the	same	paper	showed	L-DOPA	to	induce	angiogenesis	and	the	expression	of	VEGF	as	well	as	an	antidyskinetic	effect	of	the	VEGF	receptor	antagonist	vandetanib.	It	has	been	hypothesized	that	an	affected	BBB	might	be	involved	in	the	process	(Ohlin	et	al.	2011),	and	a	correlation	between	VEGF	and	BBB	leakage	has	been	shown(Janelidze	et	al.	2015).	As	stated	previously	though,	VEGF	might	also	have	a	neuroprotective	effect	on	DA	neurons	(Yasuhara	et	al.	2005).	VEGF	stimulation	of	endothelial	cells	also	triggers	the	secretion	of	BDNF(Louissaint	et	al.	2002).	Specific	polymorphisms	of	BDNF	are	shown	to	decrease	the	time	for	LID	development(Foltynie	et	al.	2009),	and	BDNF	also	upregulates	the	D1	receptor(Do	et	al.	2007)	potentially	involved	in	LID	development.	
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Chapter	6:	Materials	and	methods	
	
6.1	Patient	recruitment:	
	Before	 the	 initial	 recruitment	 procedures,	 the	 ethical	 committee	 of	 the	 Region	 of	 Southern	Denmark	 was	 contacted	 and	 gave	 permission	 to	 the	 execution	 of	 the	 study	 (s-20130098).	Later	supplementary	applications	including	the	use	of	blood	analyses	and	new	analyses	were	made	and	accepted.			For	this	thesis	we	planned	the	inclusion	of	at	least	30	PD	patients	from	the	Dept.	of	Neurology,	Sygehus	 Sønderjylland.	 The	 primary	 contact	 person	 at	 the	 hospital	 (Harald	 Floer,	 Helle	Østerballe)	 identified	suitable	patients	 for	 the	project	and	 initially	 informed	them	about	 the	project	 during	 their	 regular	 visit	 to	 the	 outpatient	 clinic.	 If	 they	 were	 interested,	 further	information,	both	written	and	oral,	was	given.	A	written	and	oral	 consent	was	given	before	entering	the	study.		Inclusion	 criteria	 included	 fulfilling	 the	 UKBBC(Gibb	 &	 Lees	 1988),	 and	 no	 patients	 with	suspected	 APD	 were	 included;	 furthermore	 patients	 with	 severe	 dementia,	 severe	 clinical	depression	 or	 psychosis,	 DBS	 treated	 and	 patients	 with	 contraindications	 for	 performing	lumbar	puncture	(LP)	were	excluded.		Patient	 recruitment	 began	 late	 2014,	 with	 the	 first	 patient	 being	 seen	 in	 October	 2014.	Although	many	patients	were	informed	about	the	project	only	few	would	accept	entering	the	study.	Many	were	deterred	by	the	lumbar	puncture	procedure	involved.	By	2015	it	was	clear	that	too	few	patients	were	being	recruited.	This	was	solved	in	two	ways:	1. We	now	accepted	including	patients	who	would	only	give	permission	for	taking	blood	samples	for	analysis.	2. We	broadened	our	recruitment	area.	Regarding	 point	 2;	we	 got	 permission	 from	 the	 ethical	 committee	 to	 include	 patients	 from	other	 centres.	 Patients	 were	 recruited	 from	 the	 private	 neurological	 practice	 of	 Michael	Binzer	 in	 Esbjerg,	 as	 well	 as	 from	 the	 neurological	 depts.	 of	 Odense	 (assisted	 by	 Morten	Blaabjerg	and	Matthias	Bode)	and	Roskilde	(assisted	by	Helle	Thagesen,	and	Akram	Kamal).	From	September	2015	to	May	2016,	an	additional	20	patients	were	included.			
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6.2	Sampling	procedure:	
Figure	 7:	Workflow	 for	 patients	 and	 controls	 in	 the	 study.	 All	 patients	 and	 controls	were	 seen	 on	 one	 day	 each.	
n;number,	 L-DOPA;	 Levodopa,	 CSF;	 Cerebrospinal	 fluid,	 MDS-UPDRS;	 Movement	 Disorder	 Society	 Unified	
Parkinson’s	 Disease	 Rating	 Scale;	 UDysRS;	 Unified	 Dyskinesia	 Rating	 Scale.	 Not	 mentioned	 in	 this	 figure	 under	
Clinical	Rating	is:	Montreal	Cognitive	Assessment	(MOCA)	and	MiniMental	State	Examination	(MMSE).	
	A	quick	overview	of	the	process	can	be	seen	in	figure	7.	One	workday	was	assigned	for	each	patient.	 The	 patients	were	 examined	 at	 the	Dept.	 of	Neurology	 in	 Sønderborg,	Odense,	 and	Roskilde	as	well	as	Skleroseklinikken	at	Esbjerg	Sygehus.	At	09:30	am	the	 lumbar	puncture	and	blood	sampling	was	performed	on	the	fasting	patient.	For	patients	treated	with	L-DOPA,	they	were	 asked	 to	 take	 their	morning	 dose	 at	 08:00	 am	 on	 the	 day	 of	 examination	when	possible.	 This	 was	 done	 primarily	 because	 of	 the	 catecholamine	 analyses	 planned	 for	 this	study,	since	L-DOPA	significantly	alters	the	concentration	of	L-DOPA	and	DA.	The	lumbar	puncture	procedure	was	done	with	the	assistance	of	nurses	Helle	Østerballe	and	Susanne	Aabling	 (Sønderborg),	 nurse	Rikke	Bjerre	Rosengren	 (Esbjerg),	 nurse	Lene	 Schroll	
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Kromann	and	social	and	health	care	worker	Yrsa	Ragnhild	Clausen	(Odense),	and	nurse	Dea	Ledstrup	Meyer	(Roskilde).		Lumbar	puncture	was	done	as	described	 in	our	published	article	(Appendix	II)(Andersen	et	al.	 2017).	 Through	 cooperation	 with	 the	 local	 clinical	 biochemical	 departments	 in	 the	hospitals	 of	 Sønderborg,	 Esjberg,	 Odense	 and	 Roskilde,	 routine	 analysis	 of	 CSF	 was	performed.	As	described	in	appendix	II,	some	CSF	was	directly	aliquoted	and	frozen	on	dry	ice	for	catecholamine	analysis.	The	remaining	CSF	was	kept	in	ice	water	until	centrifuging.	Blood	 samples	 were	 taking	 in	 the	 decubital	 fossa	 using	 citrate	 tubes	 as	 described	 in	 the	appendix	III	(Havelund	et	al.	2017).	After	CSF	and	blood	sampling,	samples	were	centrifuged.	CSF	was	kept	 in	ice	water	prior	to	centrifugation	whereas	blood	samples	were	kept	at	room	temperature	(RT).	The	aim	was	to	centrifuge	samples	as	quickly	as	possible	(within	30	minutes).	CSF	was	centrifuged	at	2000	g,	4°	Celsius	for	10	minutes	before	being	aliquoted	into	Saarstedt	tubes	in	200	microliter	and	put	on	dry	ice.	Before	aliquoting	CSF,	a	subset	of	tubes	was	prepared	with	a	75	μL	mix	of	protease	and	phosphatase	inhibitors.	One	tablet	of	cOmplete™	mini	EDTA-free	(catalog	no.	11836153001,	Roche	Applied	Science,	Indianapolis,	USA)	and	PhosSTOP™	(catalog	no.	04906837001)	were	mixed	in	2	ml	Phosphate	buffered	saline	(PBS)(Gibco).	In	these	tubes	300	microliter	CSF	was	added.	Either	the	centrifuge	was	then	heated	to	RT	or	a	second	centrifuge	was	used.	Blood	samples	(citrate	 tubes)	were	 then	 centrifuged	at	RT,	1400	g	 for	10	minutes,	dividing	blood	 samples	into	plasma	and	blood	pellets.		Plasma	was	 separated	 from	 the	blood	pellets	and	centrifuged	at	RT,	3000	g	 for	10	minutes	before	being	aliquoted	into	Saarsted	tubes	in	200	microliter	portions	and	put	on	dry	ice.		Erythrocyte	pellets	were	rinsed	1:1	in	0,9%	NaCl	and	centrifuged	at	3000	g,	4°	Celsius	for	10	minutes.	 The	 supernatant	 NaCl	 was	 removed	 and	 the	 rinsing	 procedure	 performed	 twice	more.	After	the	final	centrifugation	the	supernatant	NaCl	was	removed	and	blood	pellets	were	suspended	 1:1	 in	 0,9%	 NaCl	 before	 being	 aliquoted	 into	 Saarsted	 tubes	 in	 400	 microliter	portions	and	put	on	dry	ice.		The	 same	day,	 samples	were	 transferred	 from	dry	 ice	 to	a	 -80°	Celsius	 freezer	 (Institute	of	Molecular	Medicine,	Neurobiological	research).			
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6.3	Patient	examination:	
	After	sample	processing,	patients	were	physically	examined.	For	patients	taking	L-DOPA	the	clinical	rating	was	done	50	minutes	after	L-DOPA	intake.	Two	clinical	rating	scales	were	used	that	I	will	now	describe	in	more	detail:		
6.3.1	 The	Movement	 Disorder	 Society-Sponsored	 Revision	 of	 the	 Unified	 Parkinson’s	 disease	
Rating	Scale	(MDS-UPDRS):		The	MDS-UPDRS	is	a	clinimetric	tool	for	the	assessment	of	Parkinson’s	disease	severity.	It	has	been	validated	on	a	 large	ethnically	varied	PD	population(Goetz	et	al.	 2008b)	and	has	been	translated	 into	 15	 languages	 (http://www.movementdisorders.org/MDS/Education/Rating-Scales.htm).	A	Danish	version	is	currently	in	the	process	of	validation.	The	rating	scale	tools	include	questions	asked	by	the	clinician	as	well	a	questionnaire	that	can	be	filled	out	by	the	patient	and/or	a	caregiver	as	well	as	a	clinical	examination.	For	the	use	of	the	UPDRS	Part	III	rating	 scale,	 I	 have	 completed	 an	 online	 MDS-UPDRS	 Training	 Program	 and	 Certificate	Exercise	 (appendix	 V)	 (http://www.movementdisorders.org/MDS/Education/Rating-Scales/Training-Programs.htm).		The	questions	asked	focus	on	the	average	symptom	severity	during	the	last	week	before	the	rating.	The	severity	score	follows	the	same	principle	throughout	the	entire	rating	scale:		0	=	normal,		1	 =	 slight,	 used	 when	 symptoms	 are	 just	 appreciated	 by	 the	 patient/clinician,	 but	 not	interfering	with	performance	in	any	way.		2=mild,	 more	 evident	 symptoms,	 but	 only	 with	 mild	 affection	 appreciated	 by	patient/clinician.		3=moderate,	 when	 symptoms	 are	 clearly	 appreciated	 by	 patient/clinician,	 but	 do	 not	preclude	the	patient’s	ability	to	carry	out	normal	activities	or	perform	motor	task	as	viewed	by	rater.		4=severe,	when	symptoms	preclude	carrying	out	normal	activities	or	performing	a	motor	task	as	viewed	by	clinician.	The	entire	rating	scale	is	divided	into	four	parts:			
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Part	I:	Focuses	on	non-motor	experiences	of	daily	living,	probing	into	known	non-motor	issues	such	as	cognitive	impairment,	hallucinations,	depressed	mood	and	autonomic	disturbances.		Part	II:	Focuses	 on	motor	 experiences	 of	 daily	 living,	 giving	 an	 insight	 into	 the	 patient’s	 perceived	disability	related	to	talking,	eating,	walking	etc.		Part	III:	This	part	is	the	clinical	examination	of	the	patient.	This	part	of	the	MDS-UPDRS	is	used	in	this	thesis	and	will	be	described	in	more	detail:	Initially	it	was	noted	whether	the	patient	is	in	the	ON-	or	OFF-stage,	which	will	clearly	affect	the	motor	abilities	of	the	patient.	The	use	of	anti-Parkinsonian	medication	and	the	time	since	last	 dosage	 of	 L-DOPA	 (when	 applicable)	 was	 noted.	 After	 evaluating	 speech	 and	 facial	expression,	rigidity	in	all	extremities	and	the	neck	was	rated.	Bradykinesia	was	rated	in	upper	extremities	by	finger	tapping,	hand	movements	and	pronation-supination	movements	of	the	hands.	 In	 the	 lower	 extremities	 toe	 tapping	 and	 leg	 agility	 tests	 rated	 bradykinesia.	 Each	extremity	 was	 examined	 separately	 focusing	 on	 the	 “speed,	 amplitude,	 hesitations	 and	decrementing	 amplitude”(Goetz	 et	 al.	 2008b)	 of	 the	movements.	 Arising	 from	 a	 chair,	 gait,	freezing	 of	 gait,	 postural	 stability,	 posture,	 global	 spontaneity	 of	movement	was	 rated.	 The	global	spontaneity	was	evaluated	as	an	overall	assessment	of	bradykinesia	during	the	entire	rating	process.	Tremor	assessment	then	focused	on	postural,	kinetic	and	resting	tremor,	and	any	dyskinesia	and	its	impact	on	the	rating	was	noted.			Part	 IV	 questions	 the	 patient	 about	 motor	 complications	 related	 to	 treatment	 including	dyskinesia,	dystonia,	and	ON/OFF-motor	fluctuations.		We	 translated	 the	questions	and	questionnaires	 from	part	 I,	 II	 and	 IV	 into	Danish,	 since	no	Danish	version	existed	at	 the	beginning	of	 this	project.	This	was	only	done	 from	English	 to	Danish.	All	patients	 completed	parts	 I,	 II	 and	 IV	 in	 this	 rating	 scale.	 Since	 the	 requirements	from	the	Movement	Disorder	Society	for	validating	a	translation	of	the	MDS-UPDRS	were	not	met	and	are	quite	time	consuming(Goetz	et	al.	2014),	it	was	impossible	for	us	to	validate	the	translation	 in	 the	time	frame	of	 this	project.	 I	have	argued	that	 the	UPDRS	part	 III	does	not	include	a	language	barrier	since	it	is	purely	based	on	movements,	and	since	I	was	able	to	use	
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the	original	version	for	the	completion	of	the	patient	examination,	the	results	from	the	UPDRS	part	III	motor	score	are	used	in	this	thesis.		
6.3.2	The	Unified	Dyskinesia	Rating	Scale	(UDysRS):		Goetz	et	 al	 (2008)	argued	 that	a	 scale	 featuring	 the	assessment	of	 “anatomical	distribution,	phenomenology,	 duration,	 intensity,	 disability	 and	 patient	 perceptions”(Goetz	 et	 al.	 2008a)	was	needed,	resulting	in	the	creation	of	UDysRS.	As	with	the	MDS-UPDRS	the	rating	combines	questions	asked	by	the	clinicians,	a	questionnaire	and	a	clinical	rating.	No	Danish	version	was	available,	 and	 questions	 as	well	 as	 questionnaires	were	 translated	 into	Danish.	 Ratings	 are	also	the	same	integers	ranging	from	0-4.	The	rating	scale	has	not	been	validated	on	as	large	a	patient	 population	 as	 the	 MDS-UPDRS,	 but	 the	 intra-	 and	 inter-rater	 reliability	 for	 the	objective	 assessment	 was	 deemed	 acceptable(Goetz	 et	 al.	 2008a).	 An	 online	 MDS-UDysRS	Training	 Program	 and	 Certificate	 Exercise	 has	 been	 completed	 for	 the	 use	 of	 the	 objective	assessment	 (http://www.movementdisorders.org/MDS/Education/Rating-Scales/Training-Programs.htm)	(appendix	VI).		The	rating	scale	consists	of	four	parts,	two	historical	parts	and	two	objective	parts:	
Historical:	Part	 I	 rates	historical	ON-dyskinesia.	 Initially	 it	 is	quantified	how	much	of	 the	day	a	patient	suffers	from	these	medicine-induced	dyskinesias.	Afterwards	a	questionnaire	focuses	on	the	effect	of	ON-dyskinesia	on	several	activities	of	daily	living	(ADL).		Part	II	rates	historical	OFF-dystonia.		
Objective:	The	objective	dyskinesia	assessment	centres	upon	four	tasks	representing	ADL,	recorded	on	video	for	later	rating	(Rush	Filming	Protocol).		Task	1,	communication:	The	patient	sits	in	a	chair,	describing	a	drawing	that	he/she	is	holding	with	both	hands.		Task	2,	drinking	from	a	cup:	The	patient	sits	in	a	chair,	graps	a	cup	with	water,	takes	a	sip	and	puts	down	the	cup	again;	repeats.	Task	3,	dressing:	The	patient	puts	on	a	 lab	coat,	buttons	three	buttons,	unbuttons	and	takes	off	the	lab	coat.	
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Task	4,	ambulation:	The	patient	rises	 from	a	chair,	walks	5	meters,	 turns,	walks	back	to	the	chair	and	sits.		Part	 III	 rates	 impairment	 due	 to	 dyskinesia.	 For	 each	 task	 described	 above,	 the	 severity	 of	dyskinesia	 is	 rated	 separately	 in	 the	 face,	 neck,	 extremities	 and	 trunk.	A	 final	 score	 for	 the	face,	 neck,	 extremities	 and	 trunk	will	 be	 the	most	 severe	 score	 recorded	 in	 any	of	 the	 four	tasks.		Part	IV	rates	disability	due	to	dyskinesia.	Instead	of	focusing	on	specific	body	parts	this	score	focuses	on	the	overall	effect	of	the	total	amount	of	dyskinesia	on	a	specific	task.	It	is	also	noted	whether	the	patient	exhibits	ON-dyskinesia,	OFF-dystonia	(or	transition	state),	whether	chorea	and/or	dystonia	was	present,	as	well	as	which	one	was	predominant	of	 the	two.	A	total	objective	score	is	found	by	adding	ratings	from	part	III	and	IV.	As	 with	 the	 MDS-UPDRS	 our	 Danish	 translation	 of	 the	 questions	 and	 questionnaire	 of	 the	UDysRS	was	not	validated,	and	as	such	cannot	be	used	for	further	analysis.	I	have	argued	that	scores	from	parts	III	and	IV	are	usable	for	further	analyses,	since	I	was	able	to	use	the	original	paper	for	performing	the	rating.		It	is	to	be	noted	that	permission	to	use	these	specific	parts	of	the	MDS-UPDRS	and	UDysRS	has	been	granted	by	the	Movement	Disorder	Society	(appendix	VII).		
6.3.3	Cognitive	rating:	
	Patients	 were	 evaluated	 using	 Danish	 versions	 of	 both	 the	 Mini-Mental	 State	 Examination	(MMSE)	 (https://www.sundhed.dk/sundhedsfaglig/laegehaandbogen/undersoegelser-og-proever/skemaer/geriatri/mms-mini-mental-status/)	 and	 the	 Montreal	 Cognitive	Assessment	 (MOCA)	 (http://www.mocatest.org/wp-content/uploads/2015/tests-instructions/MoCA-Test-Danish-2010.pdf).	 	 Especially	 the	 MOCA	 test	 has	 been	 proven	 to	perform	well	as	a	screening	tool	for	PD	patients(Gill	et	al.	2008).	
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6.3.4	Health	information:	
	Disease	 duration	 in	 this	 thesis	 is	 defined	 as	 the	 time	 from	 the	 patient	 noted	 the	 first	symptoms	 of	 Parkinson’s	 disease	 to	 the	 date	 of	 examination	 in	 this	 project.	 Duration	 since	receiving	the	diagnosis	by	a	professional	was	also	noted.		Information	about	other	illnesses,	medication,	hereditary	diseases	was	noted.		Patients	were	grouped	according	to	the	use	of	L-DOPA	and	the	presence/absence	of	LID.	One	patient	had	a	clear	dystonic	dyskinesia,	but	was	included	prior	to	the	use	of	the	UDysRS,	and	one	 patient	 described	 daily	 symptoms	 interpreted	 as	 being	 dyskinetic,	 but	 these	were	 not	evident	at	examination.	As	can	be	seen	in	table	2,	we	have	included	a	variable	called	amnestic	dyskinesia,	to	include	those	two	patients.	
	
6.4	Control	recruitment	and	sampling:	
	Controls	had	lumbar	puncture	performed	as	a	part	of	their	neurological	evaluation.	The	aim	was	to	include	a	group	of	age-matched	controls.	In	Sønderborg:	As	the	physician	performing	the	lumbar	puncture	due	to	my	affiliation	with	that	department,	I	was	able	to	contact	these	controls	by	phone	prior	to	their	appearance	in	the	hospital	setting.	I	was	able	 to	 inform	them	orally	about	 the	project	and	 to	ask	 them	to	be	 fasting	prior	 to	 the	lumbar	puncture.	At	 the	day	of	 the	 lumbar	puncture	we	again	 talked	about	 the	project	 and	written/oral	consent	was	given.	The	lumbar	puncture	and	blood	sampling	procedure	as	well	as	the	following	samples	processing	procedure	did	not	differ	from	patients.		Permission	 was	 given	 to	 go	 through	 the	 patient’s	 medical	 history,	 including	medicine	 use,	hereditary	diseases,	previous	illnesses	etc.		In	Odense:	Due	 to	 a	 need	 for	 more	 controls	 for	 the	 study,	 we	 gained	 permission	 from	 the	 ethical	committee	in	the	Region	of	Southern	Denmark	to	recruit	controls	from	the	Dept.	of	Neurology	in	Odense,	identifying	patients	who	had	lumbar	puncture	performed	as	a	part	of	their	check-up.	 For	 this	 group,	 due	 to	 ethical	 reasons,	 I	 was	 not	 able	 to	 contact	 these	 patients	 on	beforehand;	thus	I	could	not	ask	them	to	be	fasting.	Patients	were	informed	about	the	project	when	they	came	for	the	general	information	about	the	lumbar	puncture	procedure.	They	were	
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given	 both	 oral	 and	 written	 information,	 and	 oral/written	 consent	 was	 given	 prior	 to	 the	inclusion	in	this	study.	For	this	group	of	controls,	the	lumbar	puncture	procedures	specific	to	the	Dept.	of	Neurology	in	Odense	were	followed.	All	subjects	had	the	lumbar	puncture	done	lying	 on	 the	 left	 side.	 Prior	 to	 sampling	 of	 CSF	 the	 pressure	 of	 the	 CSF	 (mm	 H2O)	 was	measured	using	a	flexible	spinal	manometer	tube	attached	to	the	spinal	needle.	After	noting	the	CSF	pressure	CSF	was	drawn	through	the	manometer	tube.	From	this	point	the	procedure	did	not	differ	from	the	previously	described	procedures.	For	 all	 controls	 in	 this	 study	 permission	 was	 granted	 to	 inspect	 the	 patient	 file	 for	 the	conclusion	of	the	neurological	investigation	necessitating	the	lumbar	puncture.	
	
6.5	Laboratory	analyses:	
	Prior	to	all	analyses	of	plasma	and	CSF,	sample	tubes	were	thawed	slowly	in	ice	water.	
	
6.5.1	High-Performance	Liquid	Chromatography	(HPLC):	
	HPLC	analyses	were	performed	 in	Associate	Professor	 Jan	Bert	Gramsbergens	 laboratory	at	the	 Institute	 for	 Molecular	 Medicine,	 Neurobiological	 Research,	 University	 of	 Southern	Denmark.	For	the	analysis	of	monoamines	and	metabolites	HPLC	is	a	powerful	analysis	tool.	In	HPLC	a	mobile	 liquid	phase	 and	 solvent	 compounds	of	 interest	 are	 forced	 through	a	 column	under	high	pressure.	The	column	is	filled	with	a	stationary	phase	of	low	polarity	(such	as	octadecyl	carbon	chain	(C18)-bonded	silicon	dioxide);	also	called	reversed	phase	HPLC.	By	using	a	polar	solvent	(methanol)	polar	compounds	of	interest	will	spend	less	time	in	the	column	than	less	polar	compounds.	This	makes	HPLC	a	very	effective	tool	at	separating	compounds	of	interest.	Here	we	use	the	difference	in	polarity	between	monoamines	to	separate	them.	To	detect	the	compounds	 at	 the	 different	 time	 point	 escaping	 the	 column,	 we	 use	 an	 electrochemical	detector.	 In	 this	 detector	 an	 electric	 potential	 is	 applied	 between	 two	 electrodes.	 After	escaping	 the	 column,	 the	 solvent	 is	 driven	 in	 between	 the	 electrodes,	 and	 electroactive	compounds	(in	this	study,	monoamines)	are	either	reduced	or	oxidized	at	the	electrode.	The	resulting	current	change	is	recorded	as	a	peak	on	a	chromatogram	(mV;	y-axis).	By	first	using	
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a	 standard	mix	 of	monoamines,	we	 are	 able	 to	 identify	 the	 column	 retention	 time	 for	 each	monoamine,	representing	a	peak	on	a	specific	point	on	the	x-axis	(time	in	minutes).	The	area	under	 the	 peak	 represents	 the	 amount	 of	 a	 compound	 that	 has	 passed	 the	 electrochemical	detector,	 and	 by	 injecting	 a	 known	 amount	 of	 the	 standard,	 we	 know	 the	 amount	 of	 a	compound	 representing	 a	 certain	 area	 under	 the	 peak.	 In	 this	 way	 we	 can	 quantify	 the	amount	 of	 monoamines	 in	 a	 sample.	 The	 electrochemical	 detector	 is	 extremely	 sensitive,	making	it	possible	to	detect	absolute	amounts	in	the	lower	femtomol	range.	A	more	detailed	description	can	be	seen	in	appendix	II	(Andersen	et	al.	2017).					
6.5.2	Liquid-chromatography	mass-spectrometry	(LC-MS):	
	LC-MS	 analyses	 of	 tryptophan	 (TRP)	 metabolites	 in	 CSF	 and	 plasma	 were	 performed	 by	post.doc.	Jesper	Havelund	in	the	laboratory	of	Nils	J.	Færgeman,	Department	of	Biochemistry	and	 Molecular	 Biology,	 University	 of	 Southern	 Denmark.	 In	 LC-MS	 the	 separation	 of	compounds	 of	 interest	 uses	 the	 same	 column	 based	 technique	 as	 HPLC.	 Instead	 of	 an	electrochemical	 detector,	 a	mass	 spectrometer	 is	 used	which	 is	 good	 for	 separating	 atoms,	isotopes	 and	 fragments	 of	 molecules	 according	 to	 mass.	 The	 following	 is	 a	 very	 basic	description	 of	 the	 process,	 and	 details	 can	 be	 read	 in	 our	 article	 (Havelund	 et	 al.	2017)(appendix	III).	Firstly	the	liquid	sample	from	the	LC-column	is	ionized	by	electrospray	ionization	 (ESI),	which	 is	 effective	when	dealing	with	 liquid	 samples.	 	The	 ionized	particles	are	then	accelerated	through	a	negative	electrical	field.	A	magnet	then	deflects	the	ions,	with	heavier	 ions	 being	 less	 deflected	 than	 lighter	 ions.	 These	 deflected	 ions	 then	hit	 a	 detector	which	both	registers	the	deflection	determined	by	where	the	ions	specifically	hit	the	detector	plate	and	the	abundance	of	ions	hitting	the	detector	plate.	This	creates	a	graph	with	the	x-axis	depicting	 the	atomic	weight	of	 the	 ion	(according	 to	 the	deflection),	and	 the	y-axis	showing	the	abundance	of	ions	hitting	the	detector	plate	in	that	specific	spot.		
	
6.5.3	Enzyme-linked	immunosorbent	essay	(ELISA):	
	The	ELISA	was	developed	separately	by	two	research	teams	in	the	late	1960’es	and	gradually	identified	 as	 a	 powerful	 tool	 for	 identifying	 specific	 proteins,	 highly	 applicable	 for	 clinical	
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medicine	(Lequin	2005).	Both	ELISA	assays	were	performed	in	the	laboratory	of	Dr.	Niels	H.H.	Heegard	(Statens	Seruminstitut).	The	basic	procedure	is	as	follows:	Patient	samples	are	aliquoted	into	the	wells	of	an	ELISA	plate.	In	the	bottom	of	the	wells,	the	capture	antibody	with	affinity	to	the	protein	of	interest	(α-syn)	is	fixed.	After	incubating,	the	wells	are	washed,	removing	excess	unbound	protein.	Then,	a	primary	enzyme-linked	antibody	with	affinity	to	α-syn	is	applied	in	each	well,	effectively	pinching	the	protein	of	interest	between	two	antibodies.	After	incubation	and	a	washing	procedure,	rinsing	off	excess	unbound	primary	antibody,	an	enzyme	substrate	is	added	(for	both	our	assays	streptavidin	was	used).	The	antibody-linked	enzyme	acts	upon	the	substrate,	and	the	amount	of	product	made	changes	the	color	in	each	well	correspondingly.	A	plate	reader,	quantifying	the	amount	of	protein	in	each	well	by	comparing	it	to	a	standard,	measures	the	wavelength	of	the	colour	of	each	well.	The	α-syn	ELISA	in	CSF	was	done	according	to	the	Alpha-Synuclein	ELISA	Kit	Protocol	(Biolegend,	Catalog	no.	844101).	The	α-syn	ELISA	in	erythrocytes	is	described	in	detail	in	appendix	VIII.	For	CSF	ELISA	a	VERSAmax	microplate	reader	was	used,	for	erythrocyte	ELISA,		a	TECAN	ELISAreader	was	used.		
6.5.4	Multiplex	(Vascular	Endothelial	Growth	Factor,	extracellular	signal-regulated	protein	
kinase	1/2):	
	Multiplex	 analyses	were	 performed	 in	 the	 Institute	 of	Molecular	Medicine,	 Neurobiological	Research,	University	of	Southern	Denmark.	To	a	certain	extent	multiplex	analysis	is	similar	to	the	ELISA,	also	using	antibodies	against	a	 substance	of	 interest.	The	advantage	of	multiplex	analysis,	 apart	 from	 being	 quicker,	 comes	 from	 the	 fact	 that	 each	well	 in	 a	multiplex	 plate	contains	 separate	 areas	 with	 different	 capturing	 antibodies,	 permitting	 the	 simultaneous	analysis	of	several	substances.	Also,	this	assay	uses	electrochemiluminescence,	giving	a	higher	sensitivity,	broader	dynamic	range	and	low	background	noise.	The	method	briefly	described:	The	mesoscale	plates	used	in	these	assays	contain	96	wells.	In	the	bottom	of	each	well,	capturing	antibodies	are	attached	to	a	high	binding	carbon	electrode.	Samples	and	standards	are	aliquoted	 in	 the	wells.	After	a	 shorter	 incubation	 time	 the	wells	are	 washed	 to	 remove	 any	 excess	 sample	 material	 that	 hasn’t	 attached	 to	 the	 capturing	antibodies.	A	secondary	antibody	with	affinity	to	the	substrate	of	interest	is	then	added;	since	multiple	substrates	are	evaluated	simultaneously,	the	secondary	antibody	is	actually	a	mix	of	
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antibodies	 against	 each	 of	 the	 substrates	 of	 interest.	 The	 secondary	 antibodies	 are	 labelled	with	a	SULFO-TAG™	label.	After	incubation	and	a	washing	procedure	the	plate	is	read	in	the	plate	reader.	By	applying	a	current	to	the	well	electrode,	an	electrochemiluminescent	reaction	occurs	in	the	SULFO-TAG™	labels,	emitting	light,	which	is	measured	by	the	plate	reader.	Light	intensity	 depends	 on	 the	 amount	 of	 secondary	 antibody	 attached,	 and	 the	 concentration	 of	substrates	in	each	well	is	found	by	comparing	light	intensity	with	the	standard	wells.			For	both	VEGF	(Human	Growth	Factor	Panel	I	Assay),	t-ERK	1/2	and	p-ERK	1/2	(Phospho(Thr202/Tyr204;	Thr185/Tyr187)/Total	ERK1/2	Assay	Whole	Cell	Lysate	Kit),	kits	from	Meso	Scale	Diagnostics®	(Rockville,	Maryland,	USA)	were	used	and	read	on	a	MESO	Quickplex	SQ120	(Meso	Scale	Diagnostics,	Rockville,	Maryland,	USA).	 
Deviations	from	manufacturer’s	protocol: VEGF:	In	line	with	the	method	used	by	Janelidze	et	al	(Janelidze	et	al.	2015),	samples	were	incubated	at	4°C	overnight.	Otherwise	the	protocol	followed	the	manufacturers	instructions.		T-ERK,	p-ERK:	For	this	assay	we	used	CSF	tubes	with	added	phosphatase	and	protease	inhibitors	as	described	previously.	A	test	assay	had	shown	very	low	concentrations	of	these	enzymes	in	the	CSF.	To	increase	concentrations,	samples	were	vacuum	evaporated	for	24	hours	before	performing	the	multiplex	assay.	The	dry	samples	were	then	dissolved	in	25	μL	of	destilled	water	(Milli-Q,	Merck	KGaA,	Darmstadt,	Germany),	quickly	mixed	on	a	vortex	mixer,	and	the	protocol	of	the	manufacturer	was	followed.		The	percentage	of	p-ERK	compared	to	t-ERK	(p-ERK%)	was	calculated	and	used	for	analysis.		
6.5.5	L-Tryptophanol	(Trol)	fluorescence	assay:		This	assay	protocol	was	developed	by	Glynn	Jones	(PhD,	Aberdeen	University)	and	performed	at	 the	 laboratory	 of	 professor	 Bettina	 Platt	 (Aberdeen	 University,	 The	 Institute	 of	 Medical	Sciences)	used	for	both	CSF	and	plasma	samples.	A	detailed	description	can	be	seen	in	the	L-Tryptophanol	 manuscript	 (appendix	 IV).	 It	 has	 previously	 been	 shown	 that	 some	 indole-containing	compounds	are	 intrinsically	 fluorescent,	and	 that	 the	presence	of	oligomers	 (but	
Cerebrospinal	fluid	biomarkers	for	Parkinson’s	disease	and	L-DOPA-induced	dyskinesia	
	 48	
not	fibrils)	quenches	the	fluorescence	with	about	15%	(Reinke	et	al.	2009).	The	Trol	(Sigma,	UK)	molecule	was	 found	to	be	a	good	probe	 for	quantifying	Aβ-prefibrils,	not	being	specific	for	 Aβ-prefibrils	 but	 also	 other	 prefibrillary	 amyloids(Reinke	 et	al.	 2010).	 It	 is	 to	 be	 noted	though,	that	Trol	does	not	seem	to	be	quenched	by	prefibrillary	α-syn	(Reinke	et	al.	2010).	
	
6.5.6	Glucocerebrosidase	enzyme	activity	fluorescence	assay:		The	 GCase	 assay	 was	 performed	 in	 the	 laboratory	 of	 associate	 professor	 Jan	 Bert	Gramsbergen,	Institute	of	Molecular	Medicine,	Neurobiology	Research,	University	of	Southern	Denmark.	Briefly,	this	assay	measures	GCase	activity	by	the	conversion	of	the	GCase	substrate	4-Methylumbelliferyl	 beta-D-glucopyranoside(MUGIc)(Sigma,	 M3633)	 to	 the	 product	 4-Methylumbelliferone.	 CSF	 samples	 and	MUGIc	 are	mixed	 in	 the	wells	 of	 a	 fluorescent	 plate	and	incubated	for	24	hours.	Standard	wells	are	made	with	different	known	concentrations	of	the	product	4-Methylumbelliferone.	Adding	a	stop-solution	then	stops	the	enzymatic	activity,	and	the	plates	are	read	in	a	fluorescent	plate	reader.	The	higher	the	GCase	activity	in	a	given	sample,	the	more	substrate	will	be	converted	into	the	product.	This	is	measured	as	a	change	in	fluorescence	in	the	plate	reader.	The	amount	of	product	is	then	calculated	by	plotting	well	values	 in	 a	 standard	 curve.	 GCase	 activity	 (mU/mL)	 is	 then	 calculated	 with	 one	 U	 being	defined	as	the	amount	of	enzyme	that	hydrolyzes	1	nmol	of	substrate	pr.	minute	at	37°C	Dividing	individual	values	with	the	control	mean	created	normalized	values	used	for	analysis.	For	a	detailed	description	please	see	appendix	IX.		
	
6.5.7	Western	blot	assay	(α-synuclein	subspecies):		Western	 blot	 (WB)	 assays	 were	 performed	 by	 Peter	 Lønsmann	 Iversen	 (Cand.Scient.)	 and	Tomasz	 Brudek	 (Cand.Scient,	 PhD)(Research	 Laboratory	 for	 Stereology	 &	 Neuroscience,	Bispebjerg,	Copenhagen	University	Hospital).	A	 detailed	 description	 of	 the	method	 is	 described	 in	 the	master	 thesis	 by	 Peter	 Lønsmann	Iversen	(2017,	University	of	Copenhagen,	Department	of	Biology).	
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The	WB	method	uses	electrophoresis	to	separate	proteins	according	to	different	features	such	as	 molecular	 weight	 or	 charge.	 For	 these	 analyses,	 proteins	 are	 separated	 by	 molecular	weight.		Initially,	proteins	 in	CSF	samples	are	denatured,	which	results	 in	the	loss	of	their	secondary	and	 tertiary	 structure.	This	way,	proteins	 can	be	 selectively	 separated	by	 size,	measured	 in	kilo-Dalton	 (kDa).	 The	 proteins	 in	 the	 CSF	 samples	 are	 then	 covered	with	 sodium-dodecyl	sulfate	 (SDS),	 effectively	 applying	 a	 negative	 charge	 to	 the	 proteins.	 Samples	 are	 then	transferred	 into	wells	 in	one	end	of	a	polyacrylamide	gel	 (PAG).	By	applying	a	current	with	the	anode	 in	 the	opposite	end	of	 the	PAG,	 the	now	negatively	 charged	protein	particles	are	drawn	through	the	PAG	through	electrophoresis	(E).	The	entire	procedure	is	therefore	called	SDS-PAGE.	Due	to	the	size	of	the	channels	 in	the	PAG,	smaller	proteins	move	faster	through	the	PAG,	effectively	separating	proteins	by	size.		The	PAG	is	then	sandwiched	between	a	blotting	pad	and	a	nitrocellulose	membrane,	and	the	proteins	in	the	PAG	are	transferred	onto	the	blotting	pad	by	applying	a	current	perpendicular	to	surface	of	the	PAG.	A	primary	antibody	is	then	incubated	on	the	blotting	pad.	The	antibodies	are	aimed	at	specific	epitopes	of	the	α-syn	protein	(see	figure	10).	I	will	shortly	mention	the	primary	antibodies	used:	Antibodies	HLU-N1	(Lundbeck	A/S),	5-G4	(Millipore,	USA;	CN	MABN389),	MJFR1	(Abcam,	USA;	CN	ab138501),	syn-221	(Santa	Cruz	Biotechnology,	USA;	CN	sc-12767)	and	HLU-C4	(Lundbeck	A/S)	identify	normal	epitopes	on	the	α-syn	protein.	Ser-87	(Santa	Cruz	Biotechnology,	USA;	CN	sc-19893-R)	specifically	binds	to	α-syn	phosphorylated	at	the	serine	85	residue,	Tyr123-/133	(Novus	Biologicals,	USA;	CN	NBP1-26380)	binds	to	α-syn	nitrosylated	at	tyrosine	residue	125	or	133,	and	ser-129	(Santa	Cruz	Biotechnology,	USA;	CN	sc-135638)	binds	to	α-syn	phosphorylated	at	serine	residue	129.	Subsequently,	a	secondary	antibody	with	a	fluorescent	label,	binding	to	the	primary	antibody,	is	added.	Quantification	of	the	protein	of	interest	is	then	done	using	a	near-infrared	imaging	system.	 
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Figure	9:	An	epitope	map	of	the	primary	antibody	binding	site	on	the	α-syn	protein.	Potential	posttranslational	
modifications	of	α-syn	are	shown:	Green	circles	indicate	ubiquitination,	purple	circles	indicate	nitrosylation,	orange	
circles	indicate	phosphorylation,	and	scissors	indicate	truncation.	Figure	as	presented	in	master	thesis	of	Peter	
Lønsmann	Iversen	(2017),	adapted	from	(Schmid	et	al.	2013).	
	
6.6	Statistical	analysis:	
	Statistical	 analysis	was	performed	using	 STATA….	Continuous	data	was	 tested	 for	Gaussian	distribution	visually	by	histogram	as	well	as	a	qq-plot.	Shapiro-Wilks	test	 for	normality	was	additionally	used.	Parametric	data	was	analysed	using	Student’s	 t-test	between	 two	groups.	Non-parametric	 data	was	 analysed	 using	 the	Wilcoxon	 rank-sum	 test	 between	 two	 groups.	Analysis	of	variance	between	the	four	groups	in	this	study	was	done	by	ANOVA	for	parametric	data	and	Kruskall-Wallis	for	non-parametric	data.	For	parametric	data,	pairwise	comparison	was	performed	subsequently	using	Bonferronis	multiple	comparisons.	Dunn-test	was	used	for	multiple	pairwise	comparisons	for	non-parametric	data;	only	for	the	catecholamine	analyses	was	 Bonferronis	 correction	 for	 multiple	 comparisons	 not	 performed.	 Receiver	 operating	characteristics	 (ROC)	 was	 performed	 using	 a	 non-parametric	 ROC	 analysis.	 The	 maximal	Youden’s	index	score	was	determined	by	the	formula	(sensitivity+specificity-1).	With	binary	variables	as	the	dependent	variable,	a	logistic	regression	analysis	was	used.	With	continuous	
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variables	linear	regression	analysis	was	used.	All	linear	regression	analyses	were	performed	using	bootstrapping	with	1000	repetitions.	All	analyses	have	been	made	both	including	and	excluding	the	DLB	and	AD	patients.	In	the	graphical	presentation	of	results,	error	bars	represent	mean	±	standard	error	of	mean.	Statistical	significance	is	presented	as:	*	p<0.05,	**	p<0.01,	***	p<0.001,	****	p<0.0001				
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CHAPTER	7:	RESULTS	
7.1	Patient	and	control	data:	
	As	 can	 be	 seen	 in	 table	 1,	 all	 patients	 fulfil	 the	 UKBBC,	 suffering	 form	 bradykinesia,	 88%	showing	various	degrees	of	resting	tremor,	85%	suffering	from	rigidity.	15	of	the	26	patients	had	 a	DAT-scan	 performed	 as	 part	 of	 their	 diagnostic	work	 up,	 showing	 either	 bilateral	 or	unilaterally	decreased	uptake	of	FP-CIT	in	the	basal	ganglia.	92%	had	a	unilateral	debut,	with	81%	continuing	to	show	an	asymmetrical	symptomatology	with	the	debut	side	most	affected.		One	patient	fulfilled	the	inclusion	criteria	for	PD	and	showed	marked	bilateral	decrease	of	FP-CIT-uptake,	but	developed	severe	cognitive	deficits	in	an	early	disease	stage.	The	patient	was	later	 diagnosed	 as	 suffering	 from	 DLB,	 but	 was	 included	 in	 the	 analyses,	 which	 will	 be	discussed	later.	In	table	2,	more	clinical	data	for	each	patient	is	described.	Age	ranged	from	41-76	years,	with	8	patients	not	receiving	L-DOPA	(PD-N),	8	receiving	L-DOPA	but	not	dyskinetic	(PD-L),	10	L-DOPA	 treated	 and	 dyskinetic	 (PD-LID).	 Symptom	 duration	 ranged	 from	 1.5	 to	 17	 years,	significantly	 correlated	 with	 the	 use	 of	 L-DOPA	 (Linear	 regression	 analysis,	 p=0.002).	 The	UPDRS	part	III	motor	score	ranged	from	8-53,	and	UDysRS	objective	scores	ranged	from	0-15	in	the	dyskinetic	patient	group.	The	use	of	Amantadine	has	not	been	registered	in	table	2;	only	three	of	the	dyskinetic	patients	were	treated	with	Amantadine.	Cognitive	assessment	using	 the	MOCA	score	showed	 that	patients	 treated	with	L-DOPA	had	significantly	 lower	scores	 than	PD-N	(p=0.031).	Although	L-DOPA	treated	patients	were	not	significantly	 older	 than	 PD-N,	 MOCA	 scores	 are	 negatively	 correlated	 to	 age	 (p=0.001,	R2=0.24).	Patient	and	control	data	are	comparied	in	table	3.	Controls	are	significantly	younger	than	both	the	total	PD	group	and	PD-L,	with	a	preponderance	of	men	in	the	total	PD	group	compared	to	controls.	CSF	protein	concentrations	are	significantly	higher	in	the	total	PD-group	and	in	the	PD-N	 group	 compared	 to	 controls.	
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Table	1:	The	United	Kingdom	Brain	Bank	criteria	assessed	for	each	PD	patient.		
 Main 
criterium 
At least one of: Supportive criteria:  
Patient Bradykine
sia 
Resting 
tremor 
Rigidity Postural 
instability 
Unilateral 
onset 
Resting 
tremor 
Progr
essio
n 
Debute 
side most 
affected 
Excel-
lent          
L-DOPA 
respons
e 
L-DOPA-
induced 
dyskine-
sia 
L-DOPA 
response 
> 5 years 
Clinical 
course 
>10 
years 
Decreased FP-CIT-
SPECT uptake 
a ✔ ✔ ✔  ✔ ✔ ✔ ✔  ✔ ✔ ✔ ✔, unilateral 
b ✔ ✔   ✔ ✔ ✔ ✔ ✔     
c ✔ ✔ ✔ ✔  ✔       ✔, bilateral 
d ✔  ✔  ✔  ✔ ✔      
e ✔ ✔   ✔ ✔ ✔ ✔ ✔   ✔  
f ✔ ✔ ✔  ✔ ✔ ✔       
g ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔     
h ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔  
i ✔ ✔ ✔  ✔ ✔ ✔ ✔ ✔ ✔   ✔, unilateral 
j ✔ ✔ ✔  ✔ ✔ ✔ ✔ ✔ ✔   ✔, unilateral 
k ✔ ✔ ✔  ✔ ✔ ✔ ✔     ✔, bilateral 
l ✔ ✔ ✔  ✔ ✔ ✔ ✔  ✔   ✔, unilateral 
m ✔ ✔ ✔  ✔ ✔ ✔   ✔   ✔, bilateral 
n ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔     ✔, bilateral 
o ✔ ✔ ✔ ✔ ✔ ✔  ✔     ✔, unilateral 
p ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔    ✔ ✔, unilateral 
q ✔ ✔ ✔ ✔ ✔ ✔  ✔     ✔ 
r ✔ ✔ ✔  ✔ ✔ ✔      ✔ 
s ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔     ✔ 
t ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔     
u ✔ ✔  ✔ ✔  ✔ ✔  ✔   ✔ 
v ✔ ✔  ✔   ✔  ✔ ✔    
w ✔  ✔  ✔  ✔ ✔  ✔ ✔ ✔  
x ✔ ✔ ✔ ✔ ✔ ✔  ✔      
y ✔  ✔  ✔  ✔ ✔ ✔ ✔  ✔ ✔ 
z ✔ ✔ ✔ ✔ ✔ ✔  ✔      
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Table	 2:	 Clinical	 data	 and	 data	 on	medicine	 use	 for	 each	 PD	 patient.	 MAO-I;	 Monoamine-oxidase	 inhibitor,	 DA;	
dopamine,	L-DOPA;	Levodopa,	UPDRS;	Unified	Parkinson’s	Disease	Rating	Scale,	UDysRS;	Unified	Dyskinesia	Rating	
Scale,	MOCA;	Montreal	Cognitive	Assessment,	MMSE;	Mini-Mental	State	Examination,	CSF;	Cerebrospinal	fluid	
Sex Age 
(years) 
Disease 
duration 
(years) 
MAO-
I 
DA-
agonist 
L-
DOPA 
Years of 
L-DOPA 
treatment 
Daily      
L-DOPA-
equivalent 
dosage 
(mg) 
UPDRS 
III 
motor 
score 
UDysRS 
objective 
score 
Amnes-
tic 
dyskine-
sia 
MOCA 
score 
MMSE 
score 
CSF 
available 
Blood 
sample 
available 
Male 46 17 Yes Yes Yes 8 862,5 38 N/A 1 N/A 29 ✔ ✔ 
Male 73 10 No Yes Yes 8 600 35 N/A 0 N/A 28 ✔ ✔ 
Male 76 1,5 No No Yes 1 300 29 N/A 0 N/A 19 ✔ ✔ 
Male 66 3 Yes Yes No 0 300 17 0 0 28 30 ✔ ✔ 
Male 75  No Yes Yes N/A 510 34 0 0 23 30 ✔ ✔ 
Male 66 5 Yes Yes No 0 310 29 0 0 29 29 ✔ ✔ 
Male 67 6 Yes Yes Yes N/A 1385 53 3 1 24 30  ✔ 
Male 63 15 No No Yes 8 800 16 13 1 24 29 ✔ ✔ 
Male 60 7 No No Yes 4 500 36 11 1 27 30 ✔ ✔ 
Male 70 2,5 Yes Yes No 0 410 15 0 0 28 30 ✔ ✔ 
Male 75 10 No No Yes 1 450 40 0 0 23 28 ✔ ✔ 
Female 47 7 No Yes Yes 2 510 17 0 1 28 30 ✔ ✔ 
Male 60 4 No Yes Yes 0 720 23 8 1 25 29 ✔ ✔ 
Female 55 2,5 Yes Yes No 0 380 18 0 0 26 29 ✔ ✔ 
Female 60 2 No Yes No 0 320 8 0 0 30 30 ✔ ✔ 
Male 41 10 Yes Yes Yes 0,3 730 44 0 0 29 30 ✔ ✔ 
Male 51 8 Yes No No 0 100 17 0 0 30 30  ✔ 
Male 65 3,5 No Yes Yes 0,3 470 29 0 0 26 30 ✔ ✔ 
Male 66 1,5 No Yes No 0 105 18 0 0 24 26 ✔ ✔ 
Male 62 8 No Yes Yes 4 1643,75 32 0 0 28 30  ✔ 
Female 57 6 Yes Yes Yes 2,4 1060 36 7 1 27 28 ✔ ✔ 
Male 66 6 No Yes Yes 1 620 33 0 1 27 28  ✔ 
Male 68 10 No No Yes 7 950 17 13 1 26 29 ✔ ✔ 
Female 67 7 Yes Yes No 0 420 28 0 0 29 30 ✔ ✔ 
Female 65 10 No Yes Yes N/A 1160 32 15 1 28 29  ✔ 
Male 72 3,5 No No Yes 0,7 600 50 0 0 25 29 ✔ ✔ 
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Table	3:	Demographic	and	clinical	data	in	controls	and	PD	groups.	
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7.2:	Diagnostic	biomarker	candidates	
	
7.2.1	Alpha-synuclein	
	
ELISA	CSF	total	alpha-synuclein	(CSF-t-α-syn)(Fig.10A):		No	 significant	 difference	 between	 PD	 total	 and	 controls	 were	 found.	 CSF	 t-α-syn	 was	significantly	 correlated	 with	 age	 in	 the	 control	 group	when	 including	 the	 two	 AD	 patients	(p=0.023).	 Gender	 did	 not	 affect	 CSF	 t-α-syn.	 A	multiple	 regression	 analysis	 of	 CSF-t-α-syn	including	case,	age,	and	gender	did	not	show	significant	correlations.	In	the	PD	group	CSF-t-α-syn	was	not	correlated	to	L-DOPA-LED,	total	LED,	the	UPDRS	part	III	motor	 score	or	MOCA.	 Significant	 correlation	with	MMSE-score	was	due	 to	 the	DLB	patient	having	a	marked	decrease	in	score,	and	no	significance	was	attained	without	the	DLB	patient.			
ELISA	erythrocyte	total	alpha-synuclein	(ery-t-α-syn)(Fig.10B):	No	significant	difference	between	PD	total	and	controls	were	found.	Neither	age	nor	gender	affected	 ery-t-α-syn	 levels.	 No	 correlation	was	 found	 between	 ery-t-α-syn	 and	 CSF-t-α-syn,	disease	 duration,	 L-DOPA-LED,	 total	 LED,	 MOCA	 scores,	 MMSE	 scores,	 or	 UPDRS	 part	 III	motor	scores.			
	
Fig.10:	ELISA	analysis	of	CSF	(A)	and	erythrocytes	(B).	(A)	Student’s	t-test,	not	significant	(B)	Student’s	t-test,	not	
significant.		
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Western	blot	Results	 from	using	 the	antibodies	MJFR1,	syn-211	and	ser-129	were	not	significant	and	are	not	shown.	A	significant	decrease	 in	PD	CSF	α-syn	 levels	was	 found	when	 focusing	on	 full	 length	α-syn	monomers	 as	well	 as	 one	 α-syn	 dimer.	 As	 seen	 in	 figure	 10,	 using	 antibodies	 against	 5-g4	(Fig.11A),	ser-87	(Fig.11B),	tyr-125/133	(Fig.11C,	only	significant	when	including	the	AD	and	DLB-patients),	HLU-C4	 (Fig.11D),	 and	HLU-N1	 (Fig.11E,	 only	 significant	when	excluding	AD	and	DLB-patients)	 revealed	differences	between	PD	and	controls.	Controls	had	 significantly	higher	 levels	 of	 dimeric	 α-syn	 visualized	 with	 the	 HLU-C4	 antibody	 (Fig.10F,	 only	 when	including	AD	and	DLB	patients)	Age	and	gender	had	no	effect	on	α-syn	levels.	Using	the	5-G4	and	ser-87	antibodies	(Fig.12B,C),	the	tetrameric/monomeric	α-syn	ratios	were	significantly	higher	 in	PD	patients	 (5-G4:	p=0.0023,	 ser-87:	p=0.0013).	Age	and	gender	had	no	effect	on	these	ratios.	In	controls	dimer	HLUC4	levels	significantly	correlated	with	age	(p=0.03,	R2=0.4).	A	 negative	 correlation	 between	 MOCA	 scores	 and	 full	 length	 α-syn	 monomer	 levels,	specifically	5-g4	(Fig.12A).		
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Figure	11:	Western	blot	analysis.	(A):	Wilcoxon	rank-sum	test,	p=0.0016	(B)	Wilcoxon	rank-sum	test,	p=0.0023	(C)	
Student’s	t-test,	p=0.0462	(D)	Student’s	t-test,	p=0.0205	(E)	Student’s	t-test,	p=0.0497	(F)	Student’s	t-test,	p=0.0164.		
a:	Only	significant	when	including	DLB	and	AD	patients			
b:	Only	significant	when	excluding	DLB	and	AD	patients	
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Figure	 12:	 (A)	 Correlation	 between	 MOCA	 scores	 and	 full	 length	 monomeric	 α-syn	 visualized	 using	 the	 5-G4	
antibody.	Linear	regression	with	bootstrap	and	1000	repetitions.	(B)	&	(C)	show	the	ratio	between	tetramers	and	
full	length	monomers	the	5-G4	and	ser-87	antibody	respectively.	(B)	Wilcoxon	rank-sum	test,	p=0.0023	(C)	Wilcoxon	
rank-sum	test,	p=0.0013.	FLM;	Full	length	monomer.	
	
7.2.2	L-Tryptophanol	assay	
	
CSF	TROL:	Trol	 scores	 in	 PD	 CSF	 are	 significantly	 lower	 compared	 to	 controls,	 also	 if	 excluding	 DLB	patient	from	the	PD	group	(Fig.13A).	Age	is	significantly	correlated	to	CSF	Trol	only	in	PD	CSF	when	 excluding	 the	 DLB	 patient.	 Gender	 does	 not	 affect	 CSF	 Trol	 scores.	 Using	 multiple	regression	analysis	including	case	and	age	shows	that	both	PD	status	and	age	affect	CSF	Trol	scores,	although	PD	status	had	a	more	marked	effect.		In	the	PD	group,	disease	duration	is	negatively	correlated	to	the	CSF	Trol	score	(Fig.15).	CSF	Trol	score	is	not	correlated	to	L-DOPA-LED,	total	LED,	MOCA-	or	MMSE-scores,	or	UPDRS	part	III	motor	scores.		
Plasma	Trol:	PD	 patients	 had	 significantly	 higher	 plasma	 Trol	 scores	 than	 controls,	 specifically	 L-DOPA	treated	 patients	 (Fig.13B).	 Age	 was	 significantly	 correlated	 to	 plasma	 Trol	 scores	 in	 total	
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(p=0.003),	 and	 also	 specifically	 in	 the	 PD	 group	 (p=0.018),	 but	 not	 in	 controls	 specifically.	Females	 had	 significantly	 lower	plasma	Trol	 scores	 in	 total	 (p=0.016),	 as	well	 as	 in	 the	PD	group	when	excluding	the	DLB	patient	(p=0.049).	In	a	multiple	regression	analysis	including	case,	age	and	gender,	only	age	was	significantly	correlated	to	plasma	Trol	scores.	In	 the	 PD	 group,	 plasma	Trol	 scores	were	 not	 correlated	 to	 disease	 duration,	 L-DOPA-LED,	total	LED,	MOCA-	or	MMSE-scores,	or	the	UPDRS	part	III	motor	score.			
Plasma/CSF	Trol	ratio:		In	PD	we	 found	a	significantly	higher	plasma/CSF	Trol	 ratio	 than	controls,	 specifically	 in	L-DOPA	treated	patients	(Fig.13C).	Age	was	not	significantly	correlated	to	the	plasma/CSF	Trol	ratio.	 In	 total	 females	 had	 significantly	 lower	 ratios,	 but	 not	 in	 PD	 and	 control	 groups	separately.		Multiple	 regression	 analysis	 including	 case,	 age	 and	 gender	 showed	 that	 PD	 status	significantly	increased	the	plasma/CSF	Trol	ratio	whereas	being	female	to	a	lesser	extent	was	negatively	correlated	to	the	plasma/CSF	Trol	ratio.	In	 the	PD	group	the	plasma/CSF	Trol	ratio	was	not	correlated	to	disease	duration,	L-DOPA-LED,	total	LED,	MOCA-	or	MMSE	scores	or	the	UPDRS	part	III	motor	score.	
	
CSF	Trol/CSF	protein	ratio:		Both	PD	total	and	all	three	PD	groups	had	significantly	lower	CSF	Trol/CSF	protein	ratios	than	controls	(Fig.13D).	Age	did	not	affect	the	ratio,	whereas	females	had	significantly	higher	ratios	in	total.	This	was	not	found	in	the	PD	or	control	group	separately.	Performing	multiple	linear	regression	analysis	including	case,	age,	and	gender,	PD	status	was	markedly	correlated	with	a	decreased	CSF	Trol/CSF	protein	ratio.		Non-parametric	ROC	analysis,	excluding	DLB	and	AD	patients	from	analysis,	yielded	an	AUC	of	0.8773.	At	the	best	cut-off	found	by	Youden’s	index,	calculating	the	CSF	Trol/CSF	protein	ratio	had	a	90%	sensitivity,	73%	specificity,	and	a	positive	predictive	value	of	83%	(Fig.14).	In	the	PD	group	the	ratio	was	negatively	correlated	with	disease	duration,	when	excluding	the	DLB	patient.	No	correlation	was	found	between	the	ratio	and	L-DOPA-LED,	total	LED,	MOCA-	or	MMSE-scores,	or	the	UPDRS	part	III	motor	score.		
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Figure	13:	L-Tryptophanol	assay	comparing	PD	total	and	controls.	(A)	Student’s	t-test,	p=0.0203	(B)	Wilcoxon	rank-
sum	test,	p=0.0137	(C)	Student’s	t-test,	p=0.0022	(D)	Student’s	t-test,	p=0.0001.		
a:	Not	significant	when	excluding	both	AD	and	DLB	patients,	still	significant	when	only	excluding	DLB	patient.	
	
		
		
	
	
Figure	 14:	 Receiver	 operating	 characteristics	 for	 CSF	
Trol/CSF	protein-ratios.	AUC;	Area	under	the	curve.			
Figure	15:	Correlation	between	CSF	Trol	scores	
and	disease	duration.	Linear	regression	analysis	
with	bootstrapping	and	1000	repetitions.	
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7.2.3	Glucocerebrosidase	
	PD	patients	had	significantly	 lower	GBA	activity	than	controls	(Fig.16A).	Age	was	negatively	correlated	 to	 GBA	 activity	 in	 the	 total	 group	 as	 well	 as	 in	 the	 control	 group	 (only	 when	including	AD	patients).	Gender	did	not	affect	GBA	activity.	Using	multiple	regression	analysis	correcting	 for	 age,	 we	 still	 found	 significantly	 lower	 GBA	 activity	 in	 PD	 CSF.	 Excluding	 AD	patients	 and	 the	 DLB	 patient,	 age	 was	 no	 longer	 significantly	 correlated	 to	 GBA	 activity,	whereas	patient	status	was.		GBA	 activity	 was	 significantly	 correlated	 with	 the	 total	 LED.	 No	 correlation	 was	 found	between	GBA	activity	and	disease	duration,	L-DOPA-LED,	MOCA-	and	MMSE-scores,	or	UPDRS	part	 III	motor	scores.	Correcting	for	the	total	protein	content	 in	CSF	by	dividing	normalized	GCase	 activity	 with	 CSF	 total	 protein	 as	 suggested	 by	 another	 study(van	 Dijk	 et	 al.	 2013),	results	were	even	more	significant	(Fig.16B).	ANOVA	showed	significant	differences	between	groups	 (p=0.0000),	 and	 subsequent	 Bonferroni	 multiple	 comparison	 showed	 significantly	lower	ratios	of	normalized	GCase	activity	compared	to	protein	concentration	in	all	PD	groups	compared	 to	 controls.	 Excluding	 the	DLB	 and	AD	 patients,	 ROC	 analysis	 yielded	 an	 AUC	 of	0.9462,	with	the	best	cutoff	at	<1.838,	showing	a	sensitivity	of	75%,	specificity	of	100%	and	positive	predictive	value	of	94%.	The	GCase	corrected/CSF	 total	protein	variable	 in	PD	and	controls	was	significantly	correlated	to	age	(p=0.007)	and	 female	subjects	had	 lower	values	(p=0.011),	but	multiple	linear	regression	showed	no	significant	correlation	to	age	or	gender	when	comparing	PD	to	controls.	
	
Figure	16:	GCase	activity	in	CSF	in	PD	and	controls.	(A):	Student’s	t-test,	p=0.0024	(B):	Student’s	t-test,	p=0.0000.	
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7.2.4	Vascular	Endothelial	Growth	Factor:	
	CSF	 VEGF	 levels	 were	 significantly	 lower	 in	 control	 CSF	 compared	 to	 PD	 CSF	 (Fig.17),	especially	between	controls	and	PD-L.	The	PD-L	group	was	significantly	older	than	the	control	group,	and	age	was	markedly	correlated	with	VEGF	levels	 in	PD+controls	and	in	the	control	group.	 In	 the	 control	 group	 females	 had	 significantly	 lower	 VEGF	 levels,	 even	 though	 they	were	not	significantly	younger	than	males.	In	multiple	regression	analysis	taking	into	account	age	and	gender,	age	was	the	only	significant	factor.		In	the	PD	group	there	was	no	correlation	between	VEGF	and	disease	duration,	L-DOPA-LED,	total	LED,	MOCA-	and	MMSE-scores,	or	UPDRS	part	III	motor	scores.			
	
Figure	17:	Vascular	endothelial	growth	factor	in	CSF.	Student’s	t-test,	p=0.0321.	
	
7.2.5	Catecholamines:	
	As	a	diagnostic	biomarker	focus	was	put	on	patients	not	receiving	L-DOPA	treatment,	which	significantly	alters	the	monoamine	profile.			As	can	be	seen	in	figure	18,	patients	not	receiving	L-DOPA	treatment	had	significantly	lower	levels	of	L-DOPA	(Fig.18A),	DA	(Fig.18B),	DOPAC	(Fig.18C)	and	HVA	(Fig.18D).	In	the	control	group,	non-fasting	subjects	had	significantly	higher	DOPAC	levels	than	fasting	subjects.	
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Figure	18:	Catecholamine	metabolites	in	CSF	in	controls	and	PD	patients	not	treated	with	L-DOPA.	(A)	Student’s	t-
test,	p=0.0146	(B)	Wilcoxon	rank-sum,	p=0.0067	(C)	Student’s	t-test,	p=0.0108	(D)	Student’s	t-test,	p=0.0235.	
	
7.2.6	Tryptophane	metabolism:	
	
Plasma:	Focusing	 on	 tryptophane	 (TRP)	 and	 TRP	 metabolites,	 there	 are	 no	 significant	 differences	between	PD	and	controls,	aside	from	an	increase	in	3-O-methyldopa	(3-OMD)	(p=0.0014),	5-hydroxytryptamine	 (5-HT)	 (p=0.0059),	 and	 L-DOPA	 (p=0.0002).	 Linear	 regression	 analysis	taking	L-DOPA	intake	into	account	clearly	showed	that	an	increase	in	these	variables	was	due	to	L-DOPA-intake	(p=0.000	for	each).	Non-fasting	did	not	significantly	affect	plasma	levels	of	any	 of	 the	 metabolites	 except	 3-OH-anthranilic	 acid	 (3-HANA)	 levels	 (linear	 regression	analysis	 with	 3-HANA	 as	 dependent	 variable,	 p=0.0156),	 and	 significantly	 higher	 levels	 in	male	 compared	 to	 female	 controls	 were	 identified	 regarding	 anthranilic	 acid	 (ANA),	 TRP,	xanthurenic	acid	(XAN)	and	KYN.	
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The	 3-HK/KYNA	 ratio	 overlaps	 between	 PD	 and	 controls,	 but	 is	 significantly	 higher	 in	 PD	(p=0.0107)(not	depicted	in	a	figure).	This	difference	is	driven	by	an	increase	in	PD-LID	(see	segment	6.3.2).	The	3-HANA/3-HK	ratio	is	significantly	lower	in	PD	(p=0.0025)(not	depicted	in	a	figure),	specifically	in	L-DOPA	treated	patients	(see	segment	6.3.2).	In	PD	plasma	ANA	and	the	plasma	3-HANA/3-HK	ratios	are	significantly	correlated	(p=0.033,	R-squared=0.1655).		In	the	PD	population	no	significant	correlation	was	found	between	variables	and	the	UPDRS	part	III	motor	score.		Linear	 regression	 analysis	 revealed	 correlations	 between	 the	 MOCA	 score	 and	 several	variables:	 Correlation	 with	 TRP	 (p=0.006,	 R2=0.21)	 and	 XAN	 (p=0.039,	 R2=0.14).	 TRP	 and	XAN	were	negatively	correlated	with	age	(p=0.011,	p=0.003	respectively),	and	taking	age	into	account	only	provided	a	near	significant	correlation	between	TRP	and	MOCA	scores	(p=0.05),	but	 not	 XAN.	 Negative	 correlation	with	 3-OMD	 (p=0.007	 R2=0.18),	 5-HT(p=0.000	 R2=0.25),	and	L-DOPA	(p=0.000).	As	mentioned	previously,	patients	receiving	L-DOPA	have	significantly	lower	MOCA	 scores	 than	 PD-N.	 All	 three	 variables	were	 significantly	 correlated	 to	 L-DOPA	intake	(p=0.000	for	all),	as	well	as	a	negative	correlation	between	age,	3-OMD	(p=0.002)	and	5-HT	(p=0.049),	and	taking	these	into	account	revealed	no	significant	correlation	with	MOCA	scores.	 KYN	 levels	 were	 not	 affected	 by	 age	 or	 L-DOPA	 intake,	 and	 correlated	 with	 MOCA	scores	(p=0.015,	R2=0.14)(Fig.19).	
		Figure	 19:	 Correlation	 between	 plasma	 kynurenine	 levels	 and	 MOCA	 scores	 in	 PD	 patients.	 Linear	 regression	
analysis	with	bootstrapping	and	1000	repetitions.	
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CSF:	ANA	and	5-HIAA	levels	are	increased	and	decreased	respectively	in	PD	(p=0.0109,	p=0.0158	respectively)(Fig.20A,B).	Neither	ANA	nor	5-HIAA	levels	correlated	with	age	or	fasting	status,	and	when	comparing	L-DOPA	treated	patients	with	PD-N,	there	was	no	significant	difference	in	ANA	and	5-HIAA	levels.		An	increase	in	L-DOPA	and	3-OMD	levels	in	PD	was	due	to	L-DOPA	intake.		In	the	PD	group,	no	significant	correlation	between	variables	and	UPDRS	part	III	motor	score	was	found.		MOCA	 scores	 correlated	 negatively	 with	 ANA	 (p=0.033,	 R2=0.19)(Fig.20C),	 a	 variable	 not	correlating	with	age.	Omitting	the	DLB	patient	did	not	change	the	results.		
	
Figure	20:	Differences	in	CSF	tryptophane	metabolite	levels	of	anthranilic	acid	and	5-HIAA	in	PD	versus	controls	and	
correlation	between	MOCA	scores	and	CSF	ANA	in	PD.	(A)	Student’s	t-test,	p=0.0109	(B)	Student’s	t-test,	p=0.0158	
(C)	Linear	regression	analysis	with	bootstrapping	and	1000	repetitions.	
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7.2.7	Combination	of	CSF	Trol/	CSF	protein	ratio	and	corrected	GCase	activity/CSF	protein	ratio:	
	Individually	 the	 CSF	 Trol	 and	 corrected	 GCase	 activity	 divided	 by	 the	 total	 CSF	 protein	concentration	were	highly	significant	in	separating	PD	from	controls.	I	combined	the	values	in	a	single	variable	by	multiplication:		 !"# !"#$!"# !"!#$ !"#$%&'× !"##$!%$& !"#$% !"#$%$#&!"# !"!!" !"#$%&' = !"# !"#$ × !"##$!%$& !"#$% !"#$%$#&!"# !"!#$ !"#$%&'! 		Logistic	 regression	 with	 case	 as	 the	 dependent	 variable	 and	 this	 new	 variable	 as	 the	independent	was	significant	(p=0.045).		Using	the	variable	in	ROC	analysis,	excluding	the	DLB	and	AD	patients,	yielded	an	AUC	of	95%,	sensitivity	85%,	specificity	90.91%,	PPV	82,1%	and	NPV	79%	with	a	cutoff	at	<4555.		
	
7.3:	Biomarker	candidates	for	L-DOPA-induced	dyskinesia		
7.3.1	Catecholamine	metabolism	in	CSF:	
	Significant	findings	regarding	monoamine	ratios	are	depicted	in	figure	21.	All	analyses	were	performed	using	Dunn’s	test,	but	without	correction	for	multiple	comparisons.	It	was	argued	that	 each	 comparison	 tested	 a	 different	 hypothesis,	 obviating	 the	 need	 for	 multiple	comparisons.	 For	 the	 thesis,	 subsequent	 analyses	 were	 performed	 with	 Bonferronis	adjustment	for	multiple	comparisons	to	observe	the	potential	differences.									(Fig.21A)	The	DA/L-DOPA	ratio	was	found	to	be	significantly	higher	in	the	PD-LID	and	control	group	 compared	 to	 PD-L.	 Correcting	 for	 multiple	 comparisons,	 only	 controls	 had	 a	significantly	higher	ratio	than	PD-L,	but	not	when	excluding	the	AD	patients.			(Fig.21B)	The	DOPAC/DA	ratio	was	significantly	lower	in	the	PD-LID	group	compared	to	PD-L,	PD-N	 and	 controls,	 and	 controls	 had	 significantly	 higher	 ratios	 than	 PD-N.	 Adjusting	 for	multiple	 comparisons,	 only	PD-LID	had	a	 significantly	 lower	DOPAC/DA	ratio	 than	 controls	and	PD-N.	(Fig.21C)	PD-N	had	significantly	higher	HVA/DA	ratio	compared	to	PD-L	and	PD-LID,	 and	 controls	 had	 a	 significantly	 higher	 ratio	 than	 PD-L.	 Adjusting	 for	 multiple	comparisons,	only	PD-LID	had	a	lower	HVA/DA	ratio	than	PD-N	and	controls.		
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(Fig.21D)	Dyskinetic	patients	and	controls	have	significantly	higher	MHPG/NA	ratios	than	PD-L,	only	when	not	performing	Bonferronis	adjustment	for	multiple	comparisons.	
	
Figure	21:	Catecholamine	ratios	 in	controls	and	PD	groups.	All	multiple	comparisons	are	performed	using	Dunn’s	
test.	 (A)	 Kruskal-Wallis,	 p=0.0838	 (B)	 Kruskal-Wallis,	 p=0.0018	 (C)	 Kruskal-Wallis	 p=0.0019	 (D)	 Kruskal-Wallis	
p=0.1410.		
a:	Only	significant	when	including	DLB	and	AD	patients.	
π:	Not	significant	when	using	Bonferronis	correction	for	multiple	comparisons	
	
7.3.2	Tryptophane	metabolism:		Plasma:	PD-L	 had	 significantly	 higher	 ANA	 (only	 when	 including	 DLB	 patient)(Fig.22A)	 and	 KYNA	levels	 than	PD-LID	(Fig.22B),	and	a	significantly	higher	KYN/TRP	ratio	compared	 to	PD-LID	(Fig.22C).	 PD-LID	 had	 significantly	 higher	 3-HK/KYNA	 (Fig.22D)	 and	 3-HK/KYN	 (Fig.22E)	ratios	than	controls	and	PD-N.	Conversely,	PD-LID	had	a	more	pronounced	decrease	in	the	3-
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HANA/3-HK	ratio	than	PD-L	(Fig.22F),	as	well	as	a	 lower	XAN/3-HK	ratio	than	controls	and	PD-N	(Fig.22G).			CSF:	PD-LID	 (but	 also	 controls	 and	 PD-N)	 had	 significantly	 lower	 ANA	 levels	 than	 PD-L	(p=0.0097)(Fig.23).		
7.3.3	Phosphorylated	Extracellular	signal-regulated	kinases:	
	Focusing	on	P-ERK%,	ANOVA	between	groups	was	not	significant.	Followed	by	uncorrected	Fisher’s	 least	significant	difference	(LSD)	 test,	 significant	difference	was	 found	between	PD-LID	and	controls	 (p=0.024)(Fig.24A).	L-DOPA	treated	 individuals	had	significantly	higher	p-ERK%	than	individuals	not	receiving	L-DOPA	(p=0.0318)(Fig.24B).			
Cerebrospinal	fluid	biomarkers	for	Parkinson’s	disease	and	L-DOPA-induced	dyskinesia		
	 70	
	
Figure	 22:	 Group	 differences	 in	 plasma	 TRP	 metabolite	 levels	 and	 their	 ratios.	 Parametric	 data	 analysed	 with	
ANOVA	 and	 subsequent	 Bonferronis	 multiple	 comparisons,	 non-parametric	 data	 analysed	 with	 Dunn’s	 test	 with	
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Bonferronis	 correction	 for	 multiple	 comparison.	 (A)	 ANOVA,	 p=0.0265	 (B)	 ANOVA,	 p=0.0415	 (C)	 Kruskal-Wallis,	
p=0.0479	(D)	Kruskal-Wallis,	p=0.0008	(E)	Kruskal-Wallis,	p=0.0038	(F)	ANOVA,	p=0.0024	(G)	ANOVA,	p=0.0005.	
a:	Not	significant	when	excluding	DLB	and	AD	patients.	
b:	Only	significant	when	excluding	DLB	and	AD	patients.	
	
	
	
	Figure	23:	CSF	levels	of	ANA	in	groups.	ANOVA,	p=0.000.	Bonferronis	multiple	comparison.		
	
Figure	24:	Percentage	of	phosphorylated	ERK	1/2	compared	to	total	ERK1/2	levels	in	CSF	and	the	effect	of	L-DOPA	
on	p-ERK%.	(A)	ANOVA,	p=0.5846.	Multiple	comparison	with	unprotected	Fischer’s	least	significant	difference	(LSD)	
(B)	Student’s	t-test,	p=0.0318		
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CHAPTER	8:	DISCUSSION	
	
8.1	Diagnostic	biomarker	candidates	
	
8.1.1	Alpha-synuclein:		In	 this	 project	 we	 have	 used	 both	 western	 blot	 and	 ELISA	 analyses	 for	 alpha-synuclein.	Results	 are	 not	 significant	when	 using	 ELISA	 analysis	 for	 t-α-syn	 in	 CSF,	 in	 line	with	 other	ELISA	studies(Trupp	et	al.	2014,	Aerts	et	al.	2012,	Foulds	et	al.	2012,	Tokuda	et	al.	2010).		One	study(Nielsen	et	al.	2014)	was	wrongly	cited	in	our	review(Andersen	et	al.	2016)	as	showing	no	difference	between	PD	and	controls.	On	 the	contrary,	 their	 results,	published	 in	another	paper(Wennstrom	 et	 al.	 2013),	 together	 with	 other	 ELISA	 studies(Fernandez	 et	 al.	 2013,	Mondello	et	al.	2014,	Parnetti	et	al.	2014)	have	found	significantly	lower	total	α-syn	levels	in	PD	 CSF.	 Also	 studies	 using	 time-resolved	 Förster’s	 resonance	 energy	 transfer	 assay	 (TR-FRET)(van	Dijk	et	al.	2014)	and	the	more	sensitive	luminex	assays	(Hall	et	al.	2012,	Hong	et	al.	 2010,	 Shi	 et	al.	 2014)	 found	 significantly	 lower	 levels	 in	 PD	CSF.	 These	 discrepancies,	 it	could	be	argued,	might	be	the	result	of	several	methodological	differences	regarding	sampling	procedures,	sample	processing	prior	to	storage,	and	the	use	of	different	capturing	antibodies.		A	 study	 has	 shown	 that	 erythrocytes	 contain	 the	 majority	 of	 α-syn	 in	 blood,	 and	 a	 mean	erythrocyte	α-syn	concentration	of	30	μg/ml	in	our	study	is	in	line	with	their	results(Barbour	
et	 al.	 2008).	 The	 results	 also	 reveal	 the	 markedly	 higher	 concentration	 of	 α-syn	 in	 blood	compared	 to	CSF,	with	 a	 factor	of	 approximately	106.	 Focusing	on	o-α-syn	 in	 the	periphery	instead	 of	 total	 α-syn	 seems	 to	 be	 a	 better	 approach	with	 one	 study	 finding	 a	 significantly	increased	o-α-syn	compared	 to	 total	blood	protein	 in	PD	compared	 to	controls	 (Wang	et	al.	2015).	In	conclusion	it	seems	debatable	whether	measuring	total	α-syn	by	itself	is	an	effective	diagnostic	tool	or	not.					Focusing	on	 the	western	blot	α-syn	analyses,	 it	 is	 interesting	 that	PD	patients	have	 lower	CSF	levels	of	monomeric	α-syn	phosphorylated	at	the	serine	87	residue	(p-ser87-α-syn).	One	would	expect	PD	patients	to	have	higher	levels	of	modified	α-syn	species,	as	was	the	case	in	one	 study	 that	 found	 increased	 levels	 (albeit	with	 overlap)	 of	 α-syn	 phosphorylated	 at	 the	serine	 129	 residue	 (p-ser129-α-syn)	 in	 PD	CSF	 (Majbour	 et	al.	 2016).	On	 the	 other	 hand	 it	may	 be	 that	 aggregation	 of	 alpha-synuclein,	 especially	 phosphorylated	 α-syn,	 is	 more	
Cerebrospinal	fluid	biomarkers	for	Parkinson’s	disease	and	L-DOPA-induced	dyskinesia		
	 73	
pronounced	 in	 PD	 CSF.	 Initially	 our	 western	 blot	 analyses	 do	 not	 show	 an	 increase	 in	oligomeric	 α-syn	 (dimeric,	 tetrametic),	 but	 since	 there	 may	 be	 other	 factors	 than	 disease	status	affecting	levels	of	t-α-syn	(and	therefore	also	levels	of	modified	and	aggregated	α-syn),	comparing	oligomeric	α-syn	to	the	amount	of	monomeric	α-syn	may	take	that	variation	into	account.	This	seems	to	be	supported	by	our	findings.	Patients	have	a	significantly	higher	ratio	between	tetrametic	and	monomeric	p-s87-α-syn	as	well	as	tetrameric	α-syn	and	monomeric	α-syn	visualized	with	the	5-G4	ab.	Other	studies	also	find	that	the	ratio	between	t-α-syn	and	modified	or	aggregated	α-syn	increases	the	discrepancy	between	PD	and	controls,	such	as	an	increased	o-α-syn/t-α-syn-ratio	(Tokuda	et	al.	2010,	Majbour	et	al.	2016,	Parnetti	et	al.	2014)	or	 an	 increased	 p-s129-α-syn/t-α-syn	 ratio(Majbour	 et	 al.	 2016).	 But	 in	 contrast	 to	 the	findings	of	the	two	aforementioned	studies	and	another	ELISA	study(Park	et	al.	2011),	we	did	not	find	significantly	increased	CSF	levels	of	oligomeric	α-syn	(such	as	dimeric	and	tetrameric	conformations).	It	may	be	due	to	the	low	number	of	observations	and	the	fact	that	the	other	studies	used	ELISA	instead	of	western	blot	analyses.			
8.1.2.	Oligomeric	protein	analysis:		In	our	L-Tryptophanol	manuscript	(Appendix	III),	the	findings	of	the	Trol	assay	are	discussed	in	detail.		It	has	to	be	noted	that	the	Trol	assay	seems	to	bind	to	prefibrillary	versions	of	Aβ	and	other	amyloids,	 but	 not	 α-syn	 (Reinke	 et	 al.	 2010).	 So	 it	 seems	 that	 the	 secondary,	 tertiary	 and	quaternary	structure	rather	than	the	primary	structure	of	the	protein	is	more	important	for	the	affinity	of	the	indole	marker	used	in	the	Trol	assay.		
CSF	Trol:	I	argue	that	lower	CSF	concentrations	of	oligomeric	proteins	might	be	due	to	the	aggregation	of	oligomeric	proteins	in	CNS	neurons	of	PD	patients.	The	argument	here	is	the	same	as	with	a	decrease	 of	 total	 α-syn	 due	 to	 aggregation.	 Potentially,	 a	 decreased	 bulk	 flow	 through	 the	brain	 parenchyma	would	 decrease	 the	 clearance	 of	 prefibrillary	 proteins	 to	 the	 CSF.	 I	 also	argue	that	L-DOPA	treatment	itself	might	induce	aggregation	of	oligomeric	proteins,	since	it	is	known	 that	 the	 toxic	 L-DOPA	 metabolite	 DOPAL	 increases	 aggregation	 of	 α-syn	 into	oligomeric	shapes(Burke	et	al.	2008).	But,	there	is	no	significant	difference	between	PD-N	and	
Cerebrospinal	fluid	biomarkers	for	Parkinson’s	disease	and	L-DOPA-induced	dyskinesia		
	 74	
L-DOPA-treated	patients	in	terms	of	CSF	Trol,	and	the	L-DOPA	daily	dose	does	not	correlate	with	CSF	Trol.	When	excluding	the	DLB	patient,	CSF	Trol	negatively	correlated	with	disease	duration,	but	not	the	 use	 of	 L-DOPA.	 A	 gradual	 decrease	 of	 CSF	 Trol	 could	 then	 represent	 the	 successive	increase	in	protein	aggregation	with	further	deterioration,	and	it	could	be	speculated	whether	CSF	Trol	scores	could	be	used	as	a	rate	marker.		
	
Plasma	Trol:	The	 significantly	higher	plasma	Trol	 scores	may	be	due	 to	peripherally	 affected	nerve	 cells	releasing	 oligomeric	 proteins,	 since	 they	 are	 in	 direct	 contact	 with	 the	 blood	 stream.	Alternatively	a	breakdown	of	the	BBB	may	release	these	proteins	into	the	bloodstream	from	the	CSF.	It	may	be,	that	other	amyloids	follow	the	same	dynamic	as	α-syn:	We	know	that	CNS	derived	exosomes	containing	α-syn	can	be	measured	in	plasma	of	PD	patients(Shi	et	al.	2014),	and	that	o-α-syn	can	be	measured	in	plasma(Pchelina	et	al.	2017).	This	notion	seems	unlikely	though,	 since	 a	 breakdown	 of	 the	 BBB	 would	 also	 be	 expected	 to	 increase	 the	 influx	 of	oligomeric	proteins	to	the	CSF,	hypothetically	increasing	CSF	Trol	scores	in	PD.	Few	 studies	 on	 plasma	 oligomeric	 α-syn	 have	 been	 performed.	 One	 ELISA	 study	 found	increased	levels	of	o-α-syn	in	PD	patients,	the	test	having	a	specificity	of	0.852,	sensitivity	of	0.529	and	PPV	of	0.818(El-Agnaf	et	al.	2006).	Conversely,	another	ELISA	study	on	drug	naïve	patients	did	not	find	this	increase,	arguing	that	anti-parkinsonian	treatment	itself	might	affect	the	conformation	of	α-syn(Park	et	al.	2011).	Perhaps	the	same	could	be	true	for	other	amyoid	species.	 One	 major	 confounder	 may	 lie	 in	 the	 selection	 of	 PD	 patients.	 GBA	 mutations,	 as	written	earlier,	are	the	most	common	genetic	cause	for	PD	development.	In	one	study,	directly	separating	sporadic	PD	patients	from	PD	patients	with	GBA	mutations,	a	significant	increase	of	p-o-α-syn	(and	decrease	of	plasma	GCase	activity)	compared	to	controls	was	only	found	in	patients	with	known	GBA	mutations,	and	not	in	sporadic	PD(Pchelina	et	al.	2017).	Maybe	the	peripherally	 decreased	 GCase	 activity	 in	 these	 patients	 has	more	 profound	 systemic	 effect,	explaining	the	increased	peripheral	production	of	o-α-syn.	If	the	selection	of	PD	patients	with	random	 GBA	 mutations	 is	 not	 uncommon,	 this	 could	 lead	 to	 a	 decreased	 p-o-α-syn	 in	 a	selected	 PD	population,	 but	would	 not	 be	 a	 shared	 feature	 of	 all	 patients.	 Perhaps	 affected	GCase	 activity	 not	 only	 affects	 α-syn	 conformation,	 but	 also	 the	 conformation	 of	 other	amyloids.	
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Decreased	CSF	Trol/plasma	Trol	ratio	in	PD:	It	could	possibly	be	argued	that	the	combination	of	central	aggregation	of	oligomeric	proteins	in	 PD,	 combined	 with	 the	 peripheral	 production	 of	 oligomeric	 proteins	 in	 the	 PNS	 could	decrease	 the	CSF	Trol/plasma	Trol	 ratio	 significantly.	 Alternatively	 it	might	 reflect	 a	 larger	escape	of	oligomeric	proteins	through	a	leaky	BBB,	although	it	could	be	expected	that	proteins	might	as	well	travel	the	opposite	direction.		Decreased	CSF	Trol/total	CSF	protein	ratio:	The	 BBB	 is	 affected	 in	 advanced	 PD	with	 a	 possible	 influx	 of	 plasma	 proteins(Pisani	 et	 al.	2012).	Assuming	that	the	decrease	of	CSF	Trol	 in	PD	is	due	to	the	aggregation	of	oligomeric	proteins	 intraneuronally,	 accordingly,	 the	 combination	 of	 an	 increased	 influx	 of	 plasma	proteins	 and	 intraneuronal	 oligomeric	 protein	 aggregation	 could	 explain	 the	 significantly	decreased	CSF	Trol/	total	CSF	protein	ratio.		
8.1.3	Glucocerebrosidase	activity:	
	In	our	 study	we	 found	 significantly	decreased	GCase	 activity	 in	PD	CSF.	 It	 has	been	 argued	that	to	minimize	the	potential	effect	on	GCase	activity	due	to	a	potentially	defective	BBB,	this	should	be	corrected	for	by	dividing	the	GCase	activity	with	the	total	CSF	protein	(van	Dijk	et	al.	2013).	When	doing	so,	our	GCase	assay	performs	very	well	in	separating	PD	from	controls,	also	 when	 excluding	 the	 DLB	 and	 AD	 patients.	 I	 identified	 three	 studies	 using	 the	 same	substrate	 for	 the	 fluorescence	assay,	with	one	study	 finding	no	difference	between	patients	and	 controls	 (van	 Dijk	 et	 al.	 2013),	 and	 two	 studies	 also	 finding	 a	 decrease	 in	 GCase	activity(Balducci	et	al.	2007,	Parnetti	et	al.	2014).		I	am	not	sure	as	to	why	there	seems	to	be	a	discrepancy.	 One	 noticeable	 difference	 is	 the	 sample	 processing.	 Whereas	 Balducci	 et	 al	collected	the	CSF	in	iced	tubes	and	we	kept	the	collected	CSF	in	ice	water	until	centrifuging,	both	also	processing	the	CSF	and	freezing	it	within	30	minutes	and	Parnetti	et	al	immediately	freezing	 the	samples,	Van	Dijk	did	not	keep	 the	CSF	cool	until	processing	and	had	a	2	hour	limit.	 It	 has	 been	 shown	 that	 GCase	 activity	 significantly	 declines	within	 a	 couple	 of	 hours	from	 LP	 if	 the	 sample	 is	 kept	 at	 RT,	 whereas	 storage	 at	 4°C	 prior	 to	 freezing	 allows	 for	 a	broader	time	span	prior	to	freezing	without	affecting	GCase	activity	significantly	(Persichetti	
et	al.	2014).			
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Nevertheless,	our	results	do	point	to	a	significantly	decreased	GCase	activity	in	a	group	of	PD	patients,	 potentially	 indicating	 that	 affection	 of	 GCase	 activity	 in	 CSF	 is	 a	 common	 feature	among	patients.	Decreased	GCase	activity	has	been	shown	 in	post-mortem	obtained	SN	and	cerebellum	of	both	PD	patients	and	PD	patients	with	GBA	mutations(Gegg	et	al.	2012).	Studies	of	blood	plasma	from	PD	patients	with	GBA	mutations	has	been	linked	to	significantly	lower	plasma	 GCase	 activity	 compared	 to	 controls,	 whereas	 PD	 patients	 with	 no	 known	 GBA	mutation	 did	 not	 have	 decreased	GCase	 activity(Pchelina	 et	 al.	 2017,	Ortega	 et	al.	 2016).	 A	larger	 study	 did	 find	 a	 decrease	 in	 GCase	 activity	 in	 blood	 from	 PD	 patients	 compared	 to	controls,	 even	 when	 excluding	 patients	 with	 known	 GBA	 mutations	 and	 a	 clinical	 history	indicating	 other	mutations	 linked	 to	 PD(Alcalay	 et	al.	 2015).	 This	 could	 point	 to	 decreased	GCase	 activity	 being	 a	 part	 of	 the	 pathophysiology	 in	 idiopathic	 PD.	 In	 a	 study	 that	 found	decreased	CSF	GCase	 activity	 in	PD	 they	did	not	 find	 a	 significant	difference	 in	PD	patients	with	and	without	GBA1	mutations	(Parnetti	et	al.	2014).	Comparing	it	 to	the	studies	finding	significantly	 decreased	 plasma	 GCase	 activity	 only	 in	 PD	 with	 GBA1	 mutations,	 this	 could	point	 to	a	difference	 in	 the	way	 the	pathophysiological	processes	 involved	 in	PD	affect	CNS	and	plasma	GCase	activity.	It	has	to	be	noted	that	even	though	patients	with	Gaucher’s	disease	type	1	have	a	significantly	higher	 risk	 of	 developing	 PD	 compared	 to	 the	 background	 population,	 only	 a	 smaller	percentage	will	develop	PD(Rosenbloom	et	al.	2011).	 If	decreased	GCase	activity	by	 itself	 is	not	enough	for	the	development	of	PD,	other	pathophysiological	pathways	involved	in	PD	may	simultaneously	affect	GCase	activity.	Even	 though	we	do	not	have	a	genetic	analysis	on	our	patients,	with	a	decrease	in	GCase	activity	among	the	entire	group,	it	seems	unlikely	that	GBA	mutations	account	for	all	the	patients	with	decreased	GCase	activity.	I	previously	mentioned	a	study	showing	that	o-α-syn	may	negatively	affect	GCase	activity(Mazzulli	et	al.	2011),	and	this	could	be	a	possible	link	between	idiopathic	PD	and	decreased	GCase	activity.	Supporting	the	notion,	one	study	also	found	patients	with	DLB	to	have	lower	CSF	GCase	activity	than	controls	and	patients	with	AD	and	frontotemporal	dementia(Parnetti	et	al.	2009).	This	could	indicate	that	GCase	dysfunction	is	a	common	feature	among	synucleinopathies.	It	is	worth	mentioning	that	the	DLB	patient	 in	this	project	had	the	lowest	GCase	activity	of	all.	GBA1	mutations	are	even	more	clearly	linked	to	DLB	development	than	PD(Nalls	et	al.	2013),	and	even	though	it	is	speculative,	one	might	suspect	that	this	patient	could	be	the	carrier	of	a	GBA1	mutation.		
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There	are	methodological	differences	 in	our	 analysis	 that	 require	mentioning	and	 that	may	have	affected	our	results.	Due	to	a	sudden	breakdown	of	the	previously	used	fluorescent	plate	reader,	some	of	our	samples	were	analysed	using	a	plate	reader	from	a	different	brand.	For	this	 reason,	 to	 compare	 results,	 all	 samples	 were	 normalized	 by	 dividing	 them	 with	 the	control	mean	of	the	different	assays.			
8.1.4.	Tryptophane	metabolites:		In	our	LC-MS	based	metabolomics	 study	we	have	not	yet	performed	detailed	analysis	of	all	detected	metabolites.	 So	 far	 our	 only	 results	 are	 the	 ones	 related	 to	 TRP	metabolism	 (see	fig.24).	Several	studies	have	assessed	a	wider	spectrum	of	plasma,	serum,	and	CSF	metabolites	(Roede	et	al.	2013,	Wuolikainen	et	al.	2016,	Bogdanov	et	al.	2008,	Johansen	et	al.	2009,	Lewitt	
et	al.	 2013,	 LeWitt	 et	al.	 2017,	Hatano	 et	al.	 2016,	 Trupp	 et	 al.	 2014,	 Ascherio	 et	al.	 2009),	identifying	changes	in	the	purin,	TRP,	and	tyrosine	metabolism	(Ascherio	et	al.	2009,	Trupp	et	al.	2014,	Lewitt	et	al.	2013,	 Johansen	et	al.	2009,	Hatano	et	al.	2016),	 as	well	 as	 identifying	metabolites	with	a	prognostic	value	with	regards	to	rate	of	disease	development	(LeWitt	et	al.	2017,	Roede	et	al.	2013).	Contrary	to	studies	 finding	decreased	TRP	in	serum	(Hatano	et	al.	2016)	and	CSF	(Trupp	et	al.	2014),	we	did	not	 find	decreased	CSF	or	plasma	TRP.	Differing	from	our	study,	Trupp	et	al	only	included	newly	diagnosed	untreated	PD	patients,	and	Hatano	et	 al	 used	 serum	 samples.	 It	 is	 known	 that	 L-DOPA	 can	 affect	 tyrosine	 metabolism(De	Deurwaerdere	 et	 al.	 2016),	 but	 L-DOPA	 can	 also	 affect	 TRP	metabolism.	 L-DOPA	 has	 been	shown	to	compete	with	TRP	for	uptake	by	an	amino	transporter	in	serotonergic	neurons.	L-DOPA	also	competes	with	TRP	for	the	amino	acid	decarboxylase	(AADC)	enzyme.	The	effect	is	a	 decreased	 serotonin	 production	 due	 to	 decreased	 TRP	 uptake	 and	metabolism	 (Borah	 &	Mohanakumar	 2007).	 Serotonin	 production	may	 also	 be	 affected	 be	 the	 concurrent	 use	 of	AADC-inhibitors	with	L-DOPA	treatment	(such	as	Sinemet®).		As	 described	 in	 our	 article	 (Havelund	 et	 al.	 2017)(Appendix	 III)	 the	 other	 degradational	pathway	for	TRP	is	 the	KYN	pathway	 in	which	TRP	is	converted	 into	KYN	by	the	enzymatic	activity	 of	 indol	 2,3-dioxygenase	 (IDO)	 and	 kynurenine	 formidase	 (fig.25).	 KYN	 may	 be	transformed	into	ANA	(due	to	kynureninase	activity),	KYNA	(due	to	kynurenine	transaminase	activity	(KAT))	or	3-HK	(due	to	kynurenine	3-monoxygenase	activity	(KMO)).	The	metabolites	in	this	pathway	are	neuroactive	and	are	related	to	psychiatric	disorders	such	as	schizophrenia	
Cerebrospinal	fluid	biomarkers	for	Parkinson’s	disease	and	L-DOPA-induced	dyskinesia		
	 78	
(Oxenkrug	et	al.	2016,	Fazio	et	al.	2015,	Kegel	et	al.	2014,	Chiappelli	et	al.	2014)	and	bipolar	disorder	(BD)(Lavebratt	et	al.	2014,	Olsson	et	al.	2012,	Sellgren	et	al.	2016,	Savitz	et	al.	2015,	Birner	et	al.	 2017).	 In	 general	 terms	 the	pathway	 leading	 to	KYNA	production	 is	 called	 the	neuroprotective	branch,	whereas	the	pathway	leading	to	3-HK	and	QUIN	production	is	called	the	neurotoxic	branch(Campbell	et	al.	2014).	A	correlation	between	MOCA	scores	and	plasma	KYN	 could	 indicate	 an	 expected	 correlation	 between	 the	 KYN	 pathway	 and	 cognitive	performance.	One	 reason	 for	 the	 direct	 correlation	 between	plasma	KYN	 and	MOCA	 scores	may	be	a	decreased	availability	of	TRP	for	KYN	production.	If	L-DOPA	treatment	decreases	the	availability	of	TRP	(patients	with	the	highest	LED	have	the	lowest	MOCA	scores),	it	may	also	decrease	serotonin	production,	which	could	affect	cognitive	performance.		We	identified	significantly	increased	CSF	ANA	in	PD	patients	with	the	same	pattern	in	plasma,	albeit	 not	 significant.	 ANA	 easily	 crosses	 the	 BBB	 by	 diffusion,	whereas	 KYN	 and	 3-HK	 are	transported	actively	across	the	BBB	by	the	large	neutral	amino	acid	carrier(Fukui	et	al.	1991).	This	 implies	 that	 the	blood	pool	of	 these	 substances,	 opposite	of	3-HANA,	KYNA	and	QUIN,	contribute	 to	 the	 CSF	 pool.	Whereas	 increased	ANA	 levels	 have	 been	measured	 in	 synovial	fluid	of	patient	with	rheumatoid	arthritis(Igari	et	al.	1987)	and	in	plasma	of	patients	with	type	1	diabetes	mellitus(Oxenkrug	et	al.	2015),	no	studies	have	previously	found	increased	ANA	in	PD	CSF.	One	potential	 source	 for	 this	 change	may	be	 related	 to	differences	 in	 the	 intestinal	microbiome.	Some	bacterial	strains	are	able	to	produce	ANA	to	be	used	as	a	precursor	for	TRP	production	(Rydon	1948),	so	changes	in	the	composition	of	intestinal	bacteria	may	affect	ANA	levels.	The	production	of	ANA	is	done	by	the	enzyme	kynureninase	(KYNU).	Since	PD	patients	have	increased	CSF	ANA	this	could	indicate	an	increased	KYNU	activity.	Our	results	show	that	plasma	ANA	levels	and	plasma	3-HANA/3-HK	ratios	are	significantly	correlated	in	PD,	which	supports	 the	 notion	 of	 increased	 KYNU	 activity.	 Recently,	 a	 study	 has	 shown	 significantly	increased	 KYNU	 activity	 compared	 to	 IDO	 activity	 in	 keratinocytes	 from	 patients	 with	 the	inflammatory	 skin	 disease	 psoriasis(Harden	 et	 al.	 2016).	 This	 would	 drive	 the	 TRP	metabolism	 towards	 the	 production	 of	 ANA	 and	 3-HANA,	 and	 in	 the	 end	 QUIN.	 The	 same	study	 found	 that	 exposing	 cells	 to	 a	 psoriatic	milieu	with	 interleukin	 17,	 interferon	 ϒ,	 and	tumor	necrosis	factor	α,	increased	the	activity	of	both	IDO	and	KYNU.	It	is	proposed	that	KYN	may	 act	 as	 an	 immunosuppressant,	 but	 that	 increased	 KYNU	 activity	 drives	 the	 KYN	metabolism	in	a	proinflammatory	direction;	especially	since	3-HANA	was	shown	to	increase	the	expression	of	proinflammatory	genes	 in	different	human	cell	 types(Harden	et	al.	2016).	
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Our	 findings	 could	 point	 to	 an	 interesting	 common	 pathogenic	 pathway	 between	inflammatory	 diseases.	 The	 constant	 proinflammatory	 activity	 may	 have	 long-term	deleterious	effects	on	neurons	due	to	ROS	production	and	microglial	activation.	Furthermore,	it	 seems	 that	psoriasis	patients	actually	do	have	a	significantly	 increased	risk	of	developing	PD,	with	a	meta	analysis	showing	a	38%	increased	risk	of	PD	in	psoriasis	patient	compared	to	subjects	without	psoriasis(Ungprasert	et	al.	2016).	In	our	study,	PD	patients	have	significantly	lower	 3-HANA/3-HK	 ratios	 than	 controls,	 indicating	 that	 they	 might	 have	 lower	 KYNU-activity.	But,	3-HANA	was	the	only	variable	of	the	TRP	metabolites	significantly	increased	in	non-fasting	controls	compared	to	 fasting	controls.	And	since	a	 larger	subset	of	controls	was	fasting,	this	is	a	plausible	explanation	for	the	increased	3-HANA/3-HK	ratios	in	controls.	ANA	was	not	significantly	affected	by	fasting	status	in	controls.		Our	 finding	 of	 an	 increased	 plasma	 3-HK/KYNA	 ratio	 in	 PD	 patients	 also	 point	 to	 a	 KYN	metabolism	 towards	 the	 neurotoxic	 branch,	 with	 a	 potentially	 increased	 KMO	 activity	compared	to	KAT	activity	in	PD	versus	controls.	The	same	pattern	was	found	in	another	CSF	study	 (Lewitt	 et	 al.	 2013).	 A	 post-mortem	 study	 also	 found	 increased	 levels	 of	 3-HK	 in	 the	putamen	 and	 SN	 of	 PD	 brains	 as	 well	 as	 a	 reduced	 KYN/3-HK	 ratio	 (Ogawa	 et	 al.	 1992).	Hypothetically,	 changing	 enzyme	 activity	 inducing	 a	 higher	 KAT/KMO	 activity	 ratio	 may	provide	neuroprotection.	Using	 the	KMO-inhibitor	Ro	61-6048	 it	has	been	shown	 in	animal	studies	that	serum	KYNA	concentrations	are	raised	acutely	(Samadi	et	al.	2005,	Gregoire	et	al.	2008).	The	same	studies	showed	that	the	KMO-inhibition	did	not	negatively	affect	the	effect	of	L-DOPA	treatment	in	animals.	It	has	to	be	noted	that	the	difference	in	3-HK/KYNA	is	largely	driven	 by	 an	 increase	 in	 PD-LID,	 and	 the	 role	 of	 KYNA	 and	 KMO-inhibition	 in	 LID	 will	 be	further	elaborated	in	the	discussion	section	7.2.1.				The	 significantly	 lower	 CSF	 5-HIAA	 levels	 in	 PD	 (Fig.20B)	 could	 be	 related	 to	 the	 L-DOPA	treatment	in	PD-L	and	PD-LID,	which	potentially	decreases	uptake	and	metabolism	of	TRP	in	serotonergic	neurons.	The	negative	correlation	between	CSF	ANA	levels	and	MOCA	scores	could	 indicate	that	KYN	metabolism	 towards	 QUIN	 has	 a	 negative	 impact	 on	 cognition.	 This	 would	 be	 in	 line	 with	findings	 linking	 an	 increased	 production	 of	 QUIN	 with	 neurocognitive	 deficits	 such	 as	dementia	in	HIV	patients	(Kandanearatchi	&	Brew	2012).		
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Figure	24:	Metabolic	pathways	for	tryptophane.	TDO;	tryptophan	2,3-dioxygenase,	IDO;	Indoleamine-	2,3-
dioxygenase,	KF;	kynurenine	formamidase,	KMO;	kynurenine	3-monooxygenase,	KYNU;	kynureninase,	KATs;	
kynurenine	aminotransferases,	3-HAO;	3-Hydroxyanthranilic	acid	dioxygenase,	AMO;	anthranilate	3-
monooxygenase,	TH;	tryptophan	hydroxylase,	AADC;	aromatic	amino	acid	decarboxylase,	MAO:	monoamine	oxi-	
dase.		
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8.1.5	Final	thoughts	on	diagnostic	biomarker	candidates:	
	The	marked	 decrease	 of	 the	 CSF	 Trol/	 CSF	 total	 protein	 ratio	 across	 the	 three	 PD	 groups	indicates	that	we	have	identified	a	potential	diagnostic	biomarker	candidate,	corroborated	by	the	good	performance	of	this	ratio	in	the	ROC.	Of	course	these	findings	have	to	be	repeated	in	much	larger	scale	to	take	into	account	random	variation.	The	strength	of	this	ratio	seems	also	to	be	indicated	by	the	lack	of	confounding	due	to	age,	gender,	or	fasting	status.	Ultimately,	we	do	 not	 know	 which	 specific	 proteins	 are	 actually	 measured	 by	 the	 L-Tryptophanol	fluorescence	assay,	meaning	that	we	do	not	know	whether	it	Aβ,	or	any	other	amyloid	that	can	also	 conform	 into	 β-sheet-configurations,	 and	 it	 is	 only	 a	 hypothesis	 that	 intraneuronal	aggregation	is	actually	the	reason	for	the	decrease	in	CSF	Trol.	Pragmatically,	 if	 findings	can	be	replicated,	 the	proposed	mechanism	behind	 the	measurable	changes	 is	 irrelevant	 from	a	clinician’s	viewpoint,	when	focusing	on	diagnostics.		
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8.2	L-DOPA	induced	dyskinesia	biomarker	candidates		
8.2.1	Tryptophane	metabolism:	
	Focusing	on	TRP	metabolites,	we	notice	some	specific	changes	in	PD-LID	compared	to	PD-L:	Dyskinetic	 patients	 in	 our	 study	 have	 significantly	 lower	 CSF	 and	 plasma	 ANA	 than	 non-dyskinetic	patients,	contrary	to	the	pattern	seen	in	PD	total	compared	to	controls.	At	the	same	time,	 dyskinetic	 patients	 also	 have	 lower	 plasma	 KYN/TRP	 ratios,	 and	when	 excluding	 the	DLB	patient,	 dyskinetic	 patients	 have	 significantly	 lower	 plasma	KYNA	 than	 non-dyskinetic	patients.		As	discussed	in	the	previous	section,	increased	KYNU	activity	(responsible	of	producing	ANA)	may	 be	 related	 to	 a	 proinflammatory	 state.	 Following	 that	 line	 of	 reasoning,	 our	 findings	might	point	to	an	increased	proinflammatory	state	in	non-dyskinetic	patients.	This	seems	to	counter	 a	 major	 review	 indicating	 that	 neural	 inflammation	 conveyed	 by	 microglia	 and	astrocytes	is	actually	related	to	development	of	LID(Carta	et	al.	2017).	It	may	of	course	be	that	other	 factors	 affect	 plasma	 ANA	 levels	 such	 as	 the	 availability	 of	 KYN,	 and	 potentially	 an	increased	activity	of	KAT	or	KMO	compared	to	KYNU	is	responsible.	As	will	be	discussed	now,	our	other	findings	may	conversely	corroborate	the	notion	of	inflammation	being	involved	in	LID	development.	In	our	study,	dyskinetic	L-DOPA	treated	patients	have	significantly	lower	plasma	KYNA	levels	than	non-dyskinetic	patients.	This	may	indicate	a	decreased	KAT	activity	or	that	KYN	is	simply	more	rapidly	being	converted	into	e.g.	3-HK.	Four	of	the	dyskinetic	patients	had	a	marked	increase	in	plasma	3-HK	driving	the	significant	difference	between	PD-LID	and	controls	as	well	as	PD-N,	in	terms	of	an	increased	plasma	3-HK/KYNA	ratio,	increased	plasma	3-HK/KYN	ratio	and	decreased	plasma	XAN/3-HK	ratio.	Both	KYNA	and	XAN	are	produced	by	KAT	activity.	Thus,	the	decreased	KAT	activity	combined	with	an	increased	KMO	activity	would	hypothetically	explain	the	differences.	The	NMDA	receptor	subunit	NR2B	is	abundant	in	the	striatum	and	is	among	many	different	functions	related	to	long	term	potentiation,	learning	and	memory(Loftis	&	Janowsky	2003),	and	a	study	found	an	increase	of	NR2B-containing	NMDA-receptors	in	dyskinetic	MPTP-treated	non-human	primates(Ouattara	et	al.	2009).	As	mentioned	previously,	glutamatergic	receptors	play	a	great	role	in	the	development	of	LID,	in	some	part	linked	to	the	TRP	metabolism.	The	two	TRP	degradational	pathways,	the	
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neuroprotective	branch	(KYNA)	or	the	neurotoxic	branch	(3-HK	and	finally	QUIN),	seem	to	have	opposing	effects	on	NMDA	receptors.	KYNA	binds	to	the	glycin	binding	site	on	the	NR1	NMDA	subunit(Parsons	et	al.	1997)	and	an	in	vivo	study	on	cortical	neurons	showed	that	KYNA	effectively	diminishes	the	agonistic	effect	of	QUIN	on	NMDA	receptors(Perkins	&	Stone	1982).	Further	supporting	the	involvement	of	glutamatergic	receptors	in	LID,	studies	have	looked	at	the	effect	of	the	KMO-inhibitor	Ro	61-6048,	which	raises	KYNA	levels	acutely.	Using	Ro	61-6048	on	a	group	of	L-DOPA	treated	MPTP-treated	primates	showed	a	20%	decrease	in	LID	(Samadi	et	al.	2005)	as	well	as	a	delayed	LID	development	(Gregoire	et	al.	2008),	potentially	related	a	prevented	increase	of	preproenkephalin	in	the	striatum	(Tamim	et	al.	2010).		Thus,	the	increased	3-HK/KYNA	ratios	in	PD-LID	plasma	(with	the	same	pattern	being	noticeable	in	CSF)	could	suggest	increased	glutamatergic	transmission	in	the	basal	ganglia	as	a	cause	for	LID.	This	provides	an	interesting	treatment	prospect	for	LID	in	PD.	Would	it	be	possible	to	treat	dyskinetic	patients	with	such	a	KMO-inhibitor,	which	seems	to	have	marked	anti-dyskinetic	effects?	Whether	the	antidyskinetic	effect	is	actually	due	to	NMDA-receptor	inhibition	is	debated,	since	an	in	vivo	animal	study	has	shown	that	Ro	61-6048	induced	increased	levels	of	CSF	KYNA	is	not	enough	to	antagonize	NMDA	receptors(Obrenovitch	&	Urenjak	2000).	KYNA	also	works	as	a	slow	onset	voltage-independent	noncompetitive	antagonist	of	the	α7	nicotinic	acetylcholine	receptor	(α7-nAChR)(Hilmas	et	al.	2001).	The	α7-nAChR	is	highly	involved	in	synaptic	plasticity(Udakis	et	al.	2016),	and	changes	in	synaptic	plasticity	may	explain	the	anti-dyskinetic	effect	of	KYNA.	Alternatively,	it	may	simply	be	due	to	a	decreased	DA	release	in	striatum:	Striatal	cholinergic	interneurons	can	induce	DA	release	in	the	striatum	due	to	activation	of	nicotinergic	receptors,	regardless	of	action	potentials	in	the	dopaminergic	neuron(Threlfell	et	al.	2012).	The	idea	of	an	anti-dyskinetic	effect	of	nAChR-inhibition	seems	to	be	contradictory	to	other	findings:	It	has	been	argued	that	neuroinflammatory	processes	involving	microglia	and	astrocytes	may	be	related	to	LID	development,	and	that	the	anti-inflammatory	potential	of	ACh	agonists	in	astrocytes	is	due	to	α7-nAChR	stimulation(Carta	et	al.	2017).	The	α7-nAChR	agonist	5-(6-((3R)-1-azabicyclo(2,2,2)oct-3-yloxy)pyridazin-3-yl)-1H-indole	(ABT-107)	has	been	shown	to	provide	a	long	term	LID	depression	in	MTPT	and	L-DOPA	treated	non-human	primates	(Zhang	et	al.	2014).	A	partial	α7-nAChR	agonist	(R)-3-(6-r-Tolyl-pyridin-3-yloxy)-1-aza-bicyclo(2.2.2)octane	(AQW051)	significantly	reduced	LID	without	decreasing	the	antiparkinsonian	effect	of	L-DOPA	and	even	prolonging	the	effect	of	the	L-DOPA	on	MTPT	
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treated	non-human	primates(Di	Paolo	et	al.	2014).	It	may	be	that	the	combined	effect	of	KYNA	on	both	glutamatergic	and	acetylcholinergic	receptors	is	involved	in	the	antidyskinetic	effects	due	to	other	mechanisms	than	the	antidyskinetic	effect	of	direct	α7-nAChR	activation.	Or	maybe	prolonged	exposure	to	α7-nAChR	agonists	induces	desensitization	or	downregulation	of	nAChR,	the	net	effect	being	decrease	nicotinergic	stimulation.			As	a	final	comment,	there	seems	to	be	an	interesting	coupling	between	LID	in	PD	and	affective	disorders	in	terms	of	changes	in	the	TRP	metabolism.	The	pattern	of	an	increased	3-HK/KYNA	ratio	has	also	been	shown	in	patients	with	bipolar	disorder(Birner	et	al.	2017).	It	may	be	that	changes	in	KYN	metabolism	are	also	involved	in	changes	in	dopaminergic	transmission.	Much	evidence	points	to	a	hyperdopaminergic	activity	in	bipolar	disorders,	especially	in	manic	phases	characterized	by	lack	of	impulse	control(Ashok	et	al.	2017).	Interestingly,	it	seems	that	impulse	control	disorders	such	as	punding	significantly	correlates	with	LID	in	PD(Silveira-Moriyama	et	al.	2006).		The	risk	of	tardive	dyskinesia	due	to	neuroleptic	treatment	seems	to	be	increased	in	bipolar	disorders(Mukherjee	et	al.	1986),	and	it	could	be	speculated	that	similar	mechanisms	are	involved	in	the	two	types	of	dyskinesia.			
8.2.2.	Catecholamines:	
	As	mentioned	in	the	methods	section,	when	writing	the	paper	on	CSF	catecholamines(Andersen	et	al.	2017),	we	did	not	use	Bonferroni	adjusting	for	multiple	comparisons.	It	could	be	argued	that	Bonferronis	adjustment,	especially	in	the	light	of	few	observations,	may	increase	the	risk	of	type	II	errors(Perneger	1998).			Previously	in	this	thesis	I	wrote	about	the	potential	causes	for	LID,	including	a	more	rapid	L-DOPA	turnover	as	well	as	a	non-dopaminergic	L-DOPA	metabolism.	PD-LID	has	a	higher	mean	CSF	DA	than	PD-L	and	a	more	marked	increase	of	DA	compared	to	controls	and	PD-N.	Combined	with	a	significantly	increased	DA/L-DOPA	ratio	in	PD-LID	compared	to	PD-L,	we	argue	that	these	changes	may	be	due	to	the	combination	of	an	increased	neuronal	release	of	DA	as	well	as	an	accelerated	decarboxylase	activity,	converting	L-DOPA	to	DA.	This	could	indicate	a	less	controlled	non-dopaminergic	L-DOPA	metabolism	and	DA	release,	e.g.	from	5-HT	terminals	lacking	an	autoregulatory	feedback	mechanism	(Carta	et	al.	2007),	which	might	
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increase	extracellular	DA	levels	in	striatum,	affecting	sensitized	D1	receptors.	It	is	also	argued	that	a	decrease	in	DAT	on	the	remaining	striatal	terminals(Sossi	et	al.	2007,	Sossi	et	al.	2009)	would	compromise	the	reuptake	of	released	DA.	PD-LID	has	significantly	lower	DOPAC/DA	ratios	than	PD-L,	further	indicating	non-dopaminergic	L-DOPA	uptake	and	release	since	DOPAC	is	made	from	DA	in	dopaminergic	neurons	by	monoamine	oxidase	activity.	The	increased	MHPG/NA	ratio	in	PD-LID	compared	to	PD-L	could	indicate	a	significantly	higher	NA	turnover	in	dyskinetic	patients.	A	study	has	found	an	increased	firing	rate	in	the	locus	coeruleus	in	dyskinetic	6-hydroxydopamine	lesioned	rats(Miguelez	et	al.	2011),	and	it	could	be	speculated	whether	an	increased	NA	turnover	is	a	general	feature	of	dyskinetic	patients.		
8.2.3:	Phosphorylated	extracellular	signal-regulated	kinase	
	The	significantly	increased	percentage	of	p-ERK	1/2	in	dyskinetic	patients	could	support	the	hypothesis	that	an	increased	D1	receptor	stimulation	increases	the	cAMP-induced	phosphorylation	of	ERK	1/2.	That	L-DOPA	has	a	marked	effect	on	the	phosphorylation	of	ERK	1/2	is	also	supported	by	the	fact	that	L-DOPA	treated	patients	have	significantly	higher	p-ERK%	than	PD-N	and	controls	combined.		
8.2.4:	Final	thoughts	on	dyskinesia	biomarker	candidates:	
	In	this	thesis	I	have	discussed	the	potential	correlation	between	changes	in	TRP	and	L-DOPA	metabolism	as	well	as	p-ERK	and	LID.	Future	studies	of	course	have	to	be	made	including	a	wider	range	of	LID	severities	as	well	as	larger	patient	groups	to	take	into	account	random	variance.	Since	LID	is	a	very	dynamic	process,	dynamic	changes	in	levels	of	several	LID	biomarker	candidates	might	be	expected.	With	many	variables	accounting	for	the	rate	of	intestinal	uptake	of	L-DOPA,	this	does	pose	a	challenge	in	terms	of	timing	the	lumbar	puncture	and	blood	sampling	with	L-DOPA	intake.	Ideally,	patients	should	be	monitored	after	L-DOPA	intake,	not	performing	the	sampling	procedure	at	a	fixed	time	interval	after	L-DOPA	intake,	but	at	the	proposed	peak	of	the	patient’s	dyskinesia.	The	logistics	of	this	study	sadly	
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did	not	make	this	possible.	Including	more	severely	dyskinetic	patients	would	also	pose	another	challenge.	Severe	truncal	dyskinesia	but	also	dyskinesia	of	the	extremities	may	prevent	the	patient	from	lying	still.	This	would	potentially	make	it	too	dangerous	to	perform	a	lumbar	puncture.		The	prognostic	value	of	these	LID	biomarker	candidates	could	also	be	assessed	in	longitudinal	studies,	sampling	CSF	from	L-DOPA	naïve	PD	patient	just	prior	to	commencing	L-DOPA	treatment.	This	may	reveal	whether	differences	in	TRP	or	L-DOPA	metabolism	is	a	general	feature	in	LID	patients	or	changes	due	to	L-DOPA	treatment	itself.	Assessing	changes	in	LID	biomarkers	candidates	in	PD	patients	treated	with	DBS	might	also	further	our	understanding	of	the	mechanisms	behind	the	antidyskinetic	effect	of	DBS.	Also	PD	patients	going	from	oral	L-DOPA	to	intestinal	continuous	Duodopa-treatment	could	be	assessed,	observing	the	potential	dynamic	changes	in	metabolism.		
8.3	General	discussion	
	One	of	the	great	challenges	in	this	project	was	the	recruitment	of	patients.	Initially,	we	sought	to	 include	 only	 patients	 who	 were	 interested	 in	 undergoing	 a	 lumbar	 puncture.	 Later,	 we	began	including	patients	who	only	wanted	to	provide	blood	samples	for	analysis.	Although	we	included	 three	other	 recruitment	places	we	were	not	 able	 to	 recruit	more	 than	26	patients	due	 to	 the	 overall	 schedule.	 Also	 control	 recruitment	 became	 a	 challenge,	 with	 only	 16	controls	being	included	in	the	study.	The	lack	of	subjects	made	it	impossible	to	select	patients	and	controls	according	to	age	or	gender.	There	are	two	major	confounders	that	we	identified	accordingly	across	many	of	our	results:	Age	and	gender.	It	becomes	hypothetical	whether	age	or	gender	did	actually	confound	the	results	or	whether	disease	status	in	a	population	of	older	predominantly	 male	 subjects	 compared	 to	 the	 control	 population	 created	 this	 correlation.	Only	by	doing	further	analyses	between	gender	and	age	matched	groups	is	it	possible	to	make	that	 distinction.	 The	 small	 sample	 sizes	 also	make	 it	 impossible	 to	 take	 into	 account	more	than	two	variables	apart	from	disease	status	in	a	multiple	regression	analysis.	Given	 the	 small	 sample	 size,	 it	 is	 also	prudent	 to	 view	 the	 results	 from	our	 group	 analyses	with	caution.	With	sample	sizes	in	the	groups	ranging	from	7	to	16,	random	variation	might	have	a	marked	effect	on	the	results.		
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Whereas	the	PD	population	was	fasting	prior	to	the	lumbar	puncture,	only	5	out	of	16	controls	were	 fasting,	due	 to	 the	 recruitment	procedure.	Especially	when	 focusing	on	metabolomics,	we	took	the	fasting	status	into	account	in	the	control	group;	but	in	our	small	control	group	it	does	not	 seem	as	 if	 fasting	 significantly	altered	anything	but	CSF	DOPAC	and	plasma	3-OH-anthranilic	acid	levels.	Due	 to	 practical	 issues,	 the	 timing	 of	 the	 lumbar	 puncture	 was	 delayed	 for	 many	 of	 the	controls	 compared	 to	 the	patients.	We	cannot	 rule	out	 that	diurnal	 changes	 in	 levels	of	 the	biomarker	candidates	may	have	affected	the	results.	Some	 substances,	 such	 as	 HVA,	 may	 be	 affected	 by	 which	 gradient	 of	 CSF	 is	 being	used(Dhondt	2004).	Even	though	I	did	not	choose	the	level	of	lumbar	puncture	according	to	the	 height	 of	 the	 patients,	 the	 tapping	 procedure	 was	 quite	 similar	 among	 patients	 and	controls.	 Approximately	 the	 same	 amount	 of	 CSF	was	 drawn	 for	 both	 PD	 and	 controls	 for	routine	analysis	prior	 to	 the	 sampling	of	CSF	 for	 special	 analyses.	The	 same	amount	of	CSF	was	drawn	and	directly	frozen	for	catecholamine	analysis,	and	subsequently	the	same	amount	was	 drawn	 in	 a	 single	 tube,	 gently	 mixed	 prior	 to	 processing	 and	 aliquoting,	 for	 all	 other	analyses.	In	this	way,	to	a	certain	extent,	we	have	taken	into	account	any	gradient	difference.		As	 mentioned	 previously,	 L-DOPA	 intake	 (and	 perhaps	 in	 general	 antiparkinsonian	medication)	 may	 have	 unknown	 effects	 on	 many	 of	 our	 measured	 variables.	 Another	consequence	 of	 not	 pausing	 medication	 is	 the	 clinical	 appearance	 of	 the	 PD	 patient.	 Even	though	I	can	only	assume	that	PD	patients	included	in	the	study	are	sufficiently	treated,	and	even	though	the	clinical	rating	was	done	at	a	fixed	interval	after	L-DOPA	intake,	 it	would	be	expected	 that	patients	 react	differently	 time	wise	 to	 the	L-DOPA	dose	prior	 to	examination.	The	ON-stage	motor	performance	of	a	single	patient	compared	to	the	mean	ON-stage	motor	performance	 of	 all	 L-DOPA	 treated	 patients	 might	 not	 reflect	 that	 patient’s	 OFF-stage	performance	 compared	 to	 the	 mean	 OFF-stage	 motor	 performance	 of	 all	 L-DOPA	 treated	patients.	 This	 could	 potentially	mask	 any	 correlation	 between	motor	 performance	 and	 the	assessed	biomarker	candidates.	From	an	ethical	perspective,	 I	did	not	 find	 it	appropriate	 to	ask	PD	patients	 not	 to	 take	 their	medication	 for	 a	 shorter	 duration.	Apart	 from	a	 potential	marked	decrease	in	daily	function	until	the	day	of	participation	in	the	study,	it	may	have	made	it	more	difficult	for	the	patients	logistically	to	arrive	at	the	study	center.	Unfortunately,	the	MDS-UPDRS	did	not	exist	in	a	Danish	version	when	the	project	was	begun.	As	 noted,	 we	 made	 our	 own	 Danish	 translation	 of	 part	 I,	 II	 and	 IV.	 Given	 the	 lack	 of	
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verification	of	our	translation,	 the	otherwise	quantifiable	data	on	non-motor	symptoms	etc.,	was	not	to	be	used.	As	a	side	note	it	can	be	mentioned	that	the	unverified	total	UPDRS	score	did	significantly	correlate	with	disease	duration,	whereas	UPDRS	part	III	did	not.	Diagnostic	 uncertainties	 have	 to	 be	 mentioned.	 Some	 patients	 had	 had	 symptoms	 of	Parkinson’s	disease	for	less	than	5	years,	and	although	patients	included	fulfilled	the	UKBBC	and	were	diagnosed	by	specialists	 in	movement	disorders,	 there	 is	always	a	risk	of	patients	actually	suffering	 from	atypical	Parkinsonian	disorders.	Some	studies	perform	post-mortem	neuropathological	verification	of	all	patients,	which	of	course	 is	not	within	the	scope	of	 this	project.		It	is	evident	that	DA	metabolites	are	significantly	affected	by	L-DOPA	intake.	It	cannot	be	ruled	out	that	in	general,	antiparkinsonian	treatment	may	affect	other	metabolic	pathways.	Therefore,	all	results	from	this	study	have	to	be	interpreted	with	caution.																					
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Chapter	9:	Conclusion		In	this	chapter	I	will	briefly	summarize	the	significant	findings	in	this	study.		
9.1:	Diagnostic	biomarker	candidates	
	
1.	 PD	 patients	 had	 significantly	 lower	 CSF	 levels	 of	 full-length	 monomeric	 α-syn	 and	 an	increased	ratio	between	full-length	monomers	and	tetramers.	
2.	 PD	 patients	 had	 significantly	 lower	 Trol	 scores	 in	 CSF	 and	 significantly	 increased	 Trol	scores	in	plasma.	The	ratio	between	CSF	and	plasma	Trol	scores	more	significantly	separated	PD	 from	 controls.	 Using	 the	 ratio	 between	 CSF	 Trol	 scores	 and	 the	 total	 CSF	 protein	concentration	resulted	in	an	even	better	distinction	between	PD	and	controls.	
3.	 CSF	 normalized	 GCase	 activity	was	 significantly	 lower	 in	 PD.	 Further	 normalizing	 GCase	activity	 according	 to	 CSF	 protein	 concentration	 provided	 a	 highly	 significant	 separation	 of	patients	and	controls.	
4.	PD	patients	not	treated	with	L-DOPA	had	significantly	lower	levels	of	DOPAC,	DA,	L-DOPA	and	HVA.	
5.	CSF	Trol	scores	correlated	with	disease	duration.	MOCA	scores	correlated	with	plasma	KYN	and	correlated	negatively	with	CSF	ANA.		
9.2:	L-DOPA	induced	dyskinesia	biomarker	candidates	
	
1.	Dyskinetic	 patients	 had	 significantly	 increased	DA/L-DOPA	 ratios,	 decreased	DOPAC/DA	ratios,	increased	HVA/DA	ratios,	and	increased	MHPG/NA	ratios.	
2.	 In	plasma,	dyskinetic	patients	had	significantly	 lower	levels	of	ANA,	KYNA.	They	also	had	increased	KYN/TRP-,	3-HK/KYN-,	and	3-HK/KYNA	ratios	as	well	as	decreased	3-HANA/3-HK-,	and	XAN/3-HK	ratios.	
3.	CSF	ANA	levels	were	significantly	decreased	in	dyskinetic	patients.	
4.	CSF	p-ERK%	was	significantly	increased	in	dyskinetic	patients.	
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Chapter	10:	Concluding	remarks	
	As	is	the	case	in	many	other	studies	on	CSF	biomarkers,	the	lack	of	subjects	included	in	this	project	is	marked.	The	lumbar	puncture,	compared	to	the	blood	sampling	procedure,	poses	a	potential	risk	of	CNS	infections,	bleedings	affecting	spinal	nerve	roots	and	severe	headaches	induced	by	the	vertical	pressure	difference	due	to	the	dural	puncture.	Many	patients	thus	fear	the	procedure	(oftentimes	mistaking	it	for	a	bone	marrow	biopsy).	But	when	performed	by	a	skilled	practician,	the	procedure	seems	benign	for	most	participants.		To	 my	 knowledge	 no	 movement	 disorder	 clinic	 in	 Denmark	 routinely	 performs	 lumbar	punctures	 as	 part	 of	 the	 diagnostic	 check	 up	 on	 patients	 with	 suspected	 PD.	 In	 a	 clinical	setting	performing	 such	a	procedure	 should	only	be	done	when	 it	 serves	 a	 clinically	 sound	purpose,	justifying	the	otherwise	infrequent	but	severe	risks	from	the	procedure.	There	may	be	 arguments	 for	doing	 so	 already:	Low	CSF	 levels	of	Aβ1-42	 seem	 to	be	 related	 to	poorer	cognitive	performance(Leverenz	et	al.	2011,	Alves	et	al.	2010,	Compta	et	al.	2012,	Montine	et	
al.	 2010),	 but	 also	 serve	 as	 a	 prognostic	 marker	 for	 cognitive	 decline	 and	 dementia	development(Siderowf	et	al.	2010,	Compta	et	al.	2013,	Alves	et	al.	2014,	Schrag	et	al.	2017).	This	 could	 provide	 clinicians	with	 a	 prognostic	 tool	 regarding	 the	 expected	 severity	 of	 the	almost	inevitable	cognitive	decline	related	to	PD.		Performed	by	many	researchers,	 longitudinal	studies	are	of	great	use	when	 focusing	on	PD.	Apart	from	the	increased	diagnostic	certainty	through	follow	up,	successive	clinical	ratings	of	both	 cognitive	 and	 motor	 performances	 may	 reveal	 a	 prognostic	 value	 of	 a	 biomarker	candidate	 (as	 just	 mentioned	 regarding	 Aβ1-42).	 Including	 medically	 un-treated	 newly	diagnosed	PD	patients	for	sample	analyses	would	also	remove	the	possible	confounding	effect	of	antiparkinsonian	treatment,	and	later	follow	up	could	verify	the	PD	diagnosis.	In	 the	 future,	 the	 inclusion	 of	 patients	with	 APD	would	 be	 of	 great	 value,	 since	 one	 of	 the	major	aspects	regarding	diagnostic	difficulties	is	related	to	the	similarity	between	PD	and	APD	in	the	early	stages.	Since	we	have	not	included	any	patients	with	MSA,	PSP	or	CBD	we	cannot	assume	 that	 the	 changes	 measured	 in	 our	 patient	 group	 are	 specific	 for	 PD	 or	 even	 for	synucleinopathies.		In	 the	 end,	 the	 essential	 question	when	 focusing	 on	 diagnostics	 seems	 to	 be:	why	 use	 CSF	biomarkers?	 Much	 evidence,	 as	 described	 earlier,	 points	 to	 a	 prior	 involvement	 of	 more	peripheral	 nerves,	 indicating	 that	 CNS	 involvement	 (and	 thus	 marked	 changes	 in	 CSF	
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biomarkers)	occurs	at	a	later	stage.	Would	it	be	better	to	focus	on	biomarker	candidates	in	the	periphery,	such	as	skin	biopsies,	urin	analyses,	imaging	of	the	autonomic	peripheral	nervous	system	 (such	 as	 cardiac	MIBG	 scintigraphy)?	 It	 could	 be	 argued	 that	 the	 clinical	 picture	 of	premotor	PD	might	be	even	more	diverse	than	the	already	heterogenous	clinical	appearance	of	motor	PD,	making	it	very	difficult	to	identify	these	patients.	Especially	since	they	might	not	even	 contact	 a	 physician	 due	 to	 such	 diffuse	 symptoms.	 Therefore	 I	 do	 think	 that	 CSF	biomarkers	will	continue	to	play	a	potential	role	in	the	diagnosis	of	PD,	as	well	as	advancing	our	knowledge	of	the	CNS	disease	processes	involved	in	PD.																									
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Diagnosis of Parkinson’s disease (PD) relies on clinical history and
physical examination, but misdiagnosis is common in early stages.
Identification of biomarkers for PD may allow early and more precise
diagnosis and monitoring of dopamine replacement strategies and
disease modifying treatments. Developments in analytical chemistry
allow the detection of large numbers of molecules in plasma or
cerebrospinal fluid, associated with the pathophysiology or
pathogenesis of PD. This systematic review includes cerebrospinal
fluid biomarker studies focusing on different disease pathways:
oxidative stress, neuroinflammation, lysosomal dysfunction and
proteins involved in PD and other neurodegenerative disorders,
focusing on four clinical domains: their ability to (1) distinguish PD
from healthy subjects and other neurodegenerative disorders as well as
their relation to (2) disease duration after initial diagnosis, (3) severity
of disease (motor symptoms) and (4) cognitive dysfunction.
Oligomeric alpha-synuclein might be helpful in the separation of PD
from controls. Through metabolomics, changes in purine and
tryptophan metabolism have been discovered in patients with PD.
Neurofilament light chain (NfL) has a significant role in distinguishing
PD from other neurodegenerative diseases. Several oxidative stress
markers are related to disease severity, with the antioxidant urate also
having a prognostic value in terms of disease severity. Increased levels
of amyloid and tau-proteins correlate with cognitive decline and may
have prognostic value for cognitive deficits in PD. In the future, larger
longitudinal studies, corroborating previous research on viable
biomarker candidates or using metabolomics identifying a vast
amount of potential biomarkers, could be a good approach.
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Introduction
Parkinson’s disease (PD) is the second most com-
mon neurodegenerative disease, with a prevalence
of 1% in the population older than 60 years (1).
When the degeneration of dopaminergic neurons
in the substantia nigra reaches 50–60%, the lack
of dopaminergic input to the striatum causes the
characteristic motor symptoms including hypoki-
nesia, postural instability, rigidity and resting tre-
mor. The diagnosis is overwhelmingly based on
these clinical symptoms (2).
There is no established disease modifying treat-
ment and the continuous progression of the disease
results in increasing disability. After 2–5 years of
treatment with monoamine oxidase inhibitors
(MAO-B), dopamine agonists or dopamine substi-
tuting treatment with L-DOPA, the treatment
gradually loses its efficiency. Patients will invari-
ably develop significant daily fluctuations of
symptom severity, and especially the treatment
with L-DOPA increases the risk of developing
potentially disabling involuntary movements,
L-DOPA-induced dyskinesia (LID) (3).
It can be very difficult to diagnose PD and is
almost impossible before the development of
motor symptoms, because premotor symptoms,
including olfactory deficiency, obstipation, sleep
1
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disorders and depression, are very unspecific (4,
5). In earlier disease stages, other neurodegenera-
tive diseases may mimic idiopathic PD. These
atypical parkinsonian disorders (APD) include
the synucleinopathies multiple system atrophy
(MSA), Lewy body dementia (DLB) and the
tauopathies progressive supranuclear palsy (PSP)
and corticobasal degeneration (CBD) and have
different prognoses and treatment responses. In a
longitudinal study using neuropathologically con-
firmed PD as gold standard, Adler et al. (6)
showed an 85% positive predictive value of the
clinical diagnosis for patients with PD with >5-
year disease duration. But the positive predictive
value in patients responsive to drug treatment
diagnosed within 5 years was only 53%, necessi-
tating follow-up when including newly diagnosed
PD patients in biomarker studies.
In summary, there is an urgent need for earlier
diagnostics, differentiating between PD and other
parkinsonian syndromes, a better understanding
of PD pathogenesis and assessment of disease
progression to evaluate the use of potential dis-
ease modifying drugs. There has been extensive
reviews of the research in biomarkers, for exam-
ple by Jimenez-Jimenez et al. (7). This review
divides the biomarker candidates into six cate-
gories: A: neurotransmitters and neuromodula-
tors, B: oxidative stress markers, C: inflammatory
and immunological markers, D: growth factors,
E: proteins involved in PD pathology and F:
others. Under each category, we focus on their
usability in these four clinical domains:
1. Distinguishing PD from controls
2. Distinguishing PD from other neurodegenera-
tive diseases
3. Representing disease severity or cognitive abil-
ities and
4. Being of prognostic value regarding disease
severity and cognitive abilities.
Not all categories have biomarkers within these
four domains. Only cerebrospinal fluid biomarker
candidates are included.
Method
This study is based on a systematic literature
search in the database PubMed performed 21
January 2015 using the search criteria: (cere-
brospinal fluid biomarker) AND Parkinson’s dis-
ease. Inclusion criteria were original articles on
clinical studies on cerebrospinal fluid biomarkers
including at least 20 patients with PD. Articles
were excluded if only abstracts were available or
if language of full article was not in English, and
if the article was published before year 2000.
Articles focusing on the development of new
analysis methods were also excluded.
Of 295 articles identified in the database, 58
were included in this study (See Fig. 1 for details).
Results
Neurotransmitters and neuromodulators
In 2003, Braak et al. (8) showed that disease
severity in PD can be neuropathologically staged,
from premotor stages of the disease with Lewy
body (LB) pathology starting in the olfactory
bulb and dorsal motor nucleus of the vagus nerve
in the medulla, gradually ascending to the pons,
including the serotonergic neurons of the raphe
nucleus and the noradrenergic neurons of the
locus coeruleus, subsequently in stage 3 affecting
the dopaminergic neurons of the substantia nigra
in the ventral mesencephalon and in later stages
areas of the neocortex.
PD vs controls – In line with the degeneration of
catecholaminergic neurons, decreased concentra-
tions of the dopamine metabolites dihydrox-
yphenylacetate (DOPAC) and homovanillic acid
(HVA) as well as the noradrenergic metabolites
dihydroxyphenylglycol (DHPG) and 3-methoxy-4-
hydroxyphenylglycol (MHPG) have been
observed in the cerebrospinal fluid (CSF) of
patients with PD as compared to controls (see
Table 1). Treatment with dopaminergic drugs,
including levodopa, alters CSF-catecholamines
and its metabolites (9). Therefore, catecholamines
and its metabolites are best studied in drug-na€ıve
patients or following L-DOPA washout. Accord-
ingly, Goldstein et al. (9, 10) showed significant
decreases in DOPAC, DOPA, noradrenaline (NA)
and DHPG in patients with PD, including newly
diagnosed PD patients. LeWitt et al. (11) found
that CSF levels of HVA are not a reliable biomar-
ker of PD, but the ratio of the purine metabolite
xanthine over HVA seems a possible biomarker
for patients with PD as compared to controls.
In a more recent study, LeWitt et al. (12)
employed targeted metabolomics, using ultra-
high-performance liquid chromatography–tandem
mass spectrometry (UHPLC/MS/MS) and gas
chromatography–mass spectrometry (GC/MS) on
post-mortem obtained CSF from patients with
PD and controls. In this study, 19 compounds
were identified differing PD from controls includ-
ing an increased ratio of the tryptophan/kynure-
nine metabolites 3-hydroxykynurenine (3-HK) vs
kynurenic acid (KYNA). A change in the ratio
2
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of these kynurenine metabolites is particularly
interesting, as 3-HK may cause oxidative damage
by general hydroxyl radicals and it is also a pre-
cursor of the excitotoxin quinolinic acid. KYNA
is a broad-spectrum antagonist of glutamate
receptors and has neuroprotective potential.
Thus, an increased ratio of 3-HK/KYNA in the
brain may promote neurodegeneration.
PD vs other neurodegenerative diseases – Contrary
to Goldstein et al. (10) who found the cate-
cholamine and metabolite concentrations to be
similar in PD and MSA, Abdo et al. (13) found
lower concentrations of MHPG, HVA and the
serotonin metabolite 5-hydroxyindoleacetic acid
(5-HIAA) in MSA patients with predominant
parkinsonism (MSA-P), the latter explained with
a more severe degeneration of neurons in the
locus coeruleus in patients with MSA.
Disease severity and cognitive abilities – The xan-
thine/HVA ratio measured by LeWitt et al. (11)
is significantly negatively correlated with clinical
scores using the Unified Parkinson’s Disease Rat-
ing Scale (UPDRS) part III (motor score).
Oxidative stress markers
Several PD disease mechanisms seem to induce
oxidative damage in neurons. Oxidative damage
through free radicals is linked to loss of antioxida-
tive defensive capabilities, mitochondrial dysfunc-
tion, proteasomal dysfunction and microgliosis
and definitely plays a role in PD, although it might
not be the primary disease mechanism (14).
PD vs controls – A lack of antioxidative capabili-
ties might make cells more susceptible for damage
from free radicals. DJ-1 is a ubiquitous protein
that through oxidation is thought to regulate
transcription factors promoting an antioxidative
defence (15). Mutations in the DJ-1 gene PARK7
are associated with hereditary recessive early-
onset PD (16). Hong et al. (17) found a signifi-
cant decrease in DJ-1 in patients with PD, but
also found a positive correlation to a-synuclein
(a-syn), age and the amount of blood contamina-
tion in the CSF. Waragai et al. (18) found an
increase in CSF-DJ-1 in patients with PD (espe-
cially early PD), a finding which according to
Hong et al. might be related to a different
method of analysis (Western blot compared with
the more sensitive Luminex assay) and not taking
in to account blood contamination. Using an
ELISA method, Herbert et al. (19) also found an
increase in CSF-DJ-1, even when excluding sam-
ples with blood contamination. Hong et al. (17)
argues that a decrease might be seen as a lack of
adaptive response to the ageing process or a
sequestration of DJ-1 with a-syn, whereas an
increase is seen as a compensatory neuroprotec-
tive response (19). As the mean disease duration
of the patients investigated by Hong et al. is
higher than the mean disease duration of patients
investigated by Herbert et al., opposing results
might reflect a change in the amount of oxidative
stress or response to oxidative stress in different
disease stages, which seems to be the case for DJ-
1 (see Table 3).
Glutathione is in its reduced form (GSH) one
of the major antioxidative peptides, being con-
verted to oxidized glutathione (GSSG). LeWitt
et al. (12) found a decrease in GSSG in patients
with PD, being interpreted as a decrease in
antioxidative defence. Maarouf et al. (20) found
increased glutathione S-transferase Pi activity in
CSF of patients with PD, which might be a
response to increased oxidative stress.
Silicon (Si) has the ability to bind aluminium
(Al), which might be damaging to the central
Figure 1. Flowchart of article selection process.
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nervous system (CNS). Forte et al. (21) found a
significantly lower mean concentration of Si in
CSF of patients with PD, although the mean con-
centration of Al in CSF was not significantly dif-
ferent.
In 2008, Boll et al. (22) examined several aspects
of oxidative stress showing a significant increase in
copper (Cu) in CSF of patients with PD, along
with a decrease in Cu/Zn-superoxide dismutase
activity and ceruloplasmin ferroxidase activity
which plays a role in iron homeostasis. Boll et al.
also found increased markers of lipoprotein perox-
idation in CSF from patients with PD.
Abe et al. (23) and Kikuchi et al. (24) found a
significant increase in 8-hydroxyguanosine (8-
OHG), a marker of hydroxyl radical damage of
ribonucleic acid (RNA), in PD CSF as compared
to controls.
PD vs other neurodegenerative disorders – DJ-1 was
found by Hong et al. (17) to be significantly
lower in PD compared with Alzheimer’s disease
(AD), whereas Herbert et al. (19) found DJ-1 to
be significantly lower in PD compared with
MSA, and combined with total tau-protein (t-
tau) and phosphorylated tau-protein (p-tau) dis-
tinguished PD from MSA with a sensitivity of
82% and specificity of 81% (see Table 2).
Disease severity and cognitive abilities – Garcia-
Moreno et al. (25) showed, through enzyme-
linked immune assays (ELISA) that the amount
of advanced oxidized protein products (AOPP, a
marker for protein halogenation which is the
result of free radicals) in CSF increased signifi-
cantly faster in incubated CSF from PD patients
with Hoehn & Yahr (H&Y) score 1–2 compared
with H&Y score 3–4 and controls, maybe indicat-
ing a susceptibility to oxidative damage in early
disease stages. Corroborating this notion, Fernan-
dez et al. (26) showed an increase in unspecific
3-nitrotyrosine protein products (nitrosylation of
proteins being an oxidative damage mechanism)
in PD patients with H&Y score 1–2 compared
with advanced PD and controls. Under the
notion of a more pronounced oxidative damage
occurring in early PD, DJ-1 was also found by
Herbert et al. (19) to be significantly more
increased in PD patients with H&Y score 1–2
compared with H&Y score 3–4. 8-OHG was
found to be negatively correlated to disease dura-
tion (with no correlation to age) by Abe et al.
(23), which might indicate lesser oxidative stress
in advanced disease stages.
Boll et al. (22) found Cu significantly positively
correlated to both UPDRS part III motor score
and disease duration and found the ceruloplasmin
ferroxidase activity to be related to the time of
onset (understood by the authors as disease dura-
tion).
Related to cognition, Yu et al. (27) through
chemical colorimetric analysis showed that the
hydroxyl radical ˙OH was negatively correlated
to the MOCA score (MOntreal Cognitive Assess-
ment) and significantly increased in CSF of cog-
nitively impaired PD patients compared with
healthy controls. See Table 3 for an overview.
Prognostic value – In a large and well-defined
group of patients with PD participating in the
DATATOP trial (Deprenyl and Tocopherol
Antioxidative Therapy Of Parkinsonism),
Ascherio et al. (28) showed that CSF levels of the
antioxidant uric acid, the end product of the pur-
ine metabolism, were negatively correlated with
the severity of disease as assessed by the need for
L-DOPA therapy and clinical scores using the
UPDRS.
Inflammatory and immunological markers
Microglial cells are active in the substantia nigra
of patients with PD, and a secondary dysregu-
lated inflammatory response (e.g. a deregulation
of the interplay between glucocorticoids and glu-
cocorticoid receptors in dopaminergic neurons)
seems to play a role in the progression of the dis-
ease, maybe triggered by the primary disease
mechanism (29).
PD vs controls – Using a multiplex assay for
cytokines, Zhang et al. (30) found the levels of
eight cytokines altered in PD as compared to
controls. Among these were higher concentrations
of b2-microglobulin, a component of a ubiqui-
tous cell surface protein, used in staging of multi-
ple myeloma and proposed to have an
immunological function (31). They also found an
increase in IL-8 (interleukin-8), whereas Yu et al.
(27) found an increase in IL-6 and IL-1-b in cog-
nitively impaired PD patients compared with con-
trols. Yu et al. found that concentrations of the
neuroinflammatory factors interferon-gamma
(IFN-Υ) and tumour necrosis factor-alpha (TNF-
a) were also increased in PD, although the latter
only in cognitively impaired patients.
PD vs other neurodegenerative diseases – Constanti-
nescu et al. (32) showed that patients with
atypical PD had higher concentrations of b2-
microglobulin than patients with PD and con-
trols, only reaching significance when combined
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with measurement of ubiquitin and chromogranin
I and II.
The fms-related tyrosine kinase 3 ligand (flt3-
ligand) plays a role in the activation of the
immune system and is increased in CSF of
patients with amyotrophic lateral sclerosis (33).
Unlike previous findings by Shi et al. (34) of
increased flt3-ligand in MSA compared with PD,
Silajdciz et al. (33) found no differences.
Disease severity and cognitive abilities – Regarding
flt3-ligand, Silajdzic et al. (33) did find a positive
correlation to the H&Y score in patients with
PD.
Pisani et al. (35) found the CSF/serum IgG
ratio to be increased in PD patients with H&Y
score 2.4–4 and that the ratio correlated posi-
tively with the H&Y score, maybe indicating a
dysfunctional blood–brain barrier in PD.
Growth factors
PD vs controls – Brain-derived neurotrophic factor
(BDNF) plays a significant role in synaptic plastic-
ity, and the presence of the minor allele (val66met)
seems to be associated with a decrease in BDNF
secretion and a significantly increased risk of devel-
oping L-DOPA-induced dyskinesia (36). Zhang
et al. (30) found BDNF to be increased in AD and
PD patients compared with controls and correct
classification of PD, AD and controls was achieved
optimally combining the eight biomarkers t-tau,
BDNF, Il-8, amyloid-b1-42 (Ab1-42), b2-micro-
globulin vitamin D-binding protein, apolipopro-
tein AII (apoAII) and apoE, correctly classifying
95% of 38 patients with PD and 95% of 38 con-
trols compared with the clinical evaluation.
Sj€ogren et al. (37) found a protein associated
with neuronal growth and regeneration called
neuromodulin (or growth-associated protein 43;
GAP-43) to be decreased in CSF of patients with
PD.
PD vs other neurodegenerative diseases – Sj€ogren
et al. (37) also found the aforementioned neuro-
modulin to be decreased in CSF of patients with
PD compared with patients with Alzheimer’s dis-
ease (AD).
Proteins involved in PD pathology
PD vs controls – The neuropathological criteria
for PD include the identification of neuronal loss
in the substantia nigra (pars compacta) and
detection of Lewy pathology in the CNS neurons
(38). The intraneuronal Lewy bodies (LB) contain
aggregated and phosphorylated a-syn (39). The
protein a-syn is mainly localized in presynaptic
terminals and is presumed to play an important
role in synaptic plasticity and the transport of
vesicles to presynaptic terminals. Modification
(e.g. phosphorylation), misfolding (e.g. oligomeric
shapes) and accumulation of a-syn seem to play a
key role in the pathogenesis of PD (40). Muta-
tions in the a-syn gene are related to rare types of
dominantly inherited PD (17, 41), further sup-
porting the central role. Braak’s hypothesis of
spreading neuropathology from the brainstem to
more central areas of the CNS gave rise to the
idea of a prion-like spread of misfolded a-syn
(40), for example from the intestinal nervous sys-
tem via the vagal nerve to the CNS (42). Several
studies using enzyme-linked immune assays
(ELISA) have not shown differences between PD
and control CSF (19, 43–47). Using other meth-
ods to quantify a-syn such as the more sensitive
Luminex assay (17, 34, 48) and through time-
resolved F€orster’s resonance energy transfer assay
(TR-FRET) (49), but also ELISA (50–52), other
studies have shown a decrease of t-a-syn in PD
(see Table 1). Foulds et al. (47) did not find any
increase in PD of phosphorylated a-syn (p-a-syn)
or oligomeric a-syn (o-a-syn), but Tokuda et al.
(45) found an increase in o-a-syn. Calculating the
o-a-syn/t-a-syn ratio differed patients with PD
from controls with a sensitivity of 89.3% and
specificity of 90.6 with a 0.948 area under the
curve (AUC).
Neurosin, a protease enzyme involved in the
clearance of a-syn, was found by Wennstr€om
et al. (51) to be decreased in the CSF of patients
with synucleinopathies, whereas Nielsen et al.
(43) found no difference.
Another pathway of a-syn degradation is the
ubiquitin-proteasome system. Mutations in the
PARK2 gene coding for Parkin, an enzyme in
the ubiquitin-proteasome system, are responsible
for autosomal recessive juvenile parkinsonism
(53). Mondello et al. (50) found another enzyme
related to the ubiquitin-proteasome system, ubiq-
uitin carboxy-terminal hydrolase (UCHL-1), to
be decreased in PD CSF.
The breakdown of amyloid precursor protein
(APP) creates the peptide amyloid-b1-42 (Ab1-42)
which can aggregate, creating neurotoxic amyloid
plaques, that together with neurofibrillary tangles
of tau-protein triggered by amyloid-b represents
the pathological hallmark of Alzheimer’s disease
(AD) (54). In PD, a-syn might induce tau
aggregation and interact with amyloid-b1-42,
resulting in the aggregation of both peptides (55).
Whereas several authors found no changes in
17
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total tau (t-tau) or phosphorylated tau (p-tau) in
PD (19, 43, 51, 56–58) (see Table 1), one study
(59) found an increase in t-tau, another only in
patients with PDD (60). Conversely, two studies
(48, 61) found a decrease in p-tau and one found
a decrease in t-tau (30).
Ab species have also been examined (Table 1).
Again the results point in different directions
with some authors finding a decrease of Ab1–15/
16 in neurodegenerative diseases (62), decreased
APPa, Ab-38, 40 or 1-42 (43, 46, 51, 56, 58, 60)
in PD, one only finding a decrease in cognitively
impaired or demented PD patients (61). One
study found an increase in Ab1-42 (30), one study
found no changes in APPa+b (63), whereas 5
other studies found no difference in Ab1-42 con-
centrations (37, 48, 57, 59, 64).
Genetic mutations of transthyretin (TTR), a
protein transporting thyroxin (T4) and retinol (vi-
tamin A), are related to familial amyloid
polyneuropathy (FAP), and TTR seems to be
related to diseases such as AD, PD and psychi-
atric disorders. One function seems to be preven-
tion of the sequestering of Ab species that are
otherwise neurotoxic (65). Maarouf et al. (20)
found a doubling of TTR in CSF of patients with
PD, but the potential pathophysiological implica-
tions are not well understood.
In contrast to the findings of microgliosis in
the substantia nigra of patients with PD, Olsson
et al. (66) found the concentration of YKL-40, a
marker of glial activation, to be significantly
lower in patients with PD compared with con-
trols. Although this might indicate decreased
microglial activation, there were no neuropatho-
logical specimens available to support this obser-
vation.
Clusterin, also called apolipoprotein J, is a
multifunctional protein among other things
related to cell survival and protection from cyto-
toxic stress (59). Studying CSF from neuropatho-
logically verified patients with PD, Maarouf et al.
(20) found two times higher concentration of
clusterin compared with normal controls; an
increase was also found by Prikrylova Vranova
et al. (59). Another apolipoprotein, ApoE, a car-
rier of cholesterol in the CNS whose allele ApoE
e4 is associated with a marked risk of dementia,
has been shown to be either similar in PD and
controls (58), increased (20) or decreased (30).
The high-density lipoprotein (HDL) consists of
ApoA1, which has both been found decreased
(20) and unchanged (30) in patients with PD.
PD vs other neurodegenerative diseases – AD is a
neurodegenerative disease with established CSF
biomarkers, namely decreased Ab1-42 and
increased t-tau and p-tau. In accordance with the
fact that amyloid plaques play a significant role
in the pathology of AD, and probably to a higher
extent than in PD, several studies have found
patients with PD to have significantly higher
Ab1-42 concentrations than patients with AD
(30, 37, 48, 58, 64, 67) (see Table 2). Further-
more, in PD compared with AD, a lower t-tau
(30, 37, 48, 51, 56, 58) and p-tau (48, 51, 56, 58)
have been shown in several studies. Neurosin was
found by Wennstr€om et al. (51) to be signifi-
cantly lower in patients with PD compared with
AD. Alves et al. (58) found lower concentrations
of Apo E in PD compared with AD, a difference
not found by Zhang et al. (30).
When comparing PD to APD, Abdo et al. (13)
found significantly increased t-tau in PD com-
pared with MSA-P. Conversely, Herbert et al.
(19) and S€ussmuth et al. (57) found a decrease in
t-tau MSA patients and S€ussmuth et al. also in
PSP with predominant parkinsonism (PSP-P).
Using multivariate analysis incorporating the
five biomarkers Ab1-42, t-tau, p-tau, a-syn and
neurofilament light chain (NfL, see later for
description), Hall et al. (48) were able to distin-
guish PD from APD with a sensitivity of 85%
and specificity of 92% (AUC 0.93).
Several studies find that t-a-syn cannot be used
to distinguish PD from APD (19, 44, 45, 47, 48,
68) (see Table 2); however, Heegaard et al. (52)
claimed that a low t-a-syn separates PD from
DLB, MSA and PSP. Patients with PD also have
lower concentrations of t-a-syn than patients with
AD (48, 51, 68). Studying modified a-syn,
Tokuda et al. (45) found higher amounts of oli-
gomeric a-syn in PD compared with PSP and
AD, whereas Foulds et al. (47) found patients
with MSA to have higher concentrations of phos-
phorylated a-syn than PD and PDD patients.
The 542 amino acid protein NfL is the most
abundant of the three subunits in the neurofila-
ment structure. These proteins only exist in the
CNS and thus function as a biomarker for axonal
degeneration in acute nervous tissue damage and
in neurodegenerative diseases (69). Both Abdo
et al. (13), Bech et al. (67) and Hall et al. (48)
found a significantly larger concentration of NfL
in, respectively, patients with MSA, MSA, PSP
and DLB patients, and MSA, PSP and CBD
patients, maybe indicating a more rapid neurode-
generation in these diseases. Brettschneider et al.
(70) found the concentration of the subunit neu-
rofilament heavy chain (NfH) to be raised in
patients with PSP (70) and Abdo et al. (13) in
patients with MSA.
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Olsson et al. (66) showed decreased levels of
YKL-40 in PD compared with MSA, PSP and
CBD patients, maybe indicating more glial acti-
vation in the latter diseases, although their con-
centrations did not differ significantly from
controls.
Mondello et al. (50) showed that UCHL-1 con-
centrations were significantly lower in PD com-
pared with MSA, PSP and CBD, also finding a
correlation between a-syn and UCHL-1 concen-
trations, maybe indicating a connection in the
pathogenic mechanism in PD.
Disease severity and cognitive abilities – Cognitive
impairment is a common issue in patients with
PD, and the risk of developing dementia in PD
(PDD) is high, affecting especially executive and
visuospatial functions (71), and increasing mortal-
ity.
An increasing amount of evidence points to the
use of Ab1-42 in the evaluation of cognitive abili-
ties in PD (see Table 3). Alves et al. (58) found a
significant positive correlation between Ab con-
centration and memory performance, Nutu et al.
(64) found a positive correlation with the MMSE
score, and Leverenz et al. (72) found significant
positive correlation between Ab1-42 and digit
symbol performance as well as a correlation
between a decreased Ab1-42/t-tau ratio and
poorer performance on digit symbol and category
fluency. Montine et al. (61) found Ab1-42 to
change dynamically, decreasing from PD to cog-
nitively impaired PD (CI-PD) patients to PDD
patients having the lowest concentrations.
Compta et al. (60) showed that besides a positive
correlation between Ab1-42 and semantic and
phonetic fluency, naming and visuospatial score,
patients with PDD have significantly lower Ab1-
42 concentrations than non-demented patients.
Combined with an MRI study, they also showed
significant positive correlation in patients with
PDD between Ab1-42 concentrations and the
grey matter volume of cerebellum and other cor-
tical areas.
Zhang et al. (73) interestingly found the base-
line Ab1-42 to correlate negatively with baseline
UPDRS score in patients from the DATATOP
study.
Also tau pathology seems to be related to the
cognitive decline in PD (see Table 3). Liu et al.
(74) found t-tau and t-tau/Ab1-42 ratio to be
negatively correlated with the performance in the
cognitive tests, selective reminding test (SRT) and
symbol digit modalities test (SDMT). Compta
et al. (60) found a negative correlation between t-
tau, p-tau and memory, naming and visuospatial
abilities. Parnetti et al. (56) found patients with
PD to have significantly lower t-tau than patients
with PDD, and again, it seems that there is a
dynamic change from non-demented to demen-
ted; Montine et al. (61) found the percentage of
patients with an abnormal t-tau/Ab ratio increase
from 15% in patients with PD, 29% in cogni-
tively impaired PD patients to 45% of patients
with PDD. Prikrylova Vranova et al. (59) also
found patients with >2-year diagnosis of PD to
have significantly higher t-tau and t-tau/Ab1-42
ratio than PD <2 years.
Even though Mondello et al. (50) showed that
synucleinopathies had the lowest concentration of
UCH-L1, they also found an increase in UCH-L1
to be associated with an increased disease sever-
ity.
Prognostic value – Ab1-42 can be used as a signifi-
cant predictor for cognitive decline (see Table 3).
Siderowf et al. (75) found that Ab1-42 concentra-
tions below a cut-off of 192 pg/ml were associ-
ated with a significantly larger annual decline in
the Dementia Rating Scale (Version 2) (DRS-2)
and furthermore found the mean DRS score after
2-year follow-up to be below the dementia cut-off
in this group of patients. Compta et al. (76) also
found patients with PD who converted to demen-
tia at 18-month follow-up to have significantly
lower Ab1-42 concentrations at baseline, along
with worse verbal learning, semantic fluency,
visuoperceptual score and cortical thinning of
specific brain areas in MRI. Alves et al. (77)
found a low baseline Ab1-42 to be related to the
risk of developing dementia, but interestingly Liu
et al. (74) on the same cohort (DATATOP trial
patients, n = 403) did not find a correlation
between Ab1-42 and cognitive decline. Liu et al.
did find a higher p-tau and p-tau/Ab1-42 ratio to
be related to a decline in SRT and visuospatial
working memory and procedural speed.
Tau-protein has also been proposed as a mar-
ker for neural degeneration, and Zhang et al. (73)
showed a negative correlation between baseline p-
tau/t-tau ratio and the change rate in UPDRS
and UPDRS motor score, and a positive
correlation between the change rate of, respec-
tively, t-tau and t-tau/Ab1-42 ratio and the
aforementioned modalities.
Others
PD vs controls – Using gas chromatography time-
of-flight mass spectrometry (GC-TOF-MS) meta-
bolomics, Trupp et al. (46) was able to identify 4
principle drivers in the differentiation of PD and
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controls, namely a decrease in creatinine, xylitol,
3-hydroxyisovaleric acid and tryptophan. A
decrease in tryptophan might indicate an
increased production of the excitotoxic 3-OH-
kynurenine mentioned in section A (12).
Pisani et al. (35) found a higher CSF-/serum
albumin ratio in patients with PD compared with
controls, suggesting a compromised blood–brain
barrier (BBB) in PD.
Disease severity and cognitive abilities – Pisani et al.
(35) also found PD patients with H&Y score
2.5–4 to have an increased CSF-/serum albumin
ratio compared with H&Y score 1–2, maybe indi-
cating a progressive disruption of the BBB in PD.
A compromised BBB might increase the amount
of L-DOPA reaching the CNS, which may
increase risk of L-DOPA-induced dyskinesia in
later stages of the disease.
Discussion and conclusion
As this study shows, biomarker studies produce
conflicting results. Sampling and analysis proce-
dures differ from study to study, possibly obscur-
ing significant differences between patients and
controls. Methodological differences in the collec-
tion of CSF can cause significant changes in the
concentrations of the biomarker in focus as
underlined in two studies by Salvesen et al. (78)
and Simonsen et al. (79). However, since 2009,
international guidelines for the sampling and
storage of CNS can be followed, thus allowing
for reliable comparison between studies (80).
A single biomarker for Parkinson’s disease?
In the search for biomarkers to distinguish PD
from healthy controls, no single biomarker has
been unequivocally significant. As a potential
early biomarker, candidate for PD the metabolite
DOPAC has been shown to be very sensitive in
identifying PD with a specificity of 89%. Alpha-
synuclein has a tendency to be decreased in the
CSF of patients with PD, and an increased focus
on modified versions such as oligomeric alpha-
synuclein might be worthwhile pursuing, with the
o-a-syn/t-a-syn ratio being one of the most sensi-
tive and specific tests distinguishing PD from
controls in this review, albeit only in one study
with 28 patients with PD. As idiopathic Parkin-
son’s disease is not a single homogenic disease
but a clinical syndrome with different underly-
ing disease mechanisms, the search for biomark-
ers has to reflect that difference. A broader
potentially more fruitful approach is the use of
untargeted metabolomics as performed by LeWitt
et al. (12), which can serve both as a tool for
more precise diagnosis and creating new hypothe-
ses regarding the pathogenesis of PD.
Parkinson’s disease and atypical Parkinson’s disease
Neurofilament light chain functions as a biomar-
ker for distinguishing PD from APD, with suffi-
cient sensitivity and specificity to be of clinical
value, and hopefully future studies will corrobo-
rate previous findings.
Cognitive impairment and disease severity
Amyloid and tau-protein analyses show a distinct
pattern related to cognitive abilities, and they
also have a prognostic value in the development
of cognitive impairment and dementia that might
also be of clinical value.
Although this review does not point towards a
specific biomarker, many indicators of oxidative
stress seem to be related to disease duration and
severity, the latter being important for objectively
measuring the effect of potential disease modify-
ing drugs, and maybe future studies in this cate-
gory can corroborate previous findings.
Future biomarkers for dyskinesia?
To our knowledge, only few CSF studies have
focused on L-DOPA-induced dyskinesia (LID),
which is a common and oftentimes debilitating
side effect to prolonged L-DOPA treatment.
Identifying PD patients with a risk of developing
LID might make it possible to adjust the medical
treatment in earlier disease stages, preventing or
postponing the debut of LID. Lunardi et al. (81)
found an increased HVA/dopamine ratio in dysk-
inetic patients, which indicates an increased dopa-
mine metabolism in non-dopaminergic cells, as
catechol-O-methyltransferase (COMT), the
enzyme responsible for the production of HVA,
is not present in dopaminergic neurons. Apart
from markers of dopamine turnover, other
biomarkers may be identified by metabolomics
and assays for BDNF and vascular endothelial
growth factor (VEGF), associated with abnormal
plasticity in animal models of LID (82).
In future, standardized longitudinal studies
with a wider biomarker focus (e.g. metabolo-
mics), especially including patients with possible
premotor symptoms of PD, are expected to
play an important role in the ongoing search
for PD biomarkers for early diagnosis and
prognosis, and will help in elucidating the
20
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pathological mechanism of the Parkinson’s dis-
ease complex.
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Abstract
Levodopa (L-DOPA, L-3,4-dihydroxyphenylalanine) is the most
effective drug in the symptomatic treatment of Parkinson’s
disease (PD), but chronic use initiates a maladaptive process
leading to L-DOPA-induced dyskinesia (LID). Risk factors for
early onset LID include younger age, more severe disease at
baseline and higher daily L-DOPA dose, but biomarkers to
predict the risk of motor complications are not yet available.
Here, we investigated whether CSF levels of catecholamines
and its metabolites are altered in PD patients with LID [PD-
LID, n = 8)] as compared to non-dyskinetic PD patients
receiving L-DOPA (PD-L, n = 6), or not receiving L-DOPA
(PD-N, n = 7) as well as non-PD controls (n = 16). PD
patients were clinically assessed using the Uniﬁed Parkinson’s
Disease Rating Scale and Uniﬁed Dyskinesia Rating Scale
and CSF was collected after overnight fasting and 1–2 h after
oral intake of L-DOPA or other anti-Parkinson medication. CSF
catecholamines and its metabolites were analyzed by HPLC
with electrochemical detection. We observed (i) decreased
levels of dihydroxyphenylacetic acid (DOPAC) and homovanil-
lic acid in PD patients not receiving L-DOPA (ii) higher
dopamine (DA) levels in PD-LID as compared to controls (iii)
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Abbreviations used: 3-OMD, 3-O-methyldopa; 5-HIAA, 5-hydro-
xyindoleacetic acid; 6FD, 6-18F-ﬂuoro-L-DOPA; AADC, aromatic
amino acid decarboxylase; AD, Alzheimer’s disease; AUC, area under
the curve; BDNF, brain-derived neurotrophic factor; DA, dopamine;
DAergic, dopaminergic; DAT, dopamine transporter; DAT-ir,
DAT-immunoreactivity; DLB, Lewy body dementia; DOPAC,
dihydroxyphenylacetic acid; HVA, homovanillic acid; LC, locus
coeruleus; LED, levodopa equivalent dose; LID, levodopa-induced
dyskinesia; MAO, monoamine oxidase; MDS-UPDRS, Movement
Disorder Society Uniﬁed Parkinson’s Disease Rating Scale; MHPG, 3-
methoxy-4-hydroxyphenylglycol; MMSE, Mini-Mental State Exami-
nation; MOCA, Montreal Cognitive Assessment; NAergic, noradren-
ergic; PCA, perchloric acid; PD-LID, Parkinson’s disease patients
receiving L-DOPA, dyskinetic; PD-L, Parkinson’s disease patients
receiving L-DOPA, non-dyskinetic; PD-N, Parkinson’s disease
patients not receiving L-DOPA; PD, Parkinson’s disease; PET,
positron emission tomography; ROC, receiver operating characteris-
tics; UDysRS, uniﬁed dyskinesia rating scale.
© 2017 International Society for Neurochemistry, J. Neurochem. (2017) 10.1111/jnc.13997 1
JOURNAL OF NEUROCHEMISTRY | 2017 doi: 10.1111/jnc.13997
higher DA/L-DOPA and lower DOPAC/DA ratio’s in PD-LID as
compared to PD-L and (iv) an age-dependent increase of DA
and decrease of DOPAC/DA ratio in controls. These results
suggest increased DA release from non-DA cells and deﬁcient
DA re-uptake in PD-LID. Monitoring DA and DOPAC in CSF of
L-DOPA-treated PD patients may help identify patients at risk
of developing LID.
Keywords: aging, biomarkers, dopamine, HPLC, metabolites,
neurodegeneration.
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Parkinson’s disease (PD) is a common age-related neurode-
generative disease with a prevalence of about 1% in people
over 60 years and up to 4% in the oldest age-groups (de Lau
and Breteler 2006). Diagnosis is based on clinical symptoms
including bradykinesia, and either rigidity, resting tremor, or
both (Postuma et al. 2015). The dopamine precursor L-
DOPA is the most effective drug in the symptomatic
treatment of PD, but chronic use is associated with serious
motor complications, e.g. ﬂuctuations (wearing off, on-off)
and dyskinesia (chorea, dystonia and athetosis). This
phenomenon is called L-DOPA-induced dyskinesia (LID),
and is seen in the majority of patients (80% within 5 years)
(Bastide et al. 2015). Attempts to alleviate established LID
by reducing L-DOPA dosage often result in impaired control
of Parkinsonian symptoms. Balancing this trade-off is a
major challenge in advanced PD (Marsden and Donaldson
2012). Risk factors for earlier onset of LID include younger
age, greater disease severity at baseline, higher daily L-
DOPA dosage and a polymorphism in brain derived
neurotrophic factor (Rascol et al. 2006; Olanow et al.
2013; Cheshire et al. 2014). If PD patients with increased
risk for LID could be identiﬁed, their anti-Parkinsonian
medication could be adjusted in an early phase, which may
prevent or postpone the onset of LID. Thus, there is a clinical
need to identify biomarkers for LID.
In drug-na€ıve PD or following drug washout, CSF levels of
the dopamine (DA) metabolite 3,4-dihydroxyphenylacetate
(DOPAC) are signiﬁcantly decreased as compared to age-
matched controls (Goldstein et al. 2008, 2012), which is
indicative of the reduced synthesis and metabolism of DA in
brains of PD patients not currently receiving L-DOPA. TheDA
metabolite homovanillic acid (HVA) may also be reduced in
PD CSF, but in contrast to DOPAC, it is not a reliable marker
for central DA deﬁciency (Wood 1980; LeWitt et al. 1992,
2011; Chia et al. 1993; Meiser et al. 2013).
Most treatment strategies in PD are aimed at enhancing
dopaminergic (DAergic) transmission in the basal ganglia.
Treatment with the DA precursor L-DOPA increases CSF
levels of catecholamines and its metabolites (Raftopoulos
et al. 1996), whereas treatment with a monoamine oxidase B
(MAO-B) inhibitor reduces CSF levels of the acidic
metabolites DOPAC and HVA (Heinonen et al. 1993)
Parkinson study group 1995), but increases interstitial DA
levels – due to the combined effects of blocked catabolism
and inhibition of DA-reuptake by an active metabolite of the
MAO-B-inhibitor (Knoll 1978). Chronic treatment with the
D2/D3-recepter agonist pramipexole increases DOPAC and
HVA levels and DA turnover in mice (Schulte-Herbruggen
et al. 2012), possibly due to downregulation of presynaptic
D2-receptors.
There is some evidence that chronic L-DOPA treatment
increases angiogenesis and thereby access of L-DOPA to the
brain (Ohlin et al. 2011; Janelidze et al. 2015). Apart from
this, L-DOPA-induced DA release in the striatum may be
handled differently in LID versus non-dyskinetic PD
patients, giving rise to excessive stimulation of postsynaptic
DA receptors. Such changes have been observed in exper-
imental models of LID (Bastide et al. 2015), but only a few
clinical studies have addressed possible presynaptic differ-
ences in LID versus non-dyskinetic PD. Two of these studies
reported increased DA turnover in dyskinetic patients, either
based on neurochemical analysis of CSF (Lunardi et al.
2009) or 6-18F-ﬂuoro-L-DOPA positron emission tomogra-
phy (PET) scans (Sossi et al. 2006). Studies using 6-18F-
ﬂuoro-L-DOPA-PET have further suggested that downregu-
lation of the dopamine transporter (DAT) beyond the degree
expected based on disease severity, is an independent
predictor of the development of LID (Sossi et al. 2007).
While previous CSF studies on catecholamines in PD
collected CSF from drug-na€ıve patients or after drug wash-
out, here we collected CSF from PD patients at 1.5–2 h after
oral intake of L-DOPA [+ peripheral aromatic L-amino acid
decarboxylase inhibitor (AADC-I)] intake; i.e. the time
interval where peak plasma levels are reached (Okereke et al.
2004; Huot et al. 2012). Using this approach, we studied the
L-DOPA-induced effects on DA metabolism in non-dyski-
netic and dyskinetic PD patients. After collecting CSF,
patients were clinically assessed, using the Movement
Disorder Society Uniﬁed Parkinson’s Disease Rating Scale
(MDS-UPDRS) part III and the Uniﬁed Dyskinesia Rating
Scale (UDysRS) (Goetz et al. 2008a,b).
The aim of this study was to investigate whether L-DOPA,
NA, DA and its metabolites are altered in LID compared to
non-dyskinetic PD patients and controls.
Materials and methods
Patient and control recruitment
PD patients and controls were recruited from three different
neurological clinics in the Region of Southern Denmark (Hospitals
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in Sønderborg, Odense) as well as a private neurological practice
(Esbjerg) one neurological clinical in Region Zealand (Roskilde).
The study included 20 PD patients and one Lewy body dementia
(DLB) patient, all diagnosed by movement disorder specialists using
the UK Brain Bank Criteria for idiopathic PD (Hughes et al. 1992).
Since DLB, like PD, is a synucleinopathy, we included this patient
in the PD group. Controls were patients referred by their physician
or practicing neurologist for further neurological examination, and
lumbar puncture was part of the pre-determined diagnostic set-up.
The following referring diagnoses were noted: headache n = 3,
dementia n = 3, multiple sclerosis n = 3, vertigo n = 1, ataxia
n = 1, trigeminal neuralgia n = 1, unspeciﬁed sleep disorder n = 1,
neuroborreliosis n = 2. Two controls were diagnosed as having
Alzheimer’s disease. One had a possible brain stem or cerebellar
disorder, one post concussion syndrome, and one had a potential
sleep disorder, but was discharged without a speciﬁc diagnosis.
The rest of the controls were not diagnosed with a neurological
disorder. All PD patients and controls were informed in writing
and orally about the project, and gave written consent prior to
participation in the project, which had been approved by the local
ethics committee in the Region of Southern Denmark (S-
20130098). The study conforms to The Code of Ethics of the
World Medical Association.
CSF sampling
Lumbar punctures (LP) on PD patients were performed between
09.30 and 10.00 am after overnight fasting (19 of 21 patients).
Patients using L-DOPA were instructed to (when possible) take their
morning dose at 08.00 am, but time of intake varied from 05.30 am
to 08.00 am. For PD patients the procedure was performed in a
sitting position, using an atraumatic Pencan! (B. Braun Medical
Inc., Frederiksberg, Denmark) (0.53 9 88 mm) needle at the L3/L4
level. CSF was withdrawn as follows:
Step 1: 2–3 mL CSF for routine analysis.
Step 2: 2 9 360 lL CSF was pipetted into two brown Saarstedt
tubes containing 40 lL of 1 M perchloric acid (PCA) with
antoxidants (0.2 g/L Na2SO2, 0.05 g/L Na2EDTA), immediately
placed on dry ice and stored at !80°C.
For controls, the procedure was performed between 09.30 am
!12.15 pm, using an atraumatic needle. A subgroup of controls had
not been fasting before withdrawal of CSF. Six out of 16 control
patients had the procedure done in a sitting position without
measurement of the CSF pressure, 10 had the procedure done lying
on the side with CSF pressure measurement before withdrawing
CSF as part of their investigation. Apart from this the same steps for
sampling CSF were followed as described above.
Clinical rating
Clinical rating was performed on the same day as the LP
procedure. PD motor symptom severity was rated in the ON-stage
using the MDS-UPDRS part III (Goetz et al. 2008b). For patients
using L-DOPA it was performed approximately 50 min after
intake. The procedure was recorded on video for later assessment
(apart from evaluating rigidity). UDysRS (Goetz et al. 2008a)
objective score procedure was performed with video recording for
later rating. For patients using L-DOPA, it was performed
approximately 50 min after drug intake. Cognitive rating was
done using the Mini-Mental State Examination and Montreal
Cognitive Assessment scales.
Subgroups of PD patients
PD patients were divided into three groups: patients not receiving L-
DOPA (PD-N, n = 7), patients receiving L-DOPA but without
dyskinesia (PD-L, n = 6), and patients receiving L-DOPA and
having dyskinesia (PD-LID, n = 8). PD-LID patients were assigned
to this group either with a positive UDysRS objective score (n = 6),
clearly dyskinetic presentation but recruited before the use of the
UDysRS (n = 1), or amnestic description of LID symptoms (n = 1).
Unless otherwise stated, PD-N, PD-L and PD-LID will be used to
describe the separate groups. A ﬂowchart of the clinical work
process is shown in ﬁg.1.
HPLC analysis of catecholamines and its metabolites
On the ﬁrst day of HPLC analysis, CSF-containing PCA was thawed
on ice and centrifuged at 20,627 g for 20 min at 4°C. The supernatant
was used for HPLC analysis. A small volume (50 lL) of unpuriﬁed
supernatant was used for analysis of 3-methyl-dopa (3-OMD), 3-
methoxy-4-hydroxyphenylglycol (MHPG), DOPAC, HVA, (and 5-
HIAA). 250–700 lL supernatant was used for extraction of cate-
cholamines (puriﬁcation) using RECIPE ClinRep. Plasma Assay Kit
(RECIPE,Munich,Germany). Before cleaning up, the pHof the PCA-
containing supernatant was adjusted to pH 5–6 using 5–8 lL 10 M
NaOH.
L-DOPA, noradrenaline, dopamine, serotonin, and its respective
metabolites 3-OMD, MHPG, DOPAC, HVA, and 5-HIAA were
analyzed by HPLC with electrochemical detection, essentially as
described (Gramsbergen et al. 2002; Lambertsen et al. 2012), but
with some modiﬁcations allowing detection and quantiﬁcation of all
compounds of interest.
The Merck-Hitachi HPLC system consisted of an L-7100 pump,
an L-7200 autosampler, a D-7000 interface and an electrochemical
detector with in-built column oven (Decade; Antec, Leiden, The
Netherlands), connected to a computer equipped with D-7000
version 4.0 chromatography software (Hitachi, San Jos"e, California,
USA). The electrochemical cell was set to 750 mV versus Ag/AgCl.
The mobile phase was pumped at a ﬂow rate of 0.9 mL/min through
a Waters Spherisorb S5 ODS2 guard column (4.6 9 30 mm;
Waters Corp, Milford, MA, USA) and a Waters Spherisorb S3
ODS2 cartridge analytical column (4.6 9 150 mm; Waters Corp).
A mixture of external standards of monoamines and metabolites
(Sigma-Aldrich Denmark A/S, Brøndby, Denmark) was injected
(0.25–0.5 pmol per standard) to identify and quantify the com-
pounds of interest in the CSF samples.
For analysis of L-DOPA, 3-OMD, MHPG, DOPAC, HVA, and 5-
HIAA in unpuriﬁed PCA extracts, samples were diluted 109 in
mobile phase and 2, 5 or 20 lL was injected into the HPLC system,
using a mobile phase containing 2% methanol, 0.1 M sodium
acetate, 0.035 mM disodium ethylenediaminetetraacetate
(Na2EDTA), octanesulfonic acid (0.176 mM), pH 3.15 adjusted
with glacial acetic acid.
For analysis of noradrenaline and dopamine, 50 lL of undiluted
puriﬁed samples (RECIPE, Munich, Germany) were injected into
the HPLC system using a mobile phase containing 3% acetonitrile,
94 mM NaH2PO4, 0.71 mM octanesulfonic acid, 0.2 mM
Na2EDTA, pH 3.2 adjusted with 1 M phosphoric acid. Recovery
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of internal standard, 3,4-dihydroxybenzoic acid (added to the
RECIPE cleaning up columns), was assessed by injecting 5 lL of
puriﬁed sample and revealed a recovery of 72 " 2%. Obtained
catecholamine data were not adjusted for recovery of the cleaning up
procedure.
Control and PD samples were not blinded during processing for
catecholamines. Even though we performed no blinding in regards
to samples being from patients or controls, L-DOPA treatment and
clinical scores (UDysRS, UPDRS III) of PD patients were blinded
during the neurochemical processing (Fig. 1).
Statistical analysis
Power analysis was not performed, but originally we aimed to collect
plasma and CSF samples of about 25 dyskinetic and 25 non-dyskinetic
PD patients and 25 age-matched controls. However, due to difﬁculties
in obtaining CSF samples from PD patients, we decided to proceed
analysing the rather small sample numbers obtained within the time-
limited recruitment phase of the project. Statistical calculations were
performed, using Stata/IC 14.2 (StataCorp, College Station, Texas,
USA) forMac.Comparisonsbetween twogroupswere doneusing t-test
and Mann–Whitney U-test for parametric and non-parametric numer-
ical variables, respectively, and two-sample Kolmogorov–Smirnov for
binary variables.
Comparisons between more than two groups were done using
ANOVA for normally distributed data and Kruskal–Wallis equality-of-
populations rank test for non-parametric numerical values followed
by Dunn’s Pairwise Comparison (without adjustment) for multiple
comparison. For binary values Fisher’s exact test was used. A p-
value of 0.05 was used as the level of statistical signiﬁcance. Figures
were made using Prism 7.0 for Mac OS X (GraphPad Software, Inc.,
La Jolla, California, USA).
All statistics were performed with and without inclusion of the
DLB patient in the PD-L group and with and without inclusion of
two Alzheimer’s disease patients in the control group.
Results
Demographic analysis
Patient data are summarized in Table 1. The average age of
the control group was about 10 years younger than the
average age of PD patients in PD-N and PD-L, but within the
same age-range as the PD-LID patients (Table 1). There was
a male preponderance in the combined PD group, whereas
the gender distribution reﬂected the general population in the
control group. CSF-protein levels were signiﬁcantly lower in
controls, but these levels are not correlated with CSF
catecholamine and metabolite levels in either group. PD-L
patients had signiﬁcantly higher MDS-UPDRS part III scores
than PD-N. The latter group was not treated with L-DOPA,
accordingly the calculated, lower daily L-DOPA-equivalent
dose in this group is based on the use of dopamine D2
receptor agonists (all seven in PD-N group, ropinirol n = 5,
pramipexole n = 2) and in all but two patients combined
with MAO-B-inhibitor treatment (Selegeline). PD-LID
patients were treated with the highest levodopa equivalent
dose and had a signiﬁcantly lower age of debut of disease
symptoms compared to PD-N and PD-L patients.
The Montreal Cognitive Assessment score testing execu-
tive function is slightly decreased in all PD patients with no
signiﬁcant difference between the subgroups. No difference
Fig. 1 Flowchart showing the clinical work
process. LP; lumbar puncture, MDS-
UPDRS; Movement Disorder Society
modiﬁed Uniﬁed Parkinson’s Disease
Rating Scale, UDysRS; Uniﬁed Dyskinesia
Rating Scale, PD-N; Parkinson’s disease
patients not treated with L-DOPA, PD-L;
Non-dyskinetic patients treated with L-
DOPA, PD-LID; Dyskinetic patients treated
with L-DOPA.
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is found in the Mini-Mental State Examination score across
the PD groups.
CSF catecholamines and metabolites
In Fig. 2 the measured CSF levels of L-DOPA, DA, NA and
the metabolites 3-OMD, DOPAC, HVA, MHPG and 5-
HIAA are depicted. L-DOPA treatment signiﬁcantly
increased L-DOPA, 3-OMD and DA levels in the PD-L
and PD-LID groups as compared to controls. DOPAC and
HVA levels were also elevated by L-DOPA treatment,
reaching signiﬁcance in comparison with PD-N. In the latter
PD group, we observed signiﬁcantly decreased L-DOPA,
DA, DOPAC and HVA levels as compared to controls.
In PD-L CSF levels of NA were signiﬁcantly increased as
compared to controls and PD-N. In PD-LID, NA and MHPG
levels were not different from controls. In PD-N we observed
lower MHPG levels as compared to PD-LID. The levels of 5-
HIAA are not different between controls or any of the PD
groups.
In Fig. 3 receiver operating characteristics between PD-N
and controls are shown. DA, DOPAC and HVA levels
signiﬁcantly separate the two groups.
Ratios
In Fig. 4 ratios of DA/L-DOPA, DOPAC/DA, HVA/DA and
MHPG/NA in controls and the three PD groups are depicted.
In comparison to controls, we observed that the DA/L-
DOPA-ratio is reduced in PD-L but not in PD-LID. The
DOPAC/DA and HVA/DA-ratio’s are reduced in both PD-L
and PD-LID as compared to controls and PD-N. The MHPG/
NA-ratio is only decreased in PD-L, but not in PD-LID We
observed that DA/L-DOPA (increased), DOPAC/DA (re-
duced) and MHPG/NA (increased) are altered in PD-LID as
compared to PD-L.
Age-dependent effects in controls
In Fig. 5, correlations between age and DA, the DOPAC/
DA-ratio and 5-HIAA are shown. We found a signiﬁcant
age-dependent increase in DA, and signiﬁcant age-dependent
decreases in DOPAC/DA-ratios and 5-HIAA levels.
Discussion
The main ﬁndings of this neurochemical study of CSF of PD
patients and controls are:
(i) Signiﬁcant differences in L-DOPA-induced changes of
dopamine and its metabolites in PD-LID versus PD-L;
(ii) Reduced DOPAC and HVA levels in PD not treated
with L-DOPA;
(iii) An age-related increase of dopamine and reduced
DOPAC/DA ratio in controls
These ﬁndings are discussed below.
L-DOPA-induced changes in dyskinetic and non-dyskinetic
PD patients
L-DOPA treatment has a profound effect on CSF levels of L-
DOPA and its metabolites 3-OMD and dopamine. It is clear
Table 1 Clinical characteristics of the patient and control groups
Control PD-N PD-L PD-LID PD total
Number of cases (n) 16 7 6 8 21
Age (years) 55.1 " lla 64.3 " 5.1 67 " 13.3b 58.5 " 8.3 62.9 " 9.5
Sex (F/M) 8/8 3/4 0/6 2/6 5/16
CSF protein (g/L) 0.34 " 0.08c 0.5 " 0.18 0.46 " 0.16 0.45 " 0.15 0.47 " 0.16
UPDRS III 19 " 7.3d 37.8 " 8.4 29.5 " 13.3 28.4 " 12.4
UDysRS objective score 0 0 7.9 " 5 3.1 " 4.9
Symptom duration (years) 3.4 " 2e 6.4 " 4 9 " 4.7 6.4 " 4.3
LED (mg) 10 " 40f 320.7 " 106.8g 525 " 150h 848.4 " 292.3 580.1 " 303.7
MOCA 27.7 " 2.1 25.8 " 2.5 25.9 " 1.6 26.6 " 2.1
MMSE 29.1 " 1.5 27.3 " 4.2 29.3 " 0.7 28.7 " 2.4
PD-N, Parkinson’s disease not receiving L-DOPA; PD-L, Non-dyskinetic Parkinson’s disease receiving L-DOPA; PD-LID, Dyskinetic Parkinson’s
disease receiving L-DOPA; L-DOPA, Levodopa; F, female; M, male; UPDRS, Uniﬁed Parkinson’s disease rating scale; UDysRS, Uniﬁed dyskinesia
rating scale; LED, Daily levodopa equivalent dosage; MOCA, Montreal Cognitive Assessment; MMSE, Mini mental state examination; DLB, Lewy
body dementia; AD, Alzheimer’s disease. Numerical values are described as mean " SD.
ap = 0.0264 versus PD total, p = 0.0096 versus PD-L, p = 0.0211 versus PD-N when excluding AD and DLB cases.
bp = 0.0454 versus PD-LID only when including DLB case.
cp = 0.0056 versus PD total, p = 0.0048 versus PD-N, p = 0.0424 versus PD-L, p = 0.0438 versus PD-LID.
dp = 0.013 versus PD-L.
ep = 0.0035 versus PD-LID, p = 0.018 versus PD-L when excluding DLB case.
fOne control received Ropinirol for restless legs.
gp = 0.0419 versus PD-L, p = 0.0001 versus PD-LID.
hp = 0.0397 versus PD-LID only when including DLB case.
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from our CSF analysis that L-DOPA treatment compensates
for the loss of L-DOPA and DA as observed in the PD-N
group. Our ﬁndings of increased L-DOPA, 3-OMD, DA,
DOPAC, and HVA in L-DOPA-treated PD patients are in
line with previous CSF studies (Chia et al. 1993; Raftopou-
los et al. 1996), but in the present study we looked also for
differences between the dyskinetic (PD-LID) and non-
dyskinetic, L-DOPA-treated patients (PD-L).
Although PD-LID received higher daily doses of L-DOPA
(Table 1) we did not detect higher L-DOPA CSF levels in
this dyskinetic group. 3-OMD has a longer half life than L-
DOPA, which accumulates during L-DOPA treatment
(Bartholini et al. 1972). Accordingly, CSF 3-OMD levels
are dramatically increased in L-DOPA-treated patients (low
lM range), with a tendency toward higher 3-OMD levels in
dyskinetic patients. In L-DOPA- treated patients we measured
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Fig. 2 CSF levels of dopamine, L-DOPA,
dihydroxyphenylacetic acid (DOPAC), 3-O-
methyldopa (3-OMD), homovanillic acid
(HVA), noradrenaline (NA), 3-methoxy-4-
hydroxyphenylglycol (MHPG), and 5-
hydroxyindoleacetic acid (5-HIAA) in controls
and PD. PD-N, Parkinson’s disease non-L-
DOPA-treated; PD-L, Parkinson’s disease, L-
DOPA-treated, non-dyskinetic; PD-LID,
Parkinson’s disease, L-DOPA-treated,
dyskinetic; DLB, Lewy body dementia; AD,
Alzheimer’s disease. Brackets represent
mean and SEM. (a) ANOVA p = 0.0001, (b)
ANOVA p = 0.0001, (c) ANOVA p = 0.0107, (d)
ANOVA p = 0.0001, (e) ANOVA p = 0.002, (f)
ANOVA not signiﬁcant, (g) ANOVA not signiﬁcant,
and (h) ANOVA not signiﬁcant. *p < 0.05
**p < 0.01 ***p < 0.001 ****p < 0.0001. a:
Only signiﬁcant when excluding AD patients.
b: Only signiﬁcantwhen includingDLBpatient.
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L -DOPA levels around 20 nM, which is almost a factor
50 less than 3-OMD. However, L-DOPA levels were
measured after cleaning up with the RECIPE kit, which
has a low recovery for L-DOPA, whereas 3-OMD was
measured directly in PCA extracts (without further clean-
ing up). Slightly higher 3-OMD levels in dyskinetic
patients are in line with the generally higher L-DOPA
dose these patients receive (see Table 1). Higher plasma
levels of 3-OMD in dyskinetic versus non-dyskinetic L-
DOPA-treated patients has been reported previously
(Feuerstein et al. 1977).
L-DOPA-induced dyskinesia (LID) is the result of mal-
adaptive presynaptic and postsynaptic changes due to chronic
L-DOPA treatment in advanced stages of PD (Bastide et al.
2015). CSF levels of catecholamines and their metabolites in
samples taken at peak plasma levels of L-DOPA, may be
used as markers of the integrity of the presynaptic DA-ergic
system, including reuptake of dopamine.
In this study we observed about twofold elevated DA
levels in L-DOPA-treated, non-dyskinetic patients and about
fourfold increases in PD-LID, which for the latter are
signiﬁcantly different from controls. It is likely that such
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Fig. 3 Receiver operating characteristics
analysis between controls and Parkinson’s
disease patients not receiving L-DOPA (PD-
N). (a) p = 0.0134 (Alzheimer’s disease
cases excluded), (b) p = 0.0182, (c) p =
0.0072, and (d) p = 0.0068.
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Fig. 4 CSF dopamine (DA)/L-DOPA-,
dihydroxyphenylacetic acid (DOPAC)/DA-,
homovanillic acid (HVA)/DA-, and 3-
methoxy-4-hydroxyphenylglycol (MHPG)/
NA-ratios in controls and patient groups.
PD-N, Parkinson’s disease non-L-DOPA-
treated; PD-L, Parkinson’s disease, L-
DOPA-treated, non-dyskinetic; PD-LID,
Parkinson’s disease, L-DOPA-treated,
dyskinetic; DLB, Lewy body dementia; AD,
Alzheimer’s disease. Brackets represent
mean and SEM. (a) ANOVA not signiﬁcant, (b)
ANOVA p = 0.0018, (c) ANOVA p = 0.0019, and
(d) ANOVA not signiﬁcant. *p < 0.05
**p < 0.01 ***p < 0.001. a: Only signiﬁcant
whenexcludingADpatients andDLBpatient.
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elevated DA levels also occur at the postsynaptic DA
receptor level in the striatum, which may cause excessive
stimulation of sensitized D1 receptors, resulting in the
adverse dyskinetic effects (Cenci and Konradi 2010; Murer
and Moratalla 2011). Underlying causes of the elevated CSF
DA level in dyskinetic patients may include predominant
release of DA from non-DAergic cells, for instance 5-HT
terminals (Carta and Bezard 2011; Bezard et al. 2013).
Higher levels of DA might also be due to a down regulation
of dopamine transporters, possibly in excess of the degree
expected based on the loss of DAergic terminals alone (Sossi
et al. 2007, 2009).
It has also been proposed that chronic L-DOPA treatment
stimulates angiogenesis and makes the blood brain barrier
more permeable for L-DOPA, causing higher elevations of L-
DOPA and DA in the CNS (Ohlin et al. 2011; Janelidze
et al. 2015). However, we did not observe higher L-DOPA
levels in LID patients. Furthermore, we observed a signif-
icantly higher DA/L-DOPA ratio in PD-LID versus PD-L,
suggesting higher decarboxylation rate of L-DOPA in
dyskinetic patients, probably due to AADC activity in 5-
HT neurons (Carta et al. 2007).
Our study showed that L-DOPA treatment has a marked
effect on HVA and DOPAC levels, which are almost doubled
compared to controls and about 4 times higher than PD
patients not treated with L-DOPA. DOPAC is produced
intracellularly in the terminals of DAergic neurons. If
dyskinetic patients have a more severe loss of DAergic
nigrostriatal terminals, this will result in lower DOPAC levels
(De Deurwaerdere et al. 2016) and in combination with the
increased DA in PD-LID, we found a signiﬁcantly lower
DOPAC/DA ratio in PD-LID versus PD-L. Thus, the present
results may indicate increased DA production in non-DAergic
cells in combination with severely compromised re-uptake.
In PD, noradrenergic cell loss in the locus coeruleus (LC)
precedes and may be equal or even greater than nigrostriatal
dopaminergic cell loss (Zarow et al. 2003). In the present
study we observed an increased NA turnover (MPHG/NA-
ratio) in PD-LID compared to PD-L. This difference in NA
turnover is in agreement with increased ﬁring rates of LC
neurons observed in the 6-hydroxydopamine lesioned rat
model of L-DOPA-induced dyskinesia (Miguelez et al.
2011). However, the role of noradrenaline and lesions of
LC neurons in LID is complex. It seems that the relative
degree of damage to LC and substantia nigra pars compacta
neurons in combination with chronic L-DOPA treatment and
downregulation of alpha2-adrenoceptors contributes to the
alterations in LC ﬁring rates (see for references (Miguelez
et al. 2011) (Fulceri et al. 2007) (Ostock et al. 2014)
(Barnum et al. 2012).
Reduced DOPAC and HVA in PD not treated with L-DOPA
In the subgroup of PD patients not treated with L-DOPA (but
receiving MAO-B inhibitors and/or DA receptor agonists)
we observed reduced CSF levels of L-DOPA, DA, DOPAC
and HVA (but not NA and MHPG) as compared to controls.
This could reﬂect the loss of nigrostriatal DAergic neurons.
Reductions in DOPAC and HVA may also be due to
treatment with MAO-B inhibitors (Parkinson study group
1995). In the present study, ﬁve of the seven patients in the
PD-N group were also treated with MAO-B inhibitors, and
levels of L-DOPA, DOPAC and HVA were not signiﬁcantly
different compared to the two patients only treated with a
dopamine D2 receptor agonist. Chronic treatment with a
dopamine D2 receptor agonist might increase DA metabo-
lites (Schulte-Herbruggen et al. 2012).
In accordance with our ﬁndings, Goldstein et al. (2012)
reported a decrease in CSF L-DOPA levels in untreated PD,
but others did not observe signiﬁcant reductions in L-DOPA
in untreated PD (Eldrup et al. 1995). The reported reduction
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on DA levels has not been shown in other studies (Chia et al.
1993; Eldrup et al. 1995; Goldstein et al. 2012). In some of
the PD-N and control samples we could not detect DA
because amounts were below detection limit for DA in our
HPLC assay (about 10 femtomol on column). For statistical
analysis these samples were assigned the lowest detectable
level of 0.02 nmol/L. It has been suggested (Goldstein et al.
2012) that CSF levels of DA are not a good indicator of
central DA deﬁciency because DA levels are inﬂuenced by
adaptive changes compensating for the loss of DA neurons or
adaptive changes as a result of anti-Parkinsonian medication.
In this scenario changes in the CSF levels of the acidic
metabolites HVA and DOPAC are better indices of the loss
of DA neurons in untreated PD.
Decreased CSF HVA in either drug-na€ıve PD or after
drug-wash-out, has been found by others (Chase and Ng
1972; Davidson et al. 1977; Chia et al. 1993; Abdo et al.
2004; Ishibashi et al. 2010), whereas others have not
detected a change in CSF HVA levels (Zubenko et al.
1986) (LeWitt et al. 2011). There is a large inter-individual
variation in CSF HVA levels (Parkinson study group 1995) –
some of the variation may be due to gradient effects in CSF
obtained in the ﬁrst or later fractions (Dhondt 2004). In our
study, the same fraction of CSF was used when comparing
control and PD CSF.
DOPAC is considered a more reliable marker for central
DA deﬁciency than HVA because (i) HVA is a secondary
metabolite, mainly formed by the successive actions of MAO
(possibly within DOPA-decarboxylase containing neurons)
and catechol-O-methyltransferase (possibly within astrocytes
or other cell types) and (ii) DOPAC is produced in DAergic
neurons by MAO activity after leakage of DA from synaptic
vesicles or following re-uptake of extracellular DA via DAT
in the presynaptic membrane (Goldstein et al. 2012).
Accordingly, decreased DOPAC in CSF of untreated PD
has been reported previously (Zubenko et al. 1986; Eldrup
et al. 1995; Goldstein et al. 2008, 2012). It is likely that the
low levels of DOPAC and HVA in our subgroup of PD
patients not treated with L-DOPA are partly due to treatment
with MAO-B inhibitors.
Goldstein et al. (2012) reported that CSF DOPAC could
differentiate PD from controls with 100% sensitivity and
89% speciﬁcity in newly diagnosed PD patients. We
observed the same sensitivity in our subgroup of PD patients
not treated with L-DOPA, with a somewhat lower speciﬁcity
(Fig. 3a). With regards to sensitivity and speciﬁcity, CSF
DOPAC performed slightly better than CSF HVA in our
study. However, we cannot dismiss that both MAO-B
inhibitor and D2 receptor agonist treatment in the PD-N
group could affect DOPAC- and HVA-levels.
Age-related changes in monoamine turnover?
Age has several effects on DAergic neurons. The density of
tyrosine hydroxylase (TH) positive terminals in striatum
gradually decreases (McGeer et al. 1977) and the composi-
tion of neuromelanine positive cells in substantia nigra pars
compacta changes with age, with a signiﬁcant increase of
cells with decreased or no DAT-immunoreactivity (DAT-ir)
(Ma et al. 1999). It could be speculated that DAT-ir DAergic
neurons are more susceptible to age-related neurodegenera-
tion, thus favouring survival of DAergic neurons not
expressing DAT. This may explain the higher CSF DA
levels and decreased DOPAC/DA ratio (indicating reduced
DA turnover) with increasing age in controls. A 6-[18F]-
ﬂuoro-L-DOPA PET study found a potentially age-related
decrease in vesicular DA storage (Kumakura et al. 2010),
whereas results from a 6-[18F]-ﬂuoro-L-m-tyrosine PET study
points to an age-related compensatory increase in AADC
activity due to this suboptimal dopaminergic system (Braskie
et al. 2008). A compensatory increase in DA production
combined with decreased vesicular storage capacity could
increase CSF DA levels. PET-studies on healthy controls
show decreased binding of D2 receptor ligands in the
striatum (Wong et al. 1984; Volkow et al. 1996), which has
been interpreted as a downregulation of postsynaptic D2
receptors with age. We would alternatively propose that an
increase in CSF DA levels with age could decrease the
binding potential of D2 receptor ligands.
In LID we observed much higher CSF DA levels, which
seems unlikely to be attributable to age-related changes per
se, since LID patients are somewhat younger than PD-L
patients.
We also observed an age-dependent decline of the
serotonin metabolite 5-HIAA in CSF of controls. There are
no reports of an age-related decline of 5-HT neurons (Meltzer
et al. 1998), thus a decrease in 5-HIAA may also point to
decreasing 5-HT turnover with age. None of the controls
were diagnosed with severe depression, and none were
treated with selective serotonin re-uptake inhibitor or other
medication known to alter the CSF 5-HIAA levels. However,
motor activity prior to lumbar puncture may affect CSF 5-
HIAA levels (Garelis et al. 1974).
Study strengths and limitations
Through our spinal tap procedure, quickly processing the
CSF, we have minimized the breakdown of catecholamines.
Movement disorder specialists made the initial diagnoses and
undertook regular follow-up examinations. By allowing
patients to continue their L-DOPA-treatment, tapping CSF
at a ﬁxed time interval after L-DOPA-intake, we avoid large
time-dependent variations in DA CSF levels that are more
acutely affected by L-DOPA-intake, whereas the measured
DA metabolites reﬂect the L-DOPA intake of approximately
the last 24 h.
The study includes only a small number of PD patients,
with minor variation in LID severity in the LID group. The
controls were not completely age matched for the PD-N and
PD-L groups, and a subgroup of controls had not been
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fasting and had the spinal tap performed in supine position,
which might affect CSF catecholamine levels.
Conclusion
We investigated the L-DOPA-induced effects on CSF levels
of catecholamines and their metabolites in dyskinetic and
non-dyskinetic PD patients. In CSF of LID patients we
measured much higher DA levels compared to age-matched
controls, and a higher DA/L-DOPA ratio, as well as a lower
DOPAC/DA ratio compared to non-dyskinetic, L-DOPA-
treated patients.
In future longitudinal studies L-DOPA, DA and metabo-
lites would have to be monitored at the beginning of L-DOPA
therapy and at various stages of disease progression and
treatment before it can be veriﬁed that the observed changes
in DA and DOPAC/DA ratio in this study can serve as a
prognostic marker for LID development.
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Abstract
L-3,4-Dihydroxyphenylalanine (L-DOPA) is the most effective
drug in the symptomatic treatment of Parkinson’s disease, but
chronic use is associated with L-DOPA-induced dyskinesia in
more than half the patients after 10 years of treatment. L-
DOPA treatment may affect tryptophan metabolism via the
kynurenine pathway. Altered levels of kynurenine metabolites
can affect glutamatergic transmission and may play a role in
the development of L-DOPA-induced dyskinesia. In this study,
we assessed kynurenine metabolites in plasma and cere-
brospinal ﬂuid of Parkinson’s disease patients and controls.
Parkinson patients (n = 26) were clinically assessed for
severity of motor symptoms (UPDRS) and L-DOPA-induced
dyskinesia (UDysRS). Plasma and cerebrospinal ﬂuid sam-
ples were collected after overnight fasting and 1–2 h after
intake of L-DOPA or other anti-Parkinson medication. Metabo-
lites were analyzed in plasma and cerebrospinal ﬂuid of
controls (n = 14), Parkinson patients receiving no L-DOPA
Received March 22, 2017; revised manuscript received May 30, 2017;
accepted June 2, 2017.
Address correspondence and reprint requests to Jan Bert Gramsbergen,
University of Southern Denmark, Institute of Molecular Medicine,
Neurobiology Research, J.B. Winsløwvej 21, DK-5000 Odense,
Denmark. E-mail: jbgramsbergen@health.sdu.dk
1These authors contributed equally to this work.
Abbreviations used: 3-HAA, 3-hydroxyanthranilic acid; 3-HAO,
3-Hydroxyanthranilic acid dioxygenase; 3-HK, 3-hydroxykynurenine;
3-OMD, 3-O-methyldopa; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT,
5-hydroxytryptamine, serotonin; 5-HTP, 5-hydroxytryptophan; AA,
Anthranilic acid; AADC, aromatic amino acid decarboxylase; AMO,
anthranilate 3-monooxygenase; CSF, cerebrospinal ﬂuid; DA, dopamine;
DLB, lewy body dementia; DOPAC, dihydroxyphenylacetic acid; IDO,
indoleamine-2,3-dioxygenase; KATs, kynurenine aminotrans-
ferases; KF, kynurenine formamidase; KMO, kynurenine 3-mono-
oxygenase; KYNA, kynurenic acid; KYN, kynurenine; KYNU,
kynureninase; LC-MS, liquid chromatography with mass
spectrometry; L-DOPA, L-3,4-dihydroxyphenylalanine; LID,
levodopa-induced dyskinesia; MAO, monoamine oxidase; MMSE,
mini-mental state examination; MOCA, montreal cognitive assess-
ment; NMDA, N-methyl-D-aspartate; PD-LID, Parkinson’s disease
patients receiving L-DOPA, dyskinetic; PD-L, Parkinson’s disease
patients receiving L-DOPA, non-dyskinetic; PD-N, Parkinson’s
disease patients not receiving L-DOPA; PD, Parkinson’s disease;
TDO, tryptophan 2,3-dioxygenase; TRP, tryptophan; UDysRS,
uniﬁed dyskinesia rating scale; UPDRS, uniﬁed Parkinson’s disease
rating scale; XA, xanthurenic acid.
756 © 2017 International Society for Neurochemistry, J. Neurochem. (2017) 142, 756--766
JOURNAL OF NEUROCHEMISTRY | 2017 | 142 | 756–766 doi: 10.1111/jnc.14104
(n = 8), patients treated with L-DOPA without dyskinesia
(n = 8), and patients with L-DOPA-induced dyskinesia
(n = 10) using liquid chromatography-mass spectrometry.
We observed approximately fourfold increase in the 3-
hydroxykynurenine/kynurenic acid ratio in plasma of Parkin-
son’s patients with L-DOPA-induced dyskinesia. Anthranilic
acid levels were decreased in plasma and cerebrospinal ﬂuid
of this patient group. 5-Hydroxytryptophan levels were twofold
increased in all L-DOPA-treated Parkinson’s patients. We
conclude that a higher 3-hydroxykynurenine/kynurenic acid
ratio in plasma may serve as a biomarker for L-DOPA-induced
dyskinesia. Longitudinal studies including larger patients
cohorts are needed to verify whether the changes observed
here may serve as a prognostic marker for L-DOPA-induced
dyskinesia.
Keywords: 3-hydroxykynurenine, biomarkers, kynurenic acid,
levodopa, metabolomics, tryptophan.
J. Neurochem. (2017) 142, 756–766.
The most effective drug in the symptomatic treatment of
Parkinson’s disease (PD) is L-DOPA (L-3,4-dihydroxyphe-
nylalanine), but chronic use is associated with serious
motor complications, L-DOPA-induced dyskinesia (LID).
LID is observed in more than half the patients after
10 years of treatment (Schapira et al. 2009). Risk factors
for early onset LID include younger age, more severe
disease at baseline, and higher daily dose of L-DOPA
(Rascol et al. 2006; Cheshire et al. 2014), but biomarkers
to predict the risk of motor complications are not yet
available.
Only a few studies have used metabolomic approaches to
ﬁnd biomarkers for PD in plasma (Bogdanov et al. 2008;
Johansen et al. 2009; Roede et al. 2013; Trupp et al. 2014;
Hatano et al. 2016; Wuolikainen et al. 2016) or cere-
brospinal ﬂuid (CSF) (Lewitt et al. 2013; Trupp et al.
2014; Wuolikainen et al. 2016), but these studies have not
addressed the metabolic effects of L-DOPA treatment and its
long-term consequences for the development of LID. The
above-mentioned metabolomic studies of blood and CSF
suggested alterations in purine, tyrosine and tryptophan
(TRP) metabolism in PD (Ascherio et al. 2009; Johansen
et al. 2009; Lewitt et al. 2013; Trupp et al. 2014; Hatano
et al. 2016), including increased 3-hydroxykynurenine/
kynurenic acid (3-HK/KYNA) ratios in CSF from demised
patients (Lewitt et al. 2013). Most recently, a comprehensive
urinary metabolic proﬁle was reported that identiﬁed unique
metabolic markers for idiopathic PD associated with the
progression of disease (Luan et al. 2015a,b), including TRP
metabolites.
L-DOPA treatment has a major impact on tyrosine
metabolism (De Deurwaerdere et al. 2017), but the effect
of L-DOPA on TRP metabolism and its possible role in the
development of L-DOPA-induced dyskinesia has not been
clariﬁed. TRP is not only a precursor of serotonin (5-HT), but
also for kynurenine (KYN), which can be degraded to several
other neuroactive compounds, including KYNA (neuropro-
tective, antagonist of the glycine site of the N-methyl-D-
aspartate (NMDA) receptor), 3-HK (neurotoxic, generates
free radicals), and quinolinic acid (neurotoxic, NMDA
receptor agonist) (Schwarcz et al. 2012). The KYN pathway
(see Fig. 1) is the most important route of TRP degradation
in humans.
Both pre-synaptic and post-synaptic maladaptive changes
contribute to the pathophysiology of LID (Bastide et al. 2015;
De Deurwaerdere et al. 2017). Recently, we reported elevated
dopamine (DA)/L-DOPAand reduced dihydroxyphenyl acetic
acid/DA ratios in CSF of LID patients as compared to non-
dyskinetic PD patients receiving L-DOPA, suggesting
increased DA release from non-DA cells and deﬁcient DA
re-uptake in PD-LID patients (Andersen et al. 2017). In
addition to uncontrolled dopamine release acting on super-
sensitive D1 receptors, enhanced glutamatergic signaling may
contribute to LID. Experimental studies have shown that a
change in the ratio of kynurenine metabolites can alter
glutamatergic signaling and may protect against excitotoxicity
mediated via NMDA receptors. KYN metabolism can be
manipulated in vivo using tryptophan-2,3-dioxygenase or
kynurenine 3-monooxygenase (KMO) inhibitors (Campesan
et al. 2011; Breda et al. 2016). Interestingly, prolonged
systemic administration of the KMO inhibitor Ro 61-8048,
which blocks 3-HK synthesis and increases KYNA levels in
the brain, reduces LID in Parkinsonian, 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys (Gre-
goire et al. 2008).
Here, we investigated whether KYN metabolites in plasma
or CSF are altered in PD patients as compared to controls and
whether altered ratios of KYN metabolites are associated
with L-DOPA use or LID.
Methods
PD patients and controls were recruited from different neurological
clinics in the Region of Southern Denmark (Hospitals in Sønderborg
and Odense), a private neurological practice (Esbjerg) and a
neurological clinic in Region Zealand (Roskilde). Twenty-ﬁve PD
patients and one Lewy body dementia (DLB) patient (details
described under ‘subgroups of PD patients’) were included, all
diagnosed by movement disorder specialists using the UK Brain
Bank Criteria for idiopathic PD (20). Control patients were referred
by their physician or practicing neurologist for further neurological
examination including lumbar puncture. Neither controls nor PD
patients were receiving special diets, which may affect kynurenine
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Fig. 1 Kynurenine and serotonin pathway of tryptophan (TRP)
metabolism. TDO: tryptophan 2,3-dioxygenase; IDO: indoleamine-
2,3-dioxygenase; KF: kynurenine formamidase; KMO: kynurenine
3-monooxygenase; KYNU: kynureninase; KATs: kynurenine
aminotransferases; 3-HAO: 3-hydroxyanthranilic acid dioxygenase;
AMO: anthranilate 3-monooxygenase; TH: tryptophan hydroxylase;
AADC: aromatic amino acid decarboxylase; MAO: monoamine oxi-
dase.
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pathway metabolism. In Table 1, demographic and clinical data are
summarized for controls and PD patients providing plasma samples.
In Table S1, patient data are summarized for CSF samples. Further
clinical details of patients and controls can be found in Andersen
et al. (2017). All PD patients and controls were informed in writing
and orally about the project, and gave written consent prior to
participation. The project was approved by the local ethics
committee of the Region of Southern Denmark (S-20130098). The
study conforms to The Code of Ethics of the World Medical
Association.
CSF sampling
Lumbar punctures of PD patients were performed between 09.30 and
10.00 am after overnight fasting. Patients on L-DOPAwere instructed
to (when possible) take their morning dose at 08.00 am, but time of
intake varied from 05.30 am to 08.00 am. The procedure was
performed in a sitting position, using an atraumatic Pencan! (B.Braun,
Frederiksberg, Denmark) (0.53 9 88 mm) needle at the L3/L4 level.
TheCSFwas centrifuged at 4°Cfor 10 min at 2000 g. The supernatant
was aliquoted into Sarstedt! (Sarstedt, Nümbrecht, Germany) tubes
and placed on dry ice immediately until storage at !80°C.
For controls, the procedure was performed between 09.30 am and
12.15 pm using an atraumatic Pencan! (B.Braun, Frederiksberg,
Denmark) (0.53 9 88 mm) needle at the same lumbar level. A
subgroup of controls had not been fasting before withdrawal of CSF.
Five out of 14 control patients had the procedure done in a sitting
position without measurement of the CSF pressure, whereas nine had
the procedure done lying on the side with CSF pressure measurement
before withdrawing CSF as part of their investigation. Aside from this
the same steps for sampling CSF were followed as described above.
CSF samples were obtained from 14 controls and 22 PD patients.
Blood sampling
Blood was drawn from the cubital fossa immediately after the
lumbar puncture in both patients and controls. Four BD
VacutainerTM citrate tubes (Becton Dickinson A/S, Kgs.Lyngby,
Denmark) were ﬁlled and gently turned four times to prevent
coagulation. Within 30 min the four tubes were centrifuged at room
temperature for 10 min at 1800 g. The plasma supernatant was
evenly distributed into two 15 mL tubes and centrifuged at room
temperature for 10 min at 3000 g. The supernatant was then
aliquoted into Saarstedt! tubes and put on dry ice until storage at
!80°C. Plasma samples were obtained from 14 controls and 26 PD
patients.
Clinical rating
Clinical rating was performed on the same day as the LP procedure.
PD motor symptom severity was rated in the ON-stage using the
MDS-UPDRS part III (Goetz et al. 2007). For patients using L-
DOPA, this score and the uniﬁed dyskinesia rating scale (UDysRS)
objective score procedure (Goetz et al. 2008) was performed
approximately 50 min after drug intake. The procedures were
recorded on video for later assessment. Cognitive rating was done
using the mini-mental state examination (MMSE) and Montreal
cognitive assessment (MOCA) scales.
Subgroups of PD patients
PD patients were divided into three groups: patients not receiving
L-DOPA (PD-N, n = 8), patients receiving L-DOPA but without
dyskinesia (PD-L, n = 8), and patients receiving L-DOPA and
having dyskinesia (PD-LID, n = 10). A DLB patient with
bradykinesia and a dopamine transporter-scan with marked
bilateral decreased FP-CIT-uptake in the basal ganglia was
included in the PD-L group, since this patient was treated with
L-DOPA and was not dyskinetic. See Table 1 (plasma samples)
and Table S1 (CSF samples) for demographic and clinical details.
Patients assigned to PD-LID either had a positive UDysRS
objective score (n = 8), or – these patients were recruited before
the use of the UDysRS – clearly dyskinetic presentation (n = 1),
or amnestic description of LID symptoms (n = 1). One patient in
Table 1 Plasma samples – Demographic and clinical data
Control PD-N PD-L PD-LID
Cases (n) 14 8 8 10
Age (years) 55.8 " 11.6 62.6 " 6.6 67.4 " 11.8a 59.9 " 7.9
Sex (F/M) 6/8 3/5 0/8 3/7
UPDRS III – 18.8 " 6.8 36.6 " 7.5 30.1 " 11.8
UDysRS objective score – 0 0 7.8 " 5.7
Symptom duration (years) – 3.9 " 2.4 6.6 " 3.7 8.8 " 4.2
LED (mg/day)* 10 " 40 293 " 126 663 " 416 857 " 288
LED-DOPA only (mg/day) – – 439 " 329 593 " 248
MAO inhibitors 0/14 5/8 1/8 3/10
DA receptor agonists 1/14 7/8 5/8 8/10
MOCA – 28 " 2.0 26 " 2.5 26 " 1.6
MMSE – 29 " 1.4 28 " 3.7 29 " 0.7
*LED, levodopa-equivalent dose; converts the dose of any anti-parkinsonian treatment into the equivalent dose of immediate release L-DOPA.
PD-N, Parkinson’s disease not receiving L-DOPA; PD-L, Parkinson’s disease receiving L-DOPA, non-dyskinetic; PD-LID, Parkinson’s disease
receiving L-DOPA, dyskinetic; L-DOPA, Levodopa; F, female; M, male; UPDRS, Uniﬁed Parkinson’s disease rating scale; UDysRS, Uniﬁed
dyskinesia rating scale; MOCA, Montreal cognitive assessment; MMSE, Mini-mental state examination; Numerical values are mean " SD. aPD-L
older than controls (p < 0.01), but not signiﬁcantly different from PD-N and PD-LID.
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PD-L and one patient in PD-LID received anti-depressant
medication.
Blinding of samples
During LC-MS processing (see below) of plasma and CSF samples,
samples were labeled with C for controls or P for patients, but it was
not known whether patients were assigned to the PD-N, PD-L, or
PD-LID subgroups.
Sample preparation
One hundred microliters of plasma and CSF, respectively, were
thawed on ice for 1 h before addition of 350 lL 85%
methanol including heavy labeled internal standards (0.05 lM
13C2
15N-3-hydroxykynurenine (Biozol, TRC-H943697), 0.05 lM
13C6-kynurenic acid (PerkinElmer, CUSN83060000EA), 2 lM
D6-kynurenine (Cambridge isotope Laboratories, DLM-7842), and
2 lM mixture of 17 heavy isotope-labeled amino acids (Cambridge
isotope Laboratories, MSK-A2-1.2). The samples were vortexed for
30 s and left at !20°C for 30 min before centrifugation at 16 000 g
for 20 min. A quantity of 110 and 120 lL of supernatants from
plasma and CSF, respectively, were transferred to new tubes prior to
lyophilization. The lyophilized samples were resuspended in 20 lL
1% formic acid (FA).
LC-MS and data analysis
Ten microliters of sample was injected using a 1290 Inﬁnity HPLC
system (Agilent Technologies, Santa Clara, CA, USA) equipped
with a Zorbax Eclipse Plus C18 guard column (2.1 9 50 mm and
1.8 lm particle size) and an analytical column (2.1 9 150 mm and
1.8 lm particle size) kept at 40°C. The compounds were eluted
using a ﬂow rate of 300 lL/min and the following composition of
A (0.1% FA) and B (0.1% FA, acetonitrile) solvents: 97% A from
0 to 5 min, 97–85% A from 5 to 8 min, and 85-60% from 8 to
18 min before equilibration for 3 min with the initial conditions.
Eluting metabolites were detected by a 6530 quadrupole time of
ﬂight mass spectrometer (Agilent Technologies) operated in
positive ion mode scanning from 100 to 1000 m/z with the
following settings: Gas temp at 300°C, drying gas at 8 L/min,
nebulizer at 35 psig, sheath gas temp at 350°C, sheath gas ﬂow at
11 min/l, VCap at 3500 V, fragmentor at 125 V, and skimmer at
65 V. Each spectrum was internally calibrated during analysis
using the signals of purine (121.0509) and Hexakis 1H,1H,3H-
tetraﬂuoropropoxy phosphazine (922.0098), which was delivered to
a second needle in the ion source by an isocratic pump running
with a ﬂow of 20 lL/min.
A library with retention times obtained from synthetic standards
(not available for N-formyl kynurenine), and exact mass of the
metabolites of interest was constructed using MassHunter PCDL
Manager v. B.07.00 (Agilent Technologies). Chromatograms for all
compounds were extracted and quantiﬁed using Proﬁnder v. B.08.00
(Agilent Technologies) with amass tolerance of 20 ppm and retention
time tolerance of 0.1 min. Chromatograms were subsequently
manually validated. In-source-induced diagnostic fragments were
used for validation of the identiﬁcation (Table S2). A chromatogram
of a plasma sample is shown in Figure S1. Quantitative linearity for all
compounds (except N-formyl kynurenine) was tested using synthetic
standards in different amounts covering the signal range of the
measured endogenous metabolites (Figure S4).
Statistics
Statistical differences in metabolites or ratios among controls and
PD subgroups were analyzed by non-parametric ANOVA (Kruskall–
Wallis test) and shown by one or more asterisks following the
compound name in the bar charts. Subsequently, PD-LID values
were compared to controls and the other PD groups using Dunn’s
multiple comparison test. Statistical differences were calculated with
and without inclusion of the DLB patient in the PD-L group.
Signiﬁcant differences are indicated in the bar charts, where *
denotes signiﬁcance levels of p < 0.05, **p < 0.005,
***p < 0.0005, and ****p < 0.00005.
Results
LC-MS was used to quantify TRP metabolites along the KYN
and serotonin pathways. The levels of KYN and three of its
major metabolites 3-HK, KYNA, and anthranilic acid (AA) in
plasma and CSF of controls and the three PD groups are
shown in Fig. 2. Absolute quantiﬁcation was done for KYN,
3-HK, and KYNA as heavy isotope-labeled versions of these
were added during the extraction. AA and other metabolite
levels (Figure S2) were expressed as relative abundances.
Plasma KYN levels (low lM range) are about a factor 50
higher than CSF levels, whereas 3-HK and KYNA levels
(nM range) are 15–20-fold higher in plasma as compared to
CSF. AA levels in plasma and CSF could not directly be
compared because no internal, heavy isotope-labeled stan-
dard was used. The results for these metabolites showed
signiﬁcant decreases for KYNA and AA in plasma of PD-
LID patients. A similar trend was observed for these
metabolites in CSF of PD-LID, but only the decrease in
AA reached signiﬁcance as compared to PD-L (with and
without inclusion of the DLB patient).
Among controls, only two out of eight males and three out
of six females had been fasting overnight before withdrawal
of plasma or CSF. In plasma of the small non-fasting group,
mean values for most metabolites were generally somewhat
higher, but these differences did not reach statistical signif-
icance. Ratios of KYN metabolites were not affected by
Fig. 2 Plasma and cerebrospinal ﬂuid (CSF) levels of kynurenine
(a), 3-hydroxykynurenine (b), kynurenic acid (c), and anthranilic acid
(d). Anthranilic acid was quantiﬁed relatively as no internal standard
of the compound was used. Patient groups and statistics are
described in material and methods. Abbreviations of patient groups:
see legend to Table 1. ANOVA (Kruskall–Wallis test) for plasma
3-hydroxykynurenine (b) and plasma and CSF anthranilic acid (d)
revealed signiﬁcant changes among groups. ANOVA (Kruskall–Wallis
test) for plasma kynurenic acid (c) did not reach signiﬁcance
(p = 0.08), but subsequent Dunn’s test revealed signiﬁcant reduction
in PD-LID as compared to PD-L. Data are means " standard error of
mean (SEM).
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fasting status. Therefore, fasting and non-fasting controls
were pooled for comparison with PD subgroups.
Figure 3 shows the ratios for these and other KYN
metabolites in plasma and CSF. The data indicate alterations
between the different branches of KYN pathway metabolism
in PD and PD-LID. In plasma, we observed signiﬁcant,
highly elevated 3-HK/KYNA and 3-HK/KYN ratios and
signiﬁcantly decreased 3-hydroxyanthranilic acid/3-HK and
xanthurenic acid/3-HK ratios in PD-LID patients as com-
pared to controls or PD-N. Excluding the two PD patients
receiving anti-depressants (one in PD-L and one in PD-LID)
did not alter the signiﬁcant ﬁndings in plasma.
In plasma of controls, we observed signiﬁcantly higher
levels (t-test, p < 0.05) of some metabolites in males as
compared to females: tryptophan, kynurenine, anthranilic
acid, 3-hydroxyanthranilic acid, and xanthurenic acid. How-
ever, the observed male-female differences in plasma of
controls cannot account for the observed differences in 3-
HK/KYNA ratio between PD-LID (3 females, 7 males) and
controls (6 females, 8 males) or for the observed difference in
anthranilic acid between PD-L (0 females, 8 males) and PD-
LID (3 females, 7 males).
Other metabolite ratios in plasma are shown in Figure S2,
with a signiﬁcantly reduced KYN/TRP ratio in PD-LID as
compared to PD-L and no signiﬁcant differences in KYNA/
KYN and AA/KYN ratios.
In CSF, we observed a similar trend with a highly elevated
mean of 3HK/KYNA in PD-LID, but because of large
variation and lower n (Table S1), these changes did not reach
signiﬁcance. In CSF of controls, no effect of fasting status or
gender was observed for any of the metabolites.
In PD patients (all groups), plasma and CSF levels of KYN
(r2 = 0.21, p = 0.03) and 3-HK (r2 = 0.26, p = 0.02) were
signiﬁcantly correlated, but plasma and CSF levels of KYNA
were not correlated.
We assessed also L-DOPA, 3-O-methyldopa (3-OMD),
and TRP metabolites along the serotonin pathway (Figure S2
and S3). As expected, the L-DOPA-treated PD patients (PD-
L and PD-LID) showed highly elevated L-DOPA and 3-
OMD levels in plasma and CSF. TRP levels in plasma and
CSF were not different between controls and the three PD
groups, but 5-hydroxytryptophan (5-HTP) was about twofold
increased in PD-L and PD-LID.
In conclusion, we observed signiﬁcant changes in KYN
metabolism in PD-LID, differentiating this group not only
from controls, but also from non-dyskinetic PD, that is,
PD-N and PD-L.
Discussion
Here, we present evidence of an altered KYN pathway
metabolism in plasma and CSF of PD patients with L-
DOPA-induced dyskinesia. The overall change of KYN
metabolism in PD-LID is a shift toward the production of 3-
HK (Fig. 4). The major ﬁndings are the signiﬁcant decreases
of AA and KYNA in plasma of dyskinetic (PD-LID) versus
non-dyskinetic L-DOPA-treated PD patients (PD-L) and a
signiﬁcant increase of the 3-HK/KYNA ratio in plasma of
PD-LID versus controls and PD-N. The presented quantita-
tive LC-MS analysis of tryptophan and kynurenine metabo-
lites in human plasma and CSF showed absolute levels of the
measured analytes in agreement with those reported previ-
ously for plasma (Widner et al. 2002; Forrest et al. 2010;
Savitz et al. 2015) and CSF (Olsson et al. 2012; Kegel et al.
2014; de Bie et al. 2016; Sellgren et al. 2016).
The 3-HK/KYNA ratio reﬂects the balance between the
neurotoxic and neuroprotective metabolites. An increase of
this ratio may indicate increased activity of KMO in relation
to kynurenine aminotransferases and kynureninase activities
(see Fig. 1). An increased 3-HK/KYN and decreased 3HAA/
3-HK and XA/3-HK ratios in PD-LID plasma (Fig. 3) are
also in line with increased KMO activity. We did not observe
signiﬁcant changes in tryptophan or KYN levels in plasma or
CSF, indicating that kynurenine metabolism in PD-LID is
shifted toward 3-HK production – catalyzed by KMO – and a
down-regulation of KYNA (via kynurenine aminotrans-
ferases) and AA (via kynureninase) synthesis. These changes
were not observed in the two subgroups of non-dyskinetic
PD patients, indicating that the three- to fourfold increase of
3HK/KYNA ratio in plasma or CSF may be considered a
speciﬁc biomarker of LID.
The enhanced 3HK/KYNA ratio in plasma and a similar
tendency in CSF suggest that a similar change in KYN
metabolites occurs in the basal ganglia at the synaptic level,
where it may give rise to increased glutamatergic transmission,
which may facilitate LID. The rationale for this is that lower
KYNA levels allow endogenous glycine to potentiate NMDA
receptor function and pre-synaptic nicotinic acetylcholine
receptors on glutamatergic terminals are more easily activated
(Schwarcz et al. 2012). In PD spine loss occurs on the dendrites
of medium spiny striatal neurons containing dopamine D2
receptors (Neely et al. 2007). This selective spine loss may
contribute to the development of LID (Schuster et al. 2009).
Increased levels of 3-HK, which increase oxidative stress
(Okuda et al.1998), and decreased levels of KYNA, which
Fig. 3 Ratios of selected metabolites in plasma and cerebrospinal
ﬂuid (CSF). The 3-HK/KYNA ratio (a) demonstrates the relative activity
between KMO and KATs. The 3-HK/KYN ratio (b) indicates KMO
activity, the 3-HAA/3-HK ratio (c) indicates KYNU activity, and XA/3-
HK ratio (d) indicates activity of KATs. Data are means " SEM.
Abbreviations of patient groups: see legend to Table 1. Abbreviations
used for metabolites and enzymes: 3-HK: 3-hydroxykynurenine; 3-
HAA: 3-hydroxyanthranilic acid; KATs: kynurenine aminotransferases;
KMO: kynurenine 3-monooxygenase; KYN: kynurenine ;KYNA:
kynurenic acid; KYNU: kynureninase; XA: xanthurenic acid.
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increase and vulnerability for excitoxicity (Amori et al. 2009),
may contribute to striatal spine loss and the development ofLID.
In the MPTP monkey model of PD, LID symptoms can be
reduced by enhancing brain KYNA production using sys-
temic treatment with an inhibitor of kynurenine 3-monoox-
ygenase (KMO) (Gregoire et al. 2008). In addition, systemic
inhibition of KMO shows marked neuroprotective effects in a
Drosophila model of Huntington’s disease (Campesan et al.
2011). Provided that future studies conﬁrm the present results
of increased 3HK/KYNA ratios in dyskinetic PD patients,
clinical intervention studies using KMO inhibitors should be
considered to alleviate LID symptoms and to conﬁrm the
pathophysiological role of kynurenine metabolites in LID.
Other PD biomarker studies targeting TRP and KYN
metabolites have shown increases in KYN/TRP ratio in
plasma (Widner et al. 2002) and increases in 3HK/KYNA
ratio in postmortem obtained CSF (Lewitt et al. 2013).
Increases of 3-HK and decreases of KYNA have been
reported previously in brain tissue samples (frontal cortex,
putamen, substantia nigra) of PD patients with the largest
changes observed in PD patients treated with L-DOPA
(Ogawa et al. 1992). These previous studies did not address
eventual differences between L-DOPA-treated PD patients
with or without LID. Despite the small sample sizes of our
PD subgroups, our study clearly shows that KYN pathway
metabolism is changed in PD-LID with a decreased KYN/
TRP ratio and an increased 3HK/KYNA ratio, which was not
present in PD-L or PD-N.
The PD-LID group is not only characterized by the
presence of LID, but also by a younger age of onset and a
longer duration of disease (see Table 1). Some of these
factors, for example, more advanced PD, increased oxidative
stress, increased inﬂammation, may contribute to the
observed changes in KYN metabolism (Lim et al. 2017).
TRP is not only degraded via the kynurenine pathway, it is
also the precursor of 5-HTP and 5-HT, reactions catalyzed by
TRP hydroxylase and amino acid decarboxylase. In plasma
we observed about twofold increases of 5-HTP in PD-L and
PD-LID as compared to controls and PD-N. This effect can
be explained by the co-treatment with peripheral decarboxy-
lase inhibitors and also competition between L-DOPA and 5-
HTP, which are both substrates for aromatic amino acid
decarboxylase.
In agreement with a higher daily L-DOPA intake in PD-
LID patients (Table 1), we observed slightly higher L-DOPA
and 3-OMD levels in PD-LID, although not signiﬁcantly
different from PD-L. 3-OMD levels are much higher than L-
DOPA, because it has a much longer half-life than L-DOPA
(Tohgi et al. 1995). L-DOPA and 3-OMD are, like KYN,
transported into the brain via the large neutral amino acid
transporter and may inhibit the transport of KYN over the
blood-brain barrier and into astrocytes (Asanuma and
Miyazaki 2016; Sekine et al. 2016). A lower availability of
KYN in astrocytes in PD-LID, may reduce central KYNA
production. In contrast to cerebral 3-HK, which can be
derived from the circulation or from production in brain
microglia or macrophages, cerebral KYNA levels are almost
entirely dependent on synthesis in brain astrocytes (Fukui
et al. 1991; Pardridge 1998).
Changes in KYN metabolites have been observed in other
neurological and psychiatric disorders, including, Huntington’s
disease (Forrest et al. 2010; Byrne and Wild 2016), schizophre-
nia (Forrest et al.2010;Chiappelli et al.2014;Kegel et al.2014;
Fazio et al. 2015; Oxenkrug et al. 2016) bipolar disorder,
(Olsson et al. 2012; Lavebratt et al. 2014; Savitz et al. 2015;
Sellgren et al. 2016) and other brain disorders (Vecsei et al.
2013; Lovelace et al. 2016; Watzlawik et al. 2016). In
schizophrenia and bipolar disorder increased levels of KYNA
have been observed in saliva, CSF and postmortem brain tissue,
whereas inHuntington’s disease decreasedKYNAand increased
3-HK and quinolinic acid has been observed in CSF and
postmortem brain tissue. TRP metabolism is also inﬂuenced by
gut microbiota with signiﬁcant consequences for CNS function
and dysfunction (Kennedy et al. 2017). Thus it can be speculated
that differences ingutmicrobiota amongPDpatients play a role in
the response to L-DOPA therapy and the risk of developing LID.
We conclude that our present LC-MS methodology to
detect KYN metabolites in body ﬂuids provides a unique tool
to monitor L-DOPA-treated PD patients for increasing risk of
LID. Further validation of the 3HK/KYNA ratio as a
biomarker of LID in plasma is needed in larger patient
cohorts and longitudinal studies, including multiple samples
from the same patients obtained before and after develop-
ment of LID.
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Abstract	
Background:	Parkinson’s	disease	(PD)	is	a	common	neurodegenerative	disease	characterized	by	motor	symptoms	like	bradykinesia,	rigidity	and	resting	tremor	as	well	as	the	accumulation	of	Lewy	Bodies,	especially	in	the	substantia	nigra,	pars	compacta.	Misdiagnosis	is	common	in	the	early	stages	of	the	disease,	in	particular	before	the	occurrence	of	motor	symptoms.	A	better	understanding	of	the	pathophysiological	mechanisms	behind	PD	and	an	early	diagnostic	and	prognostic	marker	is	warranted.	Prefibrillary	amyloid	formation	may	play	a	role	in	the	detrimental	processes	occurring	in	neurons	in	PD.	The	substance	L-Tryptophanol	is	fluorescent	and	this	fluorescence	can	be	quenched	by	the	presence	of	prefibrillary	amyloids.		
Objective:	To	quantify	the	amount	of	prefibrillary	amyloid	proteins	in	cerebrospinal	fluid	(CSF)	and	blood	plasma	of	patients	and	controls.	
Methods:	26	PD	patients	and	15	controls	were	included.	Lumbar	punctures	and	blood	samples	were	drawn	in	the	morning.	The	same	day	PD	patients	were	clinically	rated	using	the	Unified	Parkinson’s	Disease	Rating	Scale,	the	Unified	Dyskinesia	Rating	Scale,	the	Montreal	Cognitive	Assessment	and	the	Mini-Mental	State	Examination.	PD	patients	were	divided	into	three	groups:	PD-N;	not	receiving	L-DOPA,	PD-L;	receiving	L-DOPA,	not	dyskinetic,	PD-LID;	receiving	L-DOPA,	dyskinetic.	CSF	and	blood	samples	were	analysed	using	an	L-Tryptophanol	fluorescence	assay,	providing	a	Trol	score	corresponding	to	the	load	of	prefibrillary	amyloids.	
Results:	In	PD,	CSF	Trol	was	significantly	lower	compared	to	controls,	especially	in	L-DOPA	treated	patients.	Reversely,	plasma	Trol	was	significantly	higher	in	PD.	The	plasma	Trol/CSF	Trol	ratio	even	more	significantly	separated	PD	from	controls.	PD	patients	had	higher	CSF	total	protein	concentrations,	and	the	CSF	Trol/CSF	total	protein	concentration	significantly	differed	all	PD	groups	from	the	control	group.		
Conclusion:	The	L-Tryptophanol	fluorescence	assay	could	potentially	be	used	as	a	diagnostic	tool	for	PD.	Larger	studies,	also	including	atypical	PD,	are	warranted.	
	
	 Trol	analysis	in	PD																																																																																																																																Page		 3	
Background	Parkinson’s	disease	(PD)	is	the	second	most	common	progressive	neurodegenerative	disease(1).	PD	patients	develop	the	characteristic	motor	symptoms	of	bradykinesia,	rigidity,	and/or	resting	tremor	(2)	when	30%	or	more	of	nigrostriatal	dopaminergic	neurons	are	lost(3).	Neurodegeneration	has	thus	progressed	for	potentially	many	years	when	patients	are	diagnosed	as	having	PD.	Premotor	symptoms	of	PD	include	hyposmia,	depression,	REM-sleep	behaviour	disorder		(RSBD)	and	constipation(4)	(for	review	see	(5)).	In	general	premotor	symptoms	are	not	specific	indicators	of	PD.		No	disease-modifying	treatment	exists,	slowing	down	the	neurodegenerative	processes	in	PD.		The	best	symptomatic	treatment	is	provided	by	using	levodopa	(L-DOPA).		However,	after	some	years	of	treatment	(or	at	more	advanced	stages	of	PD),	L-DOPA	will	gradually	lose	its	therapeutic	effect,	resulting	in	marked	fluctuations	of	PD	motor	symptoms	and	increasing	risk	of	developing	debilitating	side	effects	such	as	L-DOPA-induced	dyskinesia	(LID)(6).	The	presence	of	Lewy	bodies	in	specific	brain	areas	is	the	neuropathological	hallmark	of	PD(7).	Braak	et	al	proposed	a	neuropathological	staging	of	the	disease	correlating	the	degree	of	LB	pathology	with	the	clinical	Hoehn	&	Yahr	score	(8).	Alpha-synuclein	(α-syn)	is	the	main	constituent	of	LB(9),	and	point	mutations	in	the	α-syn	gene	(10)	are	related	to	autosomal-dominant	genetic	forms	of	PD.	A	point	mutation	caused	α-syn	to	form	beta-sheet	structures	that	are	prone	to	aggregation.	The	α-syn	protein	is	prone	to	aggregation,	and	especially	aggregated	oligomeric	types	of	α-syn	(o-α-syn)	play	a	significant	role	in	the	disruption	of	normal	cellular	function	and	subsequent	cell	death	in	PD(11).	O-α-syn	can	easily	spread	from	neuron	to	neuron	through	exosomal	transmission(12),	and	this	propagation	of	toxic	proteins	has	fuelled	the	hypothesis	of	PD	being	a	prion	like	disorder(13).				The	need	for	earlier	and	more	precise	diagnostic	procedures	for	PD	has	resulted	in	an	extensive	research	into	potential	biomarkers.	A	review	of	the	current	literature	has	shown	that	results	from	measuring	total	α-syn	(t-α-syn)	in	the	cerebrospinal	fluid	(CSF)	are	divergent(14).	Although	some	research	has	been	done	into	modified	versions	of	α-syn,	such	as	phosphorylated	versions	that	aggregate	more	easily,	o-α-syn	has	not	been	studied	as	intensively.	Some	of	the	studies	using	modified	versions	of	enzyme	linked	immunosorbent	assays	(ELISA)	have	shown	a	significant	increase	of	o-α-syn	in	CSF	of	PD	patients	compared	to	controls(15-19),	with	an	even	better	discrimination	using	the	o-α-syn/t-α-syn-ratio(15,	16,	19).	In	blood,	El-Agnaf	et	al(20)	found	an	increase	in	plasma	o-α-syn	in	PD	patients,	whereas	
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Park	et	al(17)	did	not	find	any	increase	in	drug	naïve	patients.	Wang	et	al(21)	found	an	increase	in	the	ratio	of	o-α-syn	to	the	total	amount	of	protein	in	red	blood	cells	of	PD	patients.	These	results	might	indicate	a	superior	diagnostic	ability	of	o-α-syn	analysis	in	bodily	fluids	compared	to	t-α-syn.				Using	a	fluorescence-based	interaction	assay,	Reinke	et	al(22)	identified	5	indole-based	compounds	that	specifically	targeted	Aβ-oligomers,	but	not	Aβ-fibrils.	Using	this	approach,	a	fluorescence	based	interaction	assay	with	a	modified	indole	compound	has	been	developed,	targeting	pre-fibrillar	beta-sheet	rich	amyloid	structures.	Extracellular	Aβ-plaques	and	intracellular	neurofibrillary	tangles	of	tau	protein	represent	the	pathological	hallmark	of	AD(23).	α-syn	and	tau	proteins	can	interact	promoting	the	polymerisation	of	each	other,	possibly	promoted	by	Aβ-species(24).	This	creates	a	possible	link	between	synucleinopathies	and	tauopathies.		In	this	study	we	applied	this	newly	developed	fluorescence	assay	to	CSF	and	plasma	from	PD	patients	and	controls.	Our	goal	was	to	evaluate	the	usefulness	of	this	fluorescence	assay	as	a	potential	state	biomarker,	distinguishing	a	group	of	PD	patients	from	controls.	We	will	also	evaluate	its	function	as	a	rate	biomarker,	correlating	the	fluorescence	score	with	clinical	data	from	the	PD	group.		
	
Method	
	
Recruitment	26	PD	patients	were	recruited	from	four	different	locations;	the	neurological	departments	in	Sønderborg,	Odense,	and	Roskilde	as	well	as	a	private	neurological	practice.	All	patients	apart	from	1	were	identified	as	PD	patients	by	movement	disorder	specialists,	with	the	one	patient	diagnosed	as	having	Lewy	body	dementia	(DLB).	All	PD	patients	met	the	United	Kingdom	Brain	Bank	Criteria	for	idiopathic	PD(25).		15	controls	were	recruited	from	the	neurological	departments	in	Sønderborg	and	Odense.	They	underwent	lumbar	puncture	as	part	of	their	diagnostic	investigation	(headache	n=3,	dementia	n=3,	multiple	sclerosis	n=3,	vertigo	n=1,	ataxia	n=1,	trigeminal	neuralgia	n=1,	sleep	disorder=1,	neuroborreliosis	n=2).	
Lumbar	puncture	
	 Trol	analysis	in	PD																																																																																																																																Page		 5	
All	lumbar	punctures	(LP)	were	performed	on	patients	from	09.30-10.00	am	after	overnight	fasting	(21	of	26	patients).	Patients	on	L-DOPA	were	instructed	to	(when	possible)	take	their	morning	dose	at	08.00	am,	but	time	of	intake	varied	from	05.30	am	to	08.00	am.	On	patients	the	procedure	was	performed	with	the	patient	in	a	sitting	position,	using	an	atraumatic	Pencan®	(0,53x88mm)	needle	in	the	L3/L4	level,	drawing	out	13	ml	CSF	for	routine	analysis	and	storage	for	further	analyses.	On	controls	the	procedure	was	performed	from	09.30	am-12.15	pm	using	an	atraumatic	needle,	and	due	to	practical	reasons	it	was	not	possible	to	ask	controls	to	be	fasting	before	the	procedure.	6	of	16	patients	had	the	procedure	done	in	a	sitting	position	without	measurement	of	the	CSF	pressure,	10	had	the	procedure	done	in	supine	position	with	CSF	pressure	measurement	before	drawing	CSF	as	part	of	their	investigation.	CSF	was	kept	in	a	15	ml	polypropylene	tube	in	ice	water.	Within	30	minutes	the	CSF	was	centrifuged	at	2000g	for	10	minutes	at	4°C;	it	was	then	aliquoted	into	Saarstedt-tubes	and	put	immediately	on	dry	ice	until	storage	at	-80°C.			
Plasma	sampling	Blood	was	drawn	after	LP	in	the	cubital	fossa	using	a	BD	Vacutainer®	Eclipse™	blood	collection	needle	with	pre-attached	holder.	4	x	4,5	ml	BD	Vacutainer®	tubes	with	citrate	were	filled,	gently	turned	4	times	to	mix	blood	with	citrate	and	kept	in	room	temperature	(RT)	until	centrifuging.	Tubes	were	centrifuged	at	1800g	for	10	minutes	at	RT.	Plasma	from	the	four	citrate	tubes	were	then	aliquoted	evenly	into	two	15	ml	polypropylene	tubes	and	centrifuged	at	3000g	for	10	minutes	at	RT.	It	was	the	aliquoted	into	Saarsted-tubes	and	put	immediately	on	dry	ice	until	storage	at	-80°C.	
	
Clinical	rating	Rating	was	performed	on	the	same	day	as	the	LP	procedure.					PD	motor	disease	severity	was	rated	in	the	ON-stage	using	the	Movement	Disorder	Society	Unified	Parkinson’s	Disease	Rating	Scale	(MDS-UPDRS)	part	III(26),	for	patients	taking	L-DOPA	it	was	performed	approximately	50	minutes	after	intake.	The	procedure	was	video	recorded	for	later	assessment	(apart	from	evaluating	rigidity).					The	Unified	Dyskinesia	Rating	Scale	(UDysRS)(27)	objective	score	procedure	was	performed	with	video	recording	for	later	rating.	For	patients	taking	L-DOPA	it	was	performed	also	approximately	50	minutes	after	L-DOPA-intake.			
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			Cognitive	rating	was	done	using	both	the	Mini-Mental	State	Examination	(MMSE)	and	MOntreal	Cognitive	Assessment	(MOCA).		
Group	division	Patients	were	divided	into	three	groups.	Patients	not	receiving	L-DOPA	but	monoamine	oxidase	inhibitors	or	DA	agonists	(PD-N).	Patients	receiving	L-DOPA	but	without	LID	(PD-L),	patients	receiving	L-DOPA	with	LID	(PD-LID),	either	by	having	a	positive	UDysRS	objective	score	or	a	description	of	symptoms	assessed	as	being	L-DOPA-induced	dyskinesia.		
Routine	CSF	analysis	Routine	analysis	including	glucose,	protein	and	erythrocyte	count	was	performed	by	the	hospital	departments	of	clinical	biochemistry	in	Sønderborg,	Esbjerg,	Odense	and	Roskilde.		
L-Tryptophanol	(TROL)	fluorescence	assay:	The	 method	 was	 originally	 described	 in	 the	 PhD	 thesis	 by	 Glynn	 Jones	 (PhD,	 Aberdeen	University)(28):	The	required	mass	of	dry	anhydrous	Trol	granules	(Sigma)	were	dissolved	in	50	ml	 ‘glycine	buffer’	 (50	mM	glycine,	pH	8	 in	50	ml	dH2O)	 to	make	a	1	mM	Trol	 stock.	To	increase	the	solubility	of	Trol	samples	were	heated	to	35°C	whilst	being	stirred	until	granules	dissolved,	 at	 which	 point	 pH	 was	 checked	 and	 adjusted	 to	 pH	 8	 if	 required.	 Following	dissolution	 the	 Trol	 stock	 was	 0.22	 µm-filtered	 using	 polyethersulfone	 membrane	 sterile	syringe	fitted	filters.	The	stock	was	further	diluted	using	0.22	µm-filtered	glycine	buffer	and	run	at	a	final	test	concentration	of	100	µM	in	all	experiments.		Trol	 assays	 were	 carried	 out	 in	 UV	 colourless,	 UV	 star®,	 µclear®	 96	well	 plates	 (Greiner,	Germany)	with	signal	level	monitored	over	time	(ΔT=	1	hour,	Tmax=	3	hours).	Samples	were	read	 from	 below	 (‘bottom	 read’)	 using	 a	 consistent	 gain	 of	 (900)	 and	 10	 flashes	 per	 well,	using		280±10	nm	and	360±10	nm,	excitation	and	emission	filters	respectively.	BMG	FLUOstar	Omega	 is	 a	 band	pass	 filter	 based	 system,	 as	 such	 rather	 than	producing	 an	excitation	beam	at	 a	 narrow	 range	of	wavelegths,	 it	 utilises	 band	pass	 filters	which	 allow	a	wider	range	of	wavelengths	to	pass.		CSF	and	 serum	were	assessed	over	3	hour	 time	courses,	however	due	 to	 stability	of	 results	T=1	hour	was	consistently	used	as	the	Trol	results	for	each	sample.			
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Statistical	analysis		Statistical	calculations	were	performed	using	Stata/IC	14.2	for	Mac.		Comparisons	between	two	groups	were	done	using	student’s	unpaired	t-test	for	parametric	numerical	variables,	Wilcoxon’s	rank-sum-test	for	non-parametrical	numerical	variables.		Comparisons	between	more	than	two	groups	were	done	using	Kruskal-Wallis	equality-of-populations	rank	test	for	non-parametric	numerical	values	followed	by	Dunn's	Pairwise	Comparison	for	multiple	comparison	with	Bonferroni	adjustment.		For	parametric	numerical	data	oneway	ANOVA	and	subsequent	Bonferroni	multiple	comparisons	was	used.		Multiple	logistic	regression	was	used	to	assess	multiple	correlations.	To	evaluate	the	diagnostic	ability	of	a	test,	receiver	operating	characteristics	(ROC)	was	performed.	Youden’s	index	was	calculated	to	find	the	optimal	cutoff.	All	statistical	analysis	was	performed	with	and	without	DLB	and	AD	cases.		
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Results:	
	
Table	1:	
	
	
Demographic	analysis:	Table	1	shows	demographic	data	for	controls	and	PD	groups.	Controls	are	only	significantly	younger	than	PD-L.	Gender	composition	in	the	control	group	reflects	the	normal	population,	whereas	the	PD	group	shows	a	preponderance	of	men.	Controls	have	lower	CSF	protein	levels	than	all	PD	patients	and	PD-N	distinctly.		In	the	PD	group,	PD-N	has	a	lower	UPDRS	III	score	than	PD-L	and	PD-L+PD-LID,	as	well	as	a	lower	LED	than	PD-L	and	PD-LID.	A	higher	UPDRS	III	score	(higher	disability)	is	significantly	correlated	to	the	daily	L-DOPA-equivalent	dose	(LED)(p=0.015).	Non-L-DOPA-treated	patients	have	higher	MOCA	scores	than	L-DOPA	treated	patients.	Disease	duration	is	significantly	shorter	in	PD-N	compared	to	PD-LID.		LED	is	highly	correlated	to	disease	duration	(p=0.004).	
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TROL	scores	in	controls	compared	to	all	PD	patients:	In	Figure	1,	Trol	fluorescence	for	CSF	and	plasma	and	the	plasma/CSF	ratio	are	shown.	CSF	Trol	scores	are	significantly	lower	in	PD	CSF	(p=0.0203)(fig.1A).	When	excluding	both	the	DLB	and	AD	patients,	the	difference	is	not	significant	(p=0.0623),	but	only	excluding	the	DLB	patient,	results	are	still	significant	(p=0.0289).	Age	is	only	significantly	correlated	with	CSF	Trol	scores	in	the	PD	group	when	excluding	the	DLB	patient	(p=0.029),	but	not	in	controls.	Neither	gender,	LED,	MOCA	scores,	MMSE	scores,	nor	UPDRS	part	III	scores	significantly	correlated	with	CSF	Trol	scores.		Plasma	Trol	scores	are	significantly	higher	in	PD	compared	to	controls	(p=0.0137)(Fig.2B).	In	controls	plasma	Trol	scores	are	not	significantly	correlated	to	age	or	gender,	but	when	including	PD	patients,	age	correlates	with	plasma	Trol	scores	(p=0.003),	and	females	have	significantly	lower	plasma	Trol	scores	(p=0.016).	In	a	total	multiple	linear	regression	model	using	age	and	the	binary	values	case/control	and	male/female,	only	age	was	significantly	correlated	to	plasma	Trol	scores	(p=0.04).	Neither	disease	duration,	LED,	MOCA	scores,	MMSE	scores,	nor	UPDRS	part	III	scores	correlated	with	plasma	Trol	scores.	The	plasma	Trol/CSF	Trol	ratio	was	significantly	higher	in	PD	compared	to	controls	(p=0.0022)(Fig.1C).	When	looking	at	both	controls	and	PD,	females	had	significantly	lower	plasma	Trol/CSF	Trol	ratios	(p=0.005).	Taking	into	account	gender	in	a	multiple	linear	regression	analysis,	PD	patients	still	had	significantly	higher	ratios	(p=0.003).	Neither	disease	duration,	LED,	MOCA	scores,	MMSE	scores,	nor	UPDRS	part	III	scores	correlated	with	plasma	Trol/CSF	Troll	ratios.		
TROL	scores	in	controls	compared	to	individual	PD	groups:	In	Figure	2	TROL	fluorescence	data	for	CSF	(Fig.2A)	and	plasma	(Fig.2B)	and	the	plasma/CSF	ratio	(Fig.2C)	are	shown	for	controls	and	the	PD	subgroups,	PD-N,	PD-L	and	PD-LID.		CSF	TROL	scores	were	significantly	decreased	only	in	PD-LID	as	compared	to	controls	(p=0.006)(Fig.2A).	Focusing	on	L-DOPA-treated	PD	as	a	single	group,	they	have	significantly	lower	CSF	TROL	scores	than	controls	(p=0.003).	Comparing	dyskinetic	to	non-dyskinetic	PD	patients	showed	significantly	lower	CSF	TROL	in	dyskinetic	patients	(p=0.0369).		Plasma	TROL	scores	tended	to	be	increased	in	PD-N	and	PD-L	as	compared	to	controls,	but	did	not	reach	significance	(Fig.2B).		Neither	dyskinesia	status	nor	L-DOPA	treatment	significantly	affected	the	plasma	TROL	score	between	PD	patients.		
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Plasma	Trol/CSF	Trol	ratios	were	significantly	higher	in	PD-LID	compared	to	controls	(p=0.006).		
	
CSF	Trol/CSF	total	protein	ratios		In	Figure	3	CSF	Trol	fluorescence	data	are	expressed	as	ratios	over	CSF	total	protein	levels.	The	CSF	Trol/CSF	total	protein	ratios	were	significantly	lower	for	the	total	PD	group	(p=0.0001)(Fig.3A),	and	also	for	all	PD	subgroups	as	compared	to	controls	(PD-N:	p=0.019,	PD-L:	p=0.031,	PD-LID:	p=0.007)(Fig.3B).		Including	both	patients	and	controls,	females	had	significantly	higher	CSF	Trol/CSF	total	protein	ratios	than	men	(p=0.023),	but	taking	gender	into	account	in	multiple	linear	regression	analysis	showed	that	disease	status	(case/control)	was	the	only	significant	independent	variable	(p=0.000).	Neither	disease	duration,	LED,	MOCA	scores,	MMSE	scores,	nor	UPDRS	part	III	scores	correlated	with	this	ratio.	In	figure	4	an	ROC	analysis	of	CSF	Trol/total	protein	ratios	is	shown.	When	excluding	AD	cases	from	controls	and	one	DLB	case	from	the	total	PD	group,	an	optimal	cut-off	point	at	<2207	separates	controls	from	PD	with	a	90%	sensitivity	and	72,73%	specificity.	Neither	in	the	control	group	or	patient	group	was	CSF	Trol	scores	significantly	correlated	to	the	total	protein	concentrations	in	CSF.	
	
Age	effect:	In	figure	5,	age-dependent	significant	increases	in	plasma	Trol	in	the	PD	group	(Fig.5A)	and	for	plasma	in	all	subjects,	including	controls	(Fig.5B).		
	
Correlation	between	disease	duration	and	CSF	Trol	scores.	Patients	with	longer	disease	duration	have	significantly	lower	CSF	Trol	scores	(Fig.6).	Taking	dyskinesia	status	into	account	(PD-LID	have	significantly	longer	symptom	duration	and	the	lowest	CSF	Trol	score)	removes	that	significance.	Multiple	regression	analysis	including	both	disease	duration	and	LED	
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Discussion:	The	main	findings	of	this	study	are:		(1) CSF	Trol	scores	are	significantly	lower	in	PD	compared	to	controls,	whereas	plasma	Trol	scores	are	higher	in	PD.		(2) The	plasma/CSF	Trol	ratio	and	the	CSF	Trol/total	protein	ratio	in	CSF	improves	differentiation	of	PD	from	controls,			(3) Plasma	TROL	scores	in	PD	is	correlated	to	age	and	disease	duration.		
1.Decreased	CSF	TROL	in	PD:	One	might	expect	that	in	PD	oligomerization	of	α-syn	and	simultaneous	aggregation	of	tau,	Aβ	and	other	amyloids	would	increase	levels	of	oligomeric	proteins	in	CSF.	However,	our	data,	indicating	lower	Trol	scores	in	CSF	of	PD	patients,	suggest	that	lower	levels	of	oligomeric	proteins	in	the	CNS	may	be	released.	Aggregation	of	defective	proteins	in	PD	may	be	the	result	of	a	dysfunctional	autosomal-lysosomal	pathway	and	as	a	result	reduce	its	capacity	to	release	oligomeric	proteins	into	the	CSF.	The	oligomerization	of	proteins	such	as	Aβ	and	α-syn	are	concentration	dependent(29,	30),	and	decreased	CSF	α-syn	in	PD	as	found	in	several	studies(31-37),	could	thus	be	due	to	aggregation	of	the	protein	decreasing	the	amount	of	free	α-syn.	An	animal	study	using	radiolabeled	Aβ-monomers	and	oligomers	has	shown	that	monomers	are	more	rapidly	cleared	from	the	brain,	and	that	clearance	of	Aβ-oligomers	to	CSF	is	markedly	decreased(38).	Also,	a	higher	CSF	oligomeric	protein	level	in	controls	might	reflect	a	generally	lower	intracellular	concentration	of	oligomeric	proteins	preventing	further	aggregation,	and	a	more	efficient	clearance	of	oligomeric	proteins.	In	the	glymphatic	system	(39),	CSF	flows	in	the	subarachnoid	space	following	an	arterial	paravascular	route	through	the	brain	parenchyma.	Through	aquaporine	4	water	channels	in	astrocytes	there	is	an	influx	of	water	from	the	paravascular	system	into	the	interstitial	fluid	(ISF).	A	bulk	flow	drives	the	fluid	through	the	brain	parenchyma	clearing	solutes	such	as	Aβ	into	a	paravenous	pathway.	From	there	it	can	follow	large	calibre	veins	to	cervical	lymph	nodes	or	again	enter	the	CSF.	Animal	studies	estimate	that	11-30%	of	CSF	is	derived	from	bulk	flow	of	ISF(40,	41).	A	decreased	bulk	flow	through	the	ISF	might	decrease	the	amount	of	oligomeric	proteins	being	driven	towards	the	CSF,	both	explaining	the	lower	CSF	concentration	of	oligomeric	proteins	and	potentially	worsening	of	the	on-going	aggregation.		
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Specifically	L-DOPA-treated	PD	patients	had	a	significant	decrease	in	CSF	TROL.	Could	L-DOPA	in	itself	induce	aggregation	of	susceptible	proteins?	Potentially	due	to	decreased	activity	of	the	enzyme	aldehyde	dehydrogenase	as	well	a	decreased	vesicular	uptake	of	dopamine(42),	an	increase	of	the	naturally	occurring	dopamine	metabolite	3,4-dihydroxyphenylacetaldehyde	(DOPAL)	has	been	found	in	brain	samples	of	PD	patients(43).		DOPAL	is	highly	neurotoxic,	especially	to	dopaminergic	neurons(44),	and	increases	the	aggregation	of	α-syn	into	oligomeric	species(45).	Using	high	performance	liquid	chromatography	identifying	dopamine	and	metabolites	in	the	same	PD	group	(46)	we	found	the	PD-LID	to	have	a	significantly	higher	level	of	dopamine	compared	to	the	metabolite	DOPAC,	which	is	the	metabolite	of	DOPAL.	An	increased	production	of	DOPAL	in	this	group	might	explain	why	they	have	the	lowest	CSF	TROL	score	of	all	patients.	Or	possibly	L-DOPA	metabolites	interfere	with	the	Trol-assay	directly.	It	has	to	be	noted	that	this	assay	is	unspecific	as	to	what	species	of	prefibrillary	proteins	are	measured.	The	TROL	fluorescence	in	controls	may	represent	a	different	composition	of	proteins	than	in	PD.		
	
2.	Increased	plasma	TROL	in	PD:			Oligomeric	proteins	are	ubiquitous	and	play	many	roles	in	the	normal	functioning	of	e.g.	cellular	membranes.	One	of	the	motifs	of	protein	oligomerization	is	the	very	stable	β-sheet	structure,	which	has	the	risk	of	polymerizing	into	an	amyloid	formation(47).	Our	findings	do	not	indicate	what	type	of	oligomeric	protein	might	be	increased	in	patients.	This	could	indicate	a	peripheral	source	for	production	of	oligomeric	proteins	in	PD:				In	PD,	a	systemic	affection	of	peripheral	nervous	system	(PNS)	has	been	proposed.	Several	studies	have	focused	on	peripheral	α-syn	aggregation	in	PD,	identifying	phosphorylated	α-syn	in	submandibular	glands(48),	α-syn	in	salivary	glands(49),	intraneuronal	phosphorylated	α-syn	in	skin	biopsies	(50)	and	intraneuronal	α-syn	aggregation	in	the	enteric	nervous	system	(ENS)	of	the	gastric	mucosa	(51,	52).	Affected	neurons	in	the	PNS	(e.g.	ENS)	might	release	a	larger	amount	of	oligomeric	proteins	into	the	bloodstream	due	to	the	continuous	aggregation	of	the	ubiquitous	α-syn	and	a	more	direct	connection	to	the	blood	stream.	It	could	be	speculated	that	other	amyloid	species	apart	from	α-syn	are	simultaneously	aggregated	into	a	prefibrillary	formation	and	released	into	the	blood	stream.	
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3.	Decreased	oligomeric/	total	protein	ratio	in	CSF	of	PD	Neither	patients	nor	controls	had	visual	blood	mixture	in	CSF	during	lumbar	puncture,	and	none	had	a	marked	increase	of	CSF	erythrocytes	(results	not	shown).	Albeit	still	in	the	normal	range,	significantly	higher	protein	levels	were	measured	in	the	CSF	of	PD	patients.	This	may	be	due	to	a)	a	more	permeable	BBB	allowing	influx	of	proteins	from	the	blood	stream	or	b)	neuroinflammation,	which	increases	CSF	protein	levels.	One	study	did	show	an	increased	CSF/serum	albumin	and	CSF/serum	IgG	ratio	in	advanced	phases	of	PD(53),	indicating	a	potential	breach	of	the	BBB.	Thus,	a	possible	explanation	for	the	decreased	oligomeric/total	protein	ration	in	CSF	of	PD	patients	is	the	combination	of	a	disrupted	BBB,	neuroinflammation	and	a	dysfunctional	clearance	of	oligomeric	proteins	from	brain	cells.	Do	oligomeric	proteins	from	the	blood	stream	would	cross	the	BBB	as	well?	If	so,	a	possible	explanation	for	our	findings	could	be	that	a	decreased	bulk	flow	of	the	ISF	would	allow	for	peripheral	oligomeric	proteins	crossing	the	BBB	to	aggregate	in	the	brain	parenchyma	before	reaching	the	CSF,	thus	explaining	the	differences	in	ratio.			
4.	Disease	duration	and	age	correlations:	Patients	with	the	longest	disease	duration	(PD-LID)	have	significantly	lower	CSF	TROL	scores	and	CSF	TROL	is	negatively	correlated	to	disease	duration,	which	means	that	CSF	TROL	scores	might	reflect	the	gradual	increase	of	protein	aggregation,	thus	potentially	functioning	as	a	rate	biomarker,	decreasing	over	time.	Due	to	the	potentially	augmenting	effect	of	L-DOPA	on	protein	aggregation	mentioned	earlier,	daily	L-DOPA	intake	might	be	a	major	confounder.	Increased	disease	duration	means	further	neurodegeneration	necessitating	larger	doses	of	L-DOPA,	and	LED	is	highly	correlated	to	disease	duration,	even	though	a	direct	correlation	between	LED	and	CSF	TROL	is	not	found.		CSF	TROL	was	not	correlated	to	severity	of	motor	symptoms	(UPDRS	III);	this	could	be	due	to	the	significant	effect	of	L-DOPA	treatment	on	motor	symptoms.	If	possible,	future	studies	should	include	CSF	samples	from	patients	after	L-DOPA	washout,	rating	severity	of	motor	symptoms	in	the	OFF-stage.			Plasma	TROL	scores	are	significantly	correlated	to	age,	even	when	including	controls,	but	not	in	controls	by	themselves.	It	seems	plausible	that	the	amount	of	oligomeric	proteins	in	plasma	increases	due	to	the	normal	ageing	process.	Supporting	this	hypothesis,	Foulds	et	al	(2013)	
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found	a	significant	increase	of	total	α-syn	in	plasma	over	time	in	PD	patients(54).	Even	then,	taking	age	into	account,	PD-N	still	had	significantly	higher	scores	than	controls.		
	
Comments	to	results:	The	study	includes	only	a	small	number	of	PD	patients.	The	controls	were	not	completely	age	matched	for	the	PD-N	and	PD-L	groups,	and	a	subgroup	of	controls	had	not	been	fasting	and	had	the	spinal	tap	performed	in	a	lying	position;	this	might	affect	measurements.	Also	the	gender	distribution	is	skewed,	although	we	didn’t	find	any	gender	effect	on	either	CSF	or	plasma	TROL.	In	terms	of	correct	PD	diagnosis,	movement	disorder	specialists	have	diagnosed	and	done	regular	follow-ups	on	all	the	clinically	well-defined	patients	in	this	study.		
	
Conclusion:	In	this	study,	for	the	first	time	to	our	knowledge,	the	indole-based	compound	L-Tryptophanol	has	been	used	to	quantify	prefibrillary	proteins	in	CSF	and	plasma	of	patients	with	a	neurodegenerative	disease.		PD	patients	have	lower	Trol	scores	in	CSF	and	higher	Trol	scores	in	plasma.	The	ratio	between	CSF	Trol	and	total	CSF	protein	concentrations	shows	a	promising	ability	to	distinguish	between	PD	and	controls.	Especially	non-L-DOPA	treated	PD	patients	have	significantly	higher	plasma	concentrations	of	oligomeric	proteins	than	controls.	The	CSF	concentration	of	oligomeric	proteins	decreases	as	the	disease	progresses.	Thus,	the	combination	of	CSF	and	plasma	measurements	of	the	total	oligomeric	protein	concentration	shows	potential	as	both	a	rate	and	state	biomarker.	
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Further	studies	are	needed	to	identify	which	protein	species	are	detected	by	the	assay	and	whether	other	constituents	(e.g.	medicine	or	metabolites)	interfere	with	the	Trol	assay.	We	suggest	future	studies	using	this	assay,	including	a	larger	group	of	PD	patients	with	a	wide	disease	spectrum.	Follow	up	studies	would	corroborate	whether	the	CSF	TROL	score	can	be	used	as	a	marker	for	disease	progression,	although	the	potential	effect	of	L-DOPA	would	have	to	be	taken	into	account.	Including	a	larger	group	of	PD	patients	with	early	symptoms	would	assess	the	function	of	this	assay	as	an	early	biomarker	for	PD.			
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Figure	1:	CSF	TROL,	plasma	TROL	scores	and	plasma/CSF	TROL	ratios	in	controls	and	
PD:	
				PD;	Parkinson’s	disease,	Trol;	L-Tryptophanol	(A)	Student’s	t-test,	p=0.0203	(B)	Wilcoxon	ranksum	test,	p=0.0137	(C)	Student’s	t-test,	p=0.0022;	Data	presented	as	mean	±	standard	error	of	mean.		*	p<0.05	**	p<0.01	
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Figure	2:	Differences	in	CSF	and	plasma	TROL	scores	and	CSF/plasma	TROL	score	ratio	
between	controls,	PD-N,	PD-L	and	PD-LID.	
	PD-N;	Parkinson’s	disease	not	receiving	L-DOPA,	PD-L;	Parkinson’s	disease	receiving	L-DOPA,	non-dyskinetic,	PD-LID;	Parkinson’s	disease	receiving	L-DOPA,	dyskinetic.	*	p<0.05	**	p<0.01	
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(A)	ANOVA	p=0.0120,	subsequent	Bonferroni	multiple	comparison	(B)	ANOVA	not	significant,	subsequent	Dunn’s	test	with	Bonferroni	correction	for	multiple	comparisons	(C)	ANOVA	p=0.0155,		subsequent	Bonferroni	multiple	comparison.		
Figure	3:	Ratio	between	CSF	Trol	score	and	CSF	total	protein	concentration	in	controls	
compared	to	PD	and	compared	to	individual	PD	groups.	
		PD-N;	Parkinson’s	disease	not	receiving	L-DOPA,	PD-L;	Parkinson’s	disease	receiving	L-DOPA,	non-dyskinetic,	PD-LID;	Parkinson’s	disease	receiving	L-DOPA,	dyskinetic.	*	p<0.05	**	p<0.01	***	p<0.001	(A)	Student’s	t-test	(B)	ANOVA	p=0.0017,	subsequent	Bonferroni	multiple	comparison		
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Figure	4:	ROC	analysis	of	plasma/CSF	TROL	score	ratio	differing	PD	from	controls	
	p=0.0006;	ROC	calculated	excluding	AD	and	DLB	cases.	At	the	optimal	cutoff	point	at	<2270	the	CSF	Trol/CSF	protein	ratio	has	a	sensitivity	of	90%	and	specificity	of	72.73	
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Figure	5:	Correlation	between	age	and	plasma	Trol	scores	in	PD	without	(A)	and	with	
(B)	controls.	
	(A)	and	(B)	shows	the	correlation	between	age	and	plasma	Trol	respectively	with	and	without	controls	((A)	p=0.012	(B)	p=0.003).	Linear	regression	analysis	with	bootstrapping.	
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Figure	6:	Correlation	between	disease	duration	and	CSF	Trol	scores:	
	The	figure	shows	the	significant	correlation	(p=0.027)	between	disease	duration	and	CSF	Trol	scores.	Linear	regression	analysis	with	bootstrapping.	
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Measuring α-synuclein-content in erythrocytes (RBC) november 2016 at 
Statens Serum-Institut (SSI) 
Sample preparation 
RBC	thawed	at	room	temperature	(RT)	and	carefully	mixed.	
5	µL	samle	mixed	with	95	µL	diluted	PBS	(1	part	PBS	10X	+	99	parts	MilliQ)	
Put	on	cold	storage	over	night	for	hemolysation.		
Then	diluted	in	PBS	(1	part	PBS	10X	+	9	parts	MilliQ)	for	the	dilution	1:1000.	
	
ELISA Assay 
MaxiSorpplade	coated	with	100	µL	5	µg/mL	HYB	366-03	per	well.	
Put	on	cold	storage	over	night.	
Washed	3x	60	seconds	with	washing	buffer	on	shake	table	at	200-300	rpm.	
Standard	row	placed	in	duplicate	100	µL/well:	Recombinant	α-synuclein	diluted	in	PBS	to	the	following	
concentrations:	0.00,	0.020,	0.040,	0.060,	0.080,	0.10,	0.12,	0.14	µg/mL	
Samles	placed	in	duplicate	100	µL/well.	
Incubated	for	60	minutes	on	shake	table	at	200-300	rpm.	
Washed	3x	60	seconds	with	washing	buffer	on	shake	table	at	200-300	rpm.	
100	µL/well	biotinylated	HYB	366-01	diluted	1:200	in	washing	buffer.	
Incubated	for	60	minutes	on	shaking	table	at	200-300	rpm.	
Washed	3x	60	seconds	with	washing	buffer	on	shaking	table	at	200-300	rpm.	
100	µL/well	streptavidin-AP	diluted	1:1000	in	washing	buffer.	
Incubated	for	60	minutes	on	shaking	table	at	200-300	rpm.	
Washed	3x	60	seconds	with	washing	buffer	on	shaking	table	at	200-300	rpm.	
100	µL/well	pNPP	diluted	in	substrate	buffer	for	AP	to	1	mg/mL.	
Incubated	for	30	minutes	on	shaking	table	at	200-300	rpm.	
Measured	at	405	nm	/	620	nm	on	ELISAreader	from	TECAN.	
	
PBS	10X	delivered	by	SSI.	Ref:	24234.	
Carbonate	buffer	pH	9,6	delivered	by	SSI.	Ref:	29779.	
Washing	buffer	pH	7,2:	PBS	with	0,1%	Triton-X100.	
Substrate	buffer	for	AP	pH	9,8	delivered	by	SSI.	Ref:	63167.	
HYB	366-03:	Monoclonal	mouse	anti-α-synuclein.	
Recombinant	α-synuclein	from	Alpha	Diagnostics	International.	Ref:	SYN11-R.	
HYB	366-01:	Monoclonal	mouse	anti-α-synuclein.	
Streptavidin-AP	from	DakoCytomation.	Ref:	D0396.	
pNPP	from	Sigma	Life	Science.	Ref:	1001964484.	
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METHOD	FOR	GLUCOCEREBROSIDASE	(GCase)	FLUORESCENCE	ASSAY		Results	used	from	the	GBA	assay	are	based	on	two	separate	runs.	Differences	between	the	two	runs	will	be	noted	in	the	following	description.	CSF	samples	were	thawed	on	ice.	MUGIc	(4-Methylumbelliferyl	beta-D-glucopyranoside)(Sigma,	M3633)	was	used	as	the	GBA	substrate.			
Reaction	buffer	(for	two	reading	plates):	10	ml	of	citrate/phosphate	reaction	buffer	was	made	by	mixing	0.2	g	0.2%	taurodeoxicholate	(Sigma,	T0875),	2.94	g	sodium	citrate	(Merck,	1.06448.1000),	sodium	phosphate	(Merck,	1.06346.1000)	and	90	ml	dH2O.	16.93	mg	of	MUGIc	was	added	in	the	dark	to	prevent	breakdown.	pH	was	adjusted	to	5.2	using	NaOH.	In	run	two	the	reaction	buffer	was	alcalic	and	pH	was	adjusted	to	5.2	using	3	ml	1M	citric	acid.	The	mixture	was	filled	to	100	ml	using	dH2O.	100	microliter	triton-x-100	was	added	to	the	mixture.	The	mixture	was	put	on	a	whirlmixer	until	use	within	30	minutes.			
Stock	of	standard:	4-Methylumbelliferone	(Sigma,	M1381)	was	used	as	standard.	1	mg	4-Methylumbelliferone	was	mixed	with	1	ml	Methanol	and	subsequently	diluted	in	Ringers	to	a	final	concentration	(μM)	on	the	assay	plate	of	10,	5,	1.67,	0.56,	0.19,	0.06,	0.02	and	0	(100%	Ringers).			
Stop	solution:	Prepared	by	mixing	15	g	glycine	(Sigma,	G7126)	and	8	g	NaOH	(Merck,	1.06498.1000)	in	450	ml	water.	pH	was	adjusted	to	10.8	with	10M	NaOH	in	first	run.	In	the	second	run	pH	was	too	high	(pH	11.25)	and	was	corrected	with	3	ml	10M	citric	acid	to	pH	10.8.		
Plate	preparation:	25	μL	of	each	standard	was	added	in	triplicates	to	wells.	25	μL	thawed	CSF	was	added	in	triplicates.	In	all	wells	being	used,	50μL	of	substrate	(MUGIc/reaction	buffer)	was	added.		The	plate	was	covered	and	incubated	in	the	dark	at	37°Celcius	for	24	hours.		
Plate	reading:	For	both	runs	the	enzyme	reaction	was	stopped	after	24	hours	by	adding	75	μL	of	stop	solution	to	each	well	being	used.	In	the	first	run	the	plates	were	read	on	an	Enspire	2300	multimode	plate	reader	(Perkin	Elmers	inc.,	Waltham,	Massachusetts,	USA)	with	software	version	4.1	(excitation	wavelength	365	nm,	emission	wavelength	445	nm).			In	the	second	run	the	plates	were	read	on	a	BMG	Labtech	Fluostar	Omega	(BMG	Tech,	Ortenberg,	Germany)	with	built	in	software	(same	excitation	and	emission	wavelengths)	(with	kind	assistance	from	Ditte	Neess	Pedersen	(MSc)	and	Lars	Duelund	(MSc),	Institute	of	Biochemistry	and	Molecular	Biology).			
Calculated	concentration:	The	mean	fluorescence	unit	(FU)	of	the	triplicate	standard	concentrations	was	corrected	(corrected	fluorescence,	CF)	by	subtracting	the	mean	FU	of	the	0	concentration	(100%	Ringers)	well.	CF	values	are	used	to	create	a	standard	curve	(CF	as	x-axis,	and	the	amount	of	
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standard	(nmol	4-MU)	added	as	the	y-axis).	Linear	regression	is	used	to	identify	the	y-intercept	(α)	and	slope	(β)	of	the	standard	curve	(see	fig.1).			Figure	1:	Standard	curve	for	calculating	actual	amount	of	4-MU	in	samples	including	simple	linear	regression	equation	
	4-MU;	4-methylumbelliferyl			The	corrected	sample	fluorescence	value	(CSF)	is	calculated	by	subtracting	the	mean	blank	sample	background	FU	from	the	mean	sample	FU.	To	calculate	the	amount	(nmol	product)	in	samples	after	24	hours,	CSF	values	are	plotted	in	the	standard	curve:			 	 nmol	4-MU	=	CSF	*	β	+	α.		Enzyme	activity	was	then	determined	in	units	(U),	with	one	U	being	defined	as	the	amount	of	enzyme	that	hydrolyzes	1	nmol	of	substrate	pr.	minute	at	37°C.		Values	were	converted	to	mU/mL	by	the	following	equation:			 GCase	activity	(mU/mL)	=	(nmol	4-MU)/(24*60)*1000/0.025		To	compare	the	two	runs	that	were	analysed	on	different	platereaders,	we	normalized	the	data	by	dividing	the	actual	GCase	activity	with	the	control	mean	GCase	activity:								normalised	GCase	activity	=	actual	GCase	activity/	GCase	activity	(control	mean)	
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